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ABSTRACT 
 
Chronic Obstructive Pulmonary Disease (COPD) presents an enormous 
public health challenge. Cigarette smoking remains the most important 
aetiological factor and although legislation to reduce smoking has been 
introduced in parts of the more developed world, consumption is increasing 
in many of the poorest parts of the world. With the predicted rise in disease 
prevalence, COPD is expected to become the world’s third largest cause of 
death by 2020. 
COPD is a disease state characterised by airflow limitation that is not fully 
reversible. Inhaled bronchodilators can only produce a small improvement 
in the airflow obstruction, but despite this, patients with COPD frequently 
use high doses of β2-agonists as the disease progresses and they develop 
breathlessness and exercise limitation.  
Short-acting ȕ2-agonists are generally used ‘as required’ to reduce 
breathlessness and reduce airflow obstruction whereas long-acting ȕ2-
agonists are prescribed on a regular twice-daily basis to reduce symptoms 
and rescue medication use and because of a potential beneficial effect on 
quality of life and exacerbation rates. 
Although generally well tolerated, the safety of inhaled ȕ2-agonists has been 
a source of some concern since the late 1960s, when an epidemic of asthma 
deaths was associated with the use of a high dose formulation of 
isoprenaline. Further controversy has followed and questions have extended 
to long-acting ȕ2-agonists, most notably after a recent large-scale post 
marketing surveillance study identified an association between the regular 
use of inhaled salmeterol and asthma-related deaths.  
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The safety of inhaled ȕ2-agonists is also an important consideration for 
patients with COPD. Being older and likely to have a history of cigarette 
consumption means that they are at risk of having symptomatic, or 
subclinical, ischaemic heart disease. ȕ2-agonists cause a number of systemic 
effects including an increase in heart rate, transient hypoxaemia and 
hypokalaemia. Since many patients with COPD are already hypoxaemic and 
may be taking other drugs that stimulate the myocardium and cause 
hypokalaemia, the additional systemic effects from ȕ2-agonists may be more 
likely to produce adverse cardiac events including dysrhythmia and 
ischaemia. 
This thesis is concerned with the safety of inhaled ȕ2-agonists in the 
management of COPD. The introduction consists of an overview of the 
epidemiology, natural history and pathology of COPD (Chapter 1) and a 
review of human ȕ2-adrenoceptor function and inhaled ȕ2-agonist 
pharmacology (Chapter 2). This is followed by a systematic literature 
review of the results from long-term clinical studies of inhaled ȕ2-agonists 
in subjects with COPD (Chapter 3). The original work consists of three 
clinical studies that have examined aspects of the effect of high dose inhaled 
ȕ2-agonists in subjects with COPD and a discussion to place these findings 
in context. 
Most published studies of inhaled ȕ2-agonists in subjects with COPD have 
focused on their efficacy, rather than safety. We were concerned that some 
individuals with COPD and limited bronchodilator reversibility may 
experience an increase in adverse systemic effects after inhaling high doses 
of ȕ2-agonists, which could lead to detrimental outcomes in certain clinical 
situations.   
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Apart from the cardiac effects mentioned above, ȕ2-agonists increase tremor, 
which causes CO2 production, and cardiac output and tissue perfuson, which 
increases the transport of CO2 to the lungs. The increase in CO2 flux to the 
lungs will normally increase ventilation. We were concerned however that 
some subjects with severe COPD would not be able to increase ventilation 
appropriately in response to the ȕ2-agonist and this would lead to an increase 
in PaCO2. Our hypothesis was that high dose inhaled ȕ2-agonists could 
worsen respiratory failure in some subjects with severe COPD.  
The first two studies in the thesis examined the effect of high dose inhaled 
salbutamol on the partial pressure of arterial oxygen and carbon dioxide in 
subjects with severe COPD.  
We initially conducted a double blind, randomised study on subjects within 
48 hours of being admitted to hospital with an acute exacerbation of COPD 
(Chapter 4). The study was designed to determine whether high dose 
salbutamol caused an increase in the partial pressure of arterial carbon 
dioxide. We randomised subjects at a ratio of 3:1 to receive either 
salbutamol or ipratropium bromide and studied the pharmacodynamic effect 
on heart rate, PaO2 and PaCO2 over five hours. Over eighteen months and 
despite extensive efforts I was only able to recruit ten subjects, of whom 
five completed the study. I found that subjects who required hospital 
admission with an acute exacerbation of COPD were either too unwell for 
the study, had co-morbidities that precluded participation or the individuals 
were unwilling to participate. Although the study was terminated 
prematurely and we were unable to perform statistical analysis, I have 
presented the findings from the five subjects who completed the study, of 
whom four were randomised to receive salbutamol. We used ascending 
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doses of salbutamol (1.25mg, 1.25mg, 25mg, 5mg, 5mg) and found no 
consistent effect on PaCO2 or PaO2 and no dose response relationship. The 
subject with the highest baseline PaCO2 did however have a rise in PaCO2 
with the highest 5mg doses of salbutamol. 
To test the hypothesis further we conducted a randomised, double blind, 
crossover study and examined the effect of salbutamol on the arterial blood 
gas tensions of fourteen patients with stable severe COPD and a history of 
chronic or intermittent hypercapnia. The study was designed to determine 
whether high dose salbutamol causes a rise in PaCO2 when inhaled by 
subjects with severe COPD and a history of alveolar hypoventilation. We 
compared the effect of two 5mg doses with two 200 µg doses of salbutamol 
on PaO2 and PaCO2 and heart rate. The subjects had severe COPD with a 
mean FEV1 of 0.71 L (27% predicted) and a mean smoking history of 53 
pack years. The mean baseline PaO2 was 7.9 kPa and the mean baseline 
PaCO2 was 7.0 kPa. The high dose of salbutamol caused a mean fall in both 
PaO2 and PaCO2 and a small increase in heart rate. There was some support 
for our hypothesis however as three subjects had a small rise in PaCO2 after 
high dose nebulised salbutamol (Chapter 5). 
The third study was a double blind, crossover, dose-response examination of 
the bronchodilator and systemic effects of inhaled formoterol in subjects 
with COPD (Chapter 6). The rapid onset and prolonged duration of action of 
formoterol offers potential for the drug to be used as rescue medication in 
addition to twice daily maintenance therapy, as is the case in the 
management of asthma. Our hypothesis was that high doses of formoterol 
would produce adverse systemic effects that would outweigh the beneficial 
bronchodilator effects in subjects with COPD and limited bronchodilator 
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response to salbutamol. We studied 20 subjects, with a mean FEV1 of 1.32 L 
(47% predicted) and a mean smoking history of 42 pack years. Each subject 
was studied on five days and after receiving placebo, formoterol 6, 12, 24 
and 48 µg in a random sequence, we examined the effect of each dose on 
FEV1, tremor, dyspnoea, heart rate, blood pressure, SpO2, walk distance, 
potassium and satisfaction. We found that all doses were well tolerated and 
although there was a small dose related increase in FEV1 and the mean 
satisfaction scores were higher with each dose of formoterol than placebo, 
there was no dose related improvement in measures that are important to the 
patient, including breathlessness and walk distance. Apart from a dose 
related increase in tremor, other systemic effects were limited.  
All three studies found that high dose inhaled ȕ2-agonists produced 
relatively modest systemic effects in subjects with COPD. This probably 
reflects the fact that almost all subjects were taking ȕ2-agonists on a regular 
basis and had developed tolerance to the systemic effects of an inhaled ȕ2-
agonist. Although the results from the three studies were generally 
reassuring, questions still remain about the balance between beneficial and 
adverse effects with high dose inhaled ȕ2-agonists in subjects with COPD. 
The results may have been different if subjects had more severe disease, 
were exposed to higher doses of ȕ2-agonists, had certain ȕ2-adrenoceptor 
polymorphisms or were ȕ2-agonist naïve. 
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1.1 INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is the accepted name for a 
condition known previously as chronic airflow limitation (CAL), chronic 
obstructive airways disease (COAD), chronic obstructive lung disease 
(COLD) and chronic bronchitis and emphysema. The term COPD was 
coined in the early 1960s and is used because it recognises that the disease is 
not confined to the airways, but also affects the lung parenchyma and 
pulmonary circulation. The Global Initiative for Obstructive Lung Disease 
(GOLD, 2001) defined COPD as ‘a disease state characterised by 
progressive development of airflow limitation that is not fully reversible [1]. 
The airflow limitation is usually progressive and usually results from an 
abnormal response of the lungs to noxious particles or gases.’ The clinical 
syndrome of COPD encompasses different disease processes from chronic 
obstructive bronchitis with small airway obstruction, to emphysema 
characterised by destruction of lung parenchyma, enlargement of air spaces, 
loss of elasticity and small airway closure. It is difficult to determine the 
precise prevalence of COPD, but it is expected to become the third largest 
cause of death worldwide by 2020 [2].  
 
1.2 HISTORICAL BACKGROUND 
Emphysema was first identified in the seventeenth century as enlarged 
respiratory air spaces on the lung surface. Ruysch (1691) noted that these 
distended airspaces could not be emptied by pressing on them and 
concluded that the bronchi were obstructed [3]. Matthew Baillie, a British 
physician, used a lung from the autopsy of the writer and philosopher 
Samuel Johnson to produce the first illustration of widespread emphysema 
 15 
in 1793 [4] and in 1819, four years after inventing the stethoscope, Rene 
Laennec used air-dried inflated lung specimens to provide a basis for the 
description of emphysema that was accepted for over a hundred years [5]. 
Bronchitis had more humble origins and was described in 1808 as “chronic 
pectoral (chest) complaints, especially those of people advanced in life” [6]. 
The importance of respiratory illnesses in the UK was highlighted by ‘the 
great smog’ of December 1952. Death rates in London rose following the 
five-day smog, with many deaths among people suffering from chronic 
respiratory or cardiovascular disease. There was a more than sevenfold 
increase in mortality from bronchitis and pneumonia. The subsequent City 
of London Act of 1954 and the Clean Air Acts of 1956 and 1968 ensured the 
use of smokeless fuels in urban areas, reducing the likelihood that smogs of 
such severity would occur again. The increased profile of chronic 
respiratory diseases in this period and the need for internationally accepted 
terminology led to the CIBA symposium in 1959, which suggested 
definitions for chronic bronchitis, emphysema, and variable and fixed 
airflow obstruction [7]. Emphysema was defined in anatomical terms, whilst 
chronic bronchitis was defined clinically as “chronic or recurrent excessive 
mucus secretion in the bronchial tree”. The introduction of the physiological 
concept of airflow limitation as a diagnostic term was new, and the report 
emphasised that mucus hypersecretion, reversible airflow obstruction and 
irreversible airflow obstruction frequently coexisted in different 
combinations. 
The British Medical Research Council report in 1965 classified chronic 
bronchitis as ‘simple’, i.e. mucus hypersecretion without airflow obstruction 
or ‘obstructive’ i.e. mucus hypersecretion associated with chronic airflow 
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obstruction related to airway pathology and/or coexistent emphysema [8]. 
‘Chronic obstructive pulmonary disease’ was proposed as a diagnostic term 
in the 1975 report of the American College of Chest Physicians-American 
Thoracic Society Joint Committee on Pulmonary Nomenclature [9]. 
Definitions of the disease evolved in the latter half of the last century 
through further British, European and American guidelines, before the 
publication of consensus guidelines (GOLD) in 2001 [1].  
In 1951, Doll and colleagues initiated a questionnaire study of over 40000 
doctors in Britain, to examine the relationship between smoking habits and 
mortality. The follow-up over five decades has provided clear evidence of 
the increased mortality associated with cigarette smoking and an increased 
incidence of lung cancer and chronic obstructive lung disease [10-15]. 
Fletcher and Peto (1976) published a landmark epidemiological study with 
data collected from working men in West London between 1961 and 1969, 
showing that cigarette smoking causes an accelerated decline of FEV1 and 
that smoking cessation slows this decline [16].  
Attempts to explain the aetiology of chronic airflow obstruction led to 
opposing theories in the 1960s. The “British hypothesis” considered asthma 
and COPD to be different conditions, postulating that infections cause 
airway narrowing and the infections occurred because prior mucus 
hypersecretion impaired the defence of the airways against infection and led 
to bacterial colonization. Workers in the Netherlands proposed that asthma 
and chronic airflow obstruction were opposing ends of the same disease 
spectrum [17]. They postulated that an interaction of endogenous host 
factors (airway hyperresponsiveness and allergy) and exogenous 
environmental factors (cigarette smoking) caused airway obstruction termed 
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‘chronic nonspecific lung disease’, a theory later termed the “Dutch 
hypothesis”.  
In 1963, α1-antitrypsin deficiency was identified and the high incidence of 
severe early onset emphysema among a small cohort of patients led to the 
serendipitous discovery of the only currently recognised genetic cause of 
COPD [18].  
 
1.3 EPIDEMIOLOGY 
1.3.1 Prevalence 
 
Accurate determination of the worldwide prevalence of COPD is difficult, 
since most data has been obtained from the developed world. The condition 
is under-diagnosed, particularly in its milder forms and there is often 
diagnostic uncertainty and overlap with other obstructive lung diseases, 
notably asthma [19]. The definition of COPD has evolved with time and 
even now different international guidelines do not have complete agreement 
in the way COPD is defined using spirometry [20]. The use of mortality data 
to determine prevalence is also flawed, since COPD is not accurately 
reported as a contributing factor to mortality or the cause of death. 
The prevalence of COPD is highest in countries where cigarette smoking is 
common. Smoking history has been used as a surrogate marker for the risk 
of developing COPD and estimated smoking rates suggest that there are 
approximately fifteen million cases in the USA and three million cases in 
the UK among adults over 40 years of age [21].  
In the UK, prevalence of COPD among males reached a plateau in the 
1990s, while annual rates among women continued to rise during the same 
time period. The Global Burden of Disease study calculated the worldwide 
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prevalence of COPD to be 9.34 per 1000 men and 7.33 per 1000 women in 
1990 [22]. In this analysis of over thirty studies worldwide COPD 
prevalence ranged from 4 to 10%, generally with a higher prevalence among 
males.  
Studies have also shown that the prevalence of COPD is greatest in areas of 
social deprivation [23] and since estimated prevalence rates include all age 
groups, they underestimate rates among the elderly. 
Although age-standardised mortality rates from COPD have fallen 
progressively amongst men in most developed countries, there has been a 
small but progressive increase in mortality rates among women over the last 
20 years, reflecting changing patterns of tobacco consumption. Between 
1979 and 1993, there was a 17% rise in age-adjusted mortality rates among 
American males, while the same time period saw a 126% rise among 
females [24]. In Australia, a study published in 1994 reported a 2.6 fold 
increase in age-standardised mortality among females between 1964 and 
1990 and predicted that female mortality rates would soon equal that of 
males [25]. 
In 1999, over 32,000-recorded deaths were attributed to COPD in the UK, 
representing 4.3% of male deaths and 5.9% of female deaths. Patients with 
COPD use many services in primary and secondary care and cost analysis 
for 1996-97 showed that the total NHS expenditure on COPD was more 
than ǧ818 million. In the United Kingdom, around 35% of resources are 
used for care of emergency admissions, with an average admission costing 
ǧ3000. In the 1990s there was a 50% rise in emergency hospital admissions 
for COPD and between 2000 and 2001 the 308,000 admissions cost the 
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NHS over ǧ587 million. Much of the burden on health resources comes 
from the morbidity associated with COPD.  
Work assessing the cost of COPD has mainly been carried out in the 
developed world, particularly the USA, where the National Heart, Lung and 
Blood Institute estimated the annual cost of COPD in 1993 to be $23.9 
billion [26]. Although often considered a disease of the elderly, over 9 
million people of working age in the USA have COPD, accounting for total 
lost productivity of approximately $9.9 billion [27]. Estimating the future 
burden of COPD is important and researchers in the Netherlands looked at 
anticipated changes in disease prevalence between 1994 and 2015 and 
predicted a rise in healthcare costs of 90% [28]. 
An ageing population and increasing cigarette consumption makes a 
worldwide increase in the prevalence and burden of COPD inevitable. In 
2020, it is estimated that COPD will be the fifth leading cause of disability-
adjusted life years (DALYs) worldwide, after ischaemic heart disease, 
unipolar major depression, road traffic accidents and cerebrovascular 
disease [2]. 
 
1.3.2 Aetiology 
COPD is due to a combination of environmental and genetic factors. 
1.3.2a Cigarette smoking 
Cigarette smoking is the most important risk factor for COPD, with 10-15% 
of smokers developing COPD. In the industrialized world, smoking 
accounts for 85-90% of cases of COPD among males [29]. The prevalence 
of smoking has fallen slightly among men, but has risen among women, 
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who accounted for 19% of deaths from COPD in 1970 and 38.5% in 1993 
[24]. 
In the 1800’s most tobacco was smoked in pipes or cigars, but the 20th 
century saw a rapid rise in the consumption of manufactured cigarettes. The 
health hazards of cigarette smoking were not apparent until the second half 
of the century, when data collected between 1922 and 1947 showed a 
fifteenfold increase in deaths from lung carcinoma [30]. 
Initial results from the landmark questionnaire study of doctors showed 
higher mortality rates among smokers than non-smokers and an increased 
death rate from chronic bronchitis among smokers [11]. A decade later, the 
authors concluded that chronic bronchitis and emphysema ‘chronic 
obstructive lung disease’ was as important a fatal effect of smoking as lung 
cancer [12], although they acknowledged that other factors such as air 
pollution may contribute. Data published after 40 years of follow up showed 
the risks from persistent smoking were greater than previously suspected, 
concluding that around half of chronic smokers would die as a consequence 
of their habit [14]. The final paper in the series showed that lifelong non-
smokers had an age standardized mortality rate from COPD of 0.11 per 
1000 men/year. Among current smokers the equivalent mortality rate from 
COPD was 1.56, increasing to 2.61 per 1000 men/year among those 
smoking more than twenty-five cigarettes per day [15]. 
Lung function increases through childhood and reaches a plateau in early 
adult life, after which it declines gradually. An early study concluded that 
smoking was not associated with an additional fall in FEV1 [31], but many 
subsequent cross-sectional and longitudinal studies have found that smokers 
have a more rapid decline in FEV1 than non-smokers. Fletcher and Peto 
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(1976) found that smokers had a steeper decline in lung function than non-
smokers, with the decline in FEV1 returning towards the same level as non-
smokers after stopping smoking [16].  
Despite differences between study populations, all longitudinal studies 
carried out over at least five years have found smokers to have a greater 
decline in FEV1 than non-smokers [16, 32-37]. Although large differences 
exist between individuals, the additional mean decline in FEV1 due to 
cigarette smoking is around 15 ml/year among males and around 10 ml/year 
for females. 
The detrimental effects of smoking are not limited to adult life, but can 
affect lung growth in utero, childhood and adolescence. Maternal smoking 
during pregnancy has been associated with a reduction in lung growth and 
the lung function of neonates [38], infants [39-41] and children of school 
age [42]. Exposure to maternal smoking during childhood and adolescence 
is also associated with impaired lung function [43-46]. Insults to the 
developing lung in utero and during childhood are likely to reduce the 
maximum lung function achieved and may put individuals at greater risk of 
developing COPD during adult life, depending on the individuals smoking 
habit and lifestyle. Smoking during adolescence is associated with mild 
airway obstruction and slowing of lung growth [47,48]. 
Most studies have examined the effect of cigarette smoking rather than the 
effects of pipe or cigar smoking. Cigar sales increased in the USA during 
the 1990s and although pipe smoking has declined since the 1960s, large 
numbers still use these methods of inhalation. The type of tobacco is 
probably less important than the amount smoked, the duration of smoking 
and the depth of inhalation [49], and both pipe and cigar smokers have also 
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been shown to have higher all cause mortality rates and higher rates of 
COPD than non-smokers [50-52].  
The US Environmental Protection Agency has classified environmental 
tobacco smoke (ETS) (‘passive smoking’) as a human carcinogen. Although 
maternal smoking impairs lung growth during pregnancy and childhood and 
ETS has been linked with adult-onset asthma [53], little is known about the 
role of passive smoking in the development of COPD. A prospective study 
of Californian adults over 39 years recently found no association between 
ETS and mortality from COPD in men or women [54].  
The Lung Health Study confirmed that smoking cessation reduces the rate of 
decline of FEV1 among subjects with established COPD, with the greatest 
benefit occurring in the first year after stopping smoking and the subsequent 
decline among sustained quitters was half that of ongoing smokers and 
comparable to never smokers [55,56]. Smoking cessation among subjects 
with COPD also reduces the presence of respiratory symptoms [57].  
 
1.3.2b Genetic factors 
Many studies have investigated the potential genetic determinants of COPD, 
but the only confirmed predisposing genetic factor is alpha1-antitrypsin (α1-
AT) deficiency. The first association between α1-AT deficiency and 
emphysema was made in 1963, when Laurell, a Swedish protein research 
scientist, carried out serum electrophoresis on all the patients of a senior 
respiratory physician. He and Eriksson, a research physician identified five 
subjects with α1-AT deficiency and noted that three had early onset severe 
emphysema [18]. Fourteen patients with α1-AT deficiency were reported 
two years later, of whom nine had premature emphysema [58]. Later work 
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by the same group identified the importance of the interaction between 
smoking and α1-AT deficiency and the genetic variations coding for α1-
antitrypsin. 
The name α1-antitrypsin originates from its ability to inhibit the pancreatic 
enzyme trypsin, although subsequent work found it also inhibited many 
other proteinases, including neutrophil elastase. Part of the serine proteinase 
inhibitor or ‘serpin’ superfamily, α1-antitrypsin is a 394 amino acid acute 
phase glycoprotein encoded on the long arm of chromosome 14q32.1. It is 
mainly produced by the liver and synthesised in smaller amounts by 
macrophages, neutrophils and intestinal and bronchial epithelial cells 
[59,60]. In healthy subjects, α1-AT prevents the neutrophil elastase released 
by triggered neutrophils from degrading elastic tissues in the lung [61,62]. 
The structure of α1-AT is crucial to its role as a proteinase inhibitor; made 
up of three β sheets, it has an exposed reactive loop that binds to the target 
proteinase, stimulating a change in conformation, which deactivates the 
proteinase, allowing recognition by hepatic receptors and removal from the 
circulation.  
Over 100 genetic variations of α1-AT have been described and are 
characterised by their ability to migrate on isoelectric focusing gels, giving 
rise to the proteinase inhibitor or Pi system. The most common deficiency 
variants result from a single point mutation; PiS (slow) and PiZ (very slow) 
are named because the rate of migration is slower than the normal M 
(medium) α1-AT. Occurring far less frequently are the so-called null alleles, 
which cause very low or even absent serum α1-AT levels. The inheritance of 
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a Pi phenotype follows an autosomal co-dominant pattern, with a varied 
frequency of PiS and PiZ alleles throughout the world.  
The highest prevalence of α1-AT deficiency is seen in Europe where the 
original mutations are thought to have occurred, with much lower 
frequencies in parts of the Far East. Estimates suggest approximately 1.1 
million subjects have severe α1-AT deficiency worldwide and 116 million 
carriers of the deficiency allele [63]. Not all of those with severe α1-AT 
deficiency have lung function impairment and it has been estimated that less 
than 6% of severely deficient individuals have been identified.  
The PiS allele results from a single base alteration in the gene at position 
264 (glutamic acid to valine) and the highest European frequency is on the 
Iberian peninsula [64]. Although homozygotes for PiS have α1-AT levels 
60% of normal, it is not usually associated with pulmonary complications. 
The PiS allele has a mean gene frequency in Southern Europe of 0.0564 (ie 
1 in 17 are PI∗SS, PI∗SZ or PI∗MS) [63]. The PiZ allele results from an 
amino acid alteration at position 342 (glutamic acid to lysine) and has the 
highest gene frequency in southern Scandinavia, with the frequency falling 
as you move South and East across the continent. The PiZ gene frequency in 
Europe varies between 0.01 and 0.05, with two studies finding that 
approximately 1 in 1500 individuals are homozygotes [65,66]. 
Homozygotes for the Z variant have 10-15% of the plasma α1-AT levels of 
the normal M allele. The Z mutation leads to α1-AT accumulation in the 
inclusions of hepatic rough endoplasmic reticulum. This predisposes the 
homozygote to childhood liver cirrhosis and the lack of circulating anti-
proteinase for neutrophil elastase renders individuals susceptible to 
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premature panlobular emphysema, particularly if they smoke. Debate exists 
around whether PiZ heterozygotes are at increased risk of developing COPD 
if they smoke. As well as reduced levels of α1-AT in the lung, the available 
glycoprotein is less effective at clearing neutrophil elastase. Different 
processes are involved in the development of emphysema with PiZ α1-AT, 
although the most important factor is cigarette smoking, which creates an 
environment where proteolytic enzymes are unopposed. The deficient and 
dysfunctional Z α1-AT is deactivated by the direct oxidative effect of 
smoking, which may also predispose Z α1-AT to polymerisation within the 
lung to an inactive form. The PiZ α1-AT polymer may also be 
chemoattractant to inflammatory cells, which then contribute to tissue 
breakdown [67]. 
PiZ homozygotes have a varied response to cigarette smoking, with 
differences in the severity of disease and some individuals maintaining 
normal lung function. Individual modifier genes may mediate the 
differences in severity, although none has been identified to date. There is 
however, a dose-response relationship with cigarette smoking and decline in 
forced expiratory volume in one second (FEV1) [68]. 
Genetic factors other than α1-antitrypsin deficiency are probably involved in 
COPD aetiology, though none has been identified. A small study in 1970 
found that first-degree relatives of patients with COPD have higher rates of 
airflow obstruction than relatives of spouses without COPD, although the 
study did not fully exclude subjects with α1-antitrypsin deficiency and 
differences in smoking history existed between groups [69]. A subsequent 
well-matched case-control study that excluded subjects with α1-antitrypsin 
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deficiency found a lower FEV1 among siblings of subjects with COPD than 
among siblings of controls [70]. Current and ex-smoking relatives of 
patients with early onset severe COPD had an increased risk of having a low 
FEV1 and FEV1/FVC ratio compared with controls after adjusting for age 
and pack-years of smoking [71]. There were no differences between non-
smoking relatives of cases and control, suggesting that genetic factors other 
than α1-AT deficiency interact with smoking to increase the risk of 
developing COPD. 
These findings and the variable clinical phenotype of individuals with α1-
AT deficiency suggest the development of COPD depends on a complex 
interaction of genetic and environmental factors. 
 
1.3.2c Airway hyperresponsiveness 
Airway hyperresponsiveness (AHR) describes an increased 
bronchoconstrictor response to pharmacological or physical stimuli. Non-
specific AHR is present when the airways respond to a wide range of stimuli 
and is measured in the laboratory as a change in lung function after inhaling 
increasing concentrations (or doses) of bronchoconstrictor stimuli or after 
physical insults (eg cold air or exercise).  
It was recognised in the 1960s that airway obstruction was often associated 
with airway hyperresponsiveness and subsequent work has examined the 
relationship between bronchial reactivity, smoking and FEV1. Dutch 
investigators proposed that host factors including airway 
hyperresponsiveness predispose to the development of “chronic nonspecific 
lung disease” [17]. The “Dutch hypothesis” created debate about the role of 
airway responsiveness in the pathogenesis of COPD and, specifically, 
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whether AHR is a cause or consequence of accelerated decline in FEV1. 
This issue is still being debated four decades later [72] as there is particular 
difficulty determining the exact impact of cigarette smoking and the 
geometric factors that occur with airway narrowing on airway 
hyperresponsiveness [73]. 
Smokers are more likely to have AHR than non-smokers. In a study of 227 
men, smokers had increased bronchial reactivity, which was associated with 
low initial FEV1 and the subsequent accelerated decline in FEV1 [74]. 
Follow up of the male smokers confirmed an accelerated decline in FEV1 
and an increase in bronchial reactivity as FEV1 fell [75].  
Airway hyperresponsiveness was associated with an accelerated decline of 
FEV1 in a four-year longitudinal study among subjects over 65 [76] and 
among middle-aged and older men in the Normative Aging Study [77]. The 
Lung Health study followed over 5000 patients with mild-moderate COPD 
for five years and measured AHR at intervals. The majority of subjects had 
increased bronchial reactivity at the start of the study and AHR predicted an 
accelerated decline in FEV1 among continuing smokers [78].  
A Dutch cohort study of risk factors for obstructive lung disease followed 
2000 subjects over three decades and after accounting for cigarette smoking, 
found that AHR was associated with an accelerated decline in FEV1, the 
development of respiratory symptoms (cough, sputum production, dyspnoea 
and wheeze) and increased mortality from COPD [79-81].  
 
1.3.2d Atopy  
Whether atopy predisposes or contributes to the pathophysiology of COPD 
also remains a matter for debate. Serum eosinophil count, total IgE and/or 
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skin prick testing have all been used to determine an allergic diathesis, but 
the interaction with cigarette smoking again complicates matters, since 
smoking has been associated with increased serum IgE [82] and eosinophil 
levels [83], but, a reduction in skin test reactivity [84].  
Studies have examined the relationship between atopy and respiratory 
symptoms and, more importantly, atopy and rate of decline of FEV1. The 
Vlagttwedde-Vlaardingen study found that serum eosinophilia was 
associated with increased respiratory symptoms and bronchial reactivity 
[85,86] and although an increased serum eosinophil count has been 
associated with a reduced FEV1 in individual studies [87], longitudinal 
studies have not consistently found an accelerated decline in FEV1 [88]. 
Similarly, elevated IgE levels have been associated with reduced FEV1 [76], 
but not an accelerated decline in FEV1 after adjusting for smoking [89]. 
Taylor and colleagues excluded asthma among 237 men and found no 
relationship between positive skin test results and decline in FEV1 over 
seven years [83], a finding similar to that seen in working men in Paris [90]. 
However, skin test positivity predicted an additional decline in FEV1 over 
three years in the Normative Aging Study [91] and a positive skin test result 
was associated with accelerated decline in FEV1 over five years among 
smokers in an occupational setting [92]. 
 
1.3.2e Chronic mucus hypersecretion 
The ‘British hypothesis’ that mucus hypersecretion is involved in the 
aetiology of COPD was undermined by the classic work of Fletcher and 
Peto [16]. They found that although both chronic mucus hypersecretion and 
progressive airflow obstruction occurred in cigarette smokers, their 
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influence on decline in FEV1 and survival was different and concluded that 
they should be considered separately. No link was found between mucus 
hypersecretion and mortality from COPD after 20-25 years of follow-up; 
one section of the paper was entitled ‘The irrelevance of mucus 
hypersecretion to COPD’ [93].   
A recent large longitudinal study reached different conclusions. The 
Copenhagen City Heart Study followed 9000 people for five years and 
found that chronic mucus hypersecretion was associated with an excess 
decline in FEV1 of 13ml and 23ml per year in women and men respectively, 
after adjusting for smoking and age [94].  
The study also found a relationship between mucus hypersecretion, all cause 
mortality and mortality from chronic obstructive lung disease [95]. The 
increased mortality may relate to systemic inflammation and chest 
infections. Subjects with chronic mucus hypersecretion had an increased 
risk of hospitalisation, even after adjusting for baseline FEV1 and further 
analysis of the data found that subjects with COPD and chronic mucus 
hypersecretion were more likely to die from pulmonary infections than those 
without mucus hypersecretion [96]. 
 
1.3.2f Bronchopulmonary infections 
Retrospective studies have shown that lower respiratory tract illnesses 
during childhood and adolescence are associated with a reduced level of 
lung function in later life [97-99]. It is however difficult to ascertain whether 
impaired lung function is the cause of infections or develops as a 
consequence. 
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The theory that recurrent bronchopulmonary infections during adult life are 
important in the development of chronic bronchitis and emphysema was 
originally rejected [16]. The cohort included subjects with mild or no 
airflow obstruction however and an infection was only diagnosed on 
individual recollection. 
The Lung Health Study found that smokers and intermittent quitters had an 
increased decline in FEV1 of 7ml/year for each lower respiratory tract illness 
[100]. Other recent evidence also supports the “British hypothesis”. Patients 
with COPD classed as frequent exacerbators had a greater decline in FEV1 
over four years (by 8 ml/year) than infrequent exacerbators
 
[101]. The same 
group found that a high or rising airway bacterial load was associated with 
an accelerated decline in FEV1 [102] and bacterial colonisation of the 
airways was associated with an increase in exacerbation frequency [103].   
 
1.3.2g Occupation 
Although an association between occupational exposures and respiratory 
symptoms has been recognised since ancient times, the association between 
occupational exposures and COPD specifically has only been recognised 
recently. Teasing out the precise effect of occupation on lung function can 
be difficult in a workforce where smoking is prevelant and where the 
“healthy worker effect” (ie subjects with good lung function are more likely 
to enter the workforce) and the “survival effect” (ie affected workers are 
withdrawn early) may be operative. Although the effect of occupational 
exposure for a particular workforce may be small, a large population is at 
risk and interactions with smoking make occupational exposure an 
important factor in the incidence of COPD. 
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Many recent studies have examined the link between occupational 
exposures and COPD, including studies from Europe, China and the USA, 
and involving both urban and rural workforces. Despite geographical and 
population differences, the results from cross-sectional and longitudinal 
studies have generally found that those subjects exposed to dusty working 
environments are more likely to develop COPD than those working in non-
dusty environment. Other specific factors include fume exposure though the 
effect is less marked than with dust exposure [104-107]. The risk of 
developing COPD from occupational exposure to dust or fumes is generally 
less than that associated with cigarette smoking. 
A variety of specific occupational exposures (coal dust, silica, cadmium and 
cotton) have been associated with airflow obstruction and an accelerated 
decline of FEV1.  
COPD is now a compensatable occupational disease in coal miners in the 
United Kingdom, since it is now accepted that exposure to coal dust 
accelerates decline in FEV1, independent of cigarette smoking and the 
presence of pneumoconiosis [108]. Centrilobular emphysema was more 
common at autopsy of miners than non-miners, with an association between 
dust exposure and degree of emphysema [109]. The effect of coal dust 
exposure and cigarette smoking appears to be additive on FEV1 decline 
[110].  
Many studies have demonstrated an increased risk of respiratory symptoms 
among workers exposed to silica, including foundry workers, quarrymen 
and goldminers. Longitudinal studies in South Africa found that decline in 
lung function was related to the silica content of gold mine dust [111] and 
the detrimental effects are particularly high among smokers [112]. The 
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higher risk of developing COPD among gold miners compared to coal 
miners is likely to relate to the higher silica content of gold mine dust [111]. 
Cadmium is an unusual occupational cause of COPD, since it causes 
emphysema. A long half-life and hepatic storage allows accurate 
measurement of cadmium exposure many years after exposure. In a case-
control study of copper-cadmium alloy foundry workers, high occupational 
exposure to cadmium was associated with an accelerated decline in FEV1 
and the transfer factor for carbon monoxide [113].  
Workers exposed to cotton dust have increased respiratory symptoms [114] 
and an accelerated decline in FEV1. The effect on FEV1 has been 
demonstrated in longitudinal occupational studies from Europe, India and 
China [115,116] and it has been proposed that adverse effects associated 
with cotton exposure relate to endotoxin content of cotton mill dust [117]. 
 
1.3.2h Gender 
The prevalence of COPD has been generally greater among men than 
women, probably because men have smoked more cigarettes, inhaled more 
deeply and started smoking at an earlier age. Women may be more 
susceptible to developing COPD however. Compared with lifetime non-
smokers, the estimated excess decline in FEV1 for light, moderate, and 
heavy continuing smokers in the Vlagtwedde-Vlaardingen study was 4.4, 
9.5 and 13.5 ml per year for men and 6.1, 10.8 and 18.8 ml per year for 
women, respectively [37]. Women had greater bronchial reactivity than men 
for all age groups in a study of 1700 Italian subjects, even after accounting 
for baseline lung function [118]. A large population study in Denmark found 
that women who smoked had a more rapid decline in FEV1 and a higher risk 
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of hospitalisation from COPD than men [119]. A study of first-degree 
relatives of subjects with severe, early onset COPD found that female 
relatives were more likely to have a reduced FEV1 [120].  
 
1.3.2i  Biomass fuels 
Work in the 1960s in Papua New Guinea identified chronic bronchitis and 
obstructive arways disease in non-smokers and postulated the aetiolgical 
role of domestic wood smoke. It is now accepted that in the developing 
world, exposure to household smoke generated from the use of biomass 
fuels is an important cause of COPD, particularly among women [121]. 
Around 75% of households in the developing world use biomass fuels for 
cooking and indoor air pollution has been thought to account for half the 
cases of COPD in certain areas [122]. 
 
1.3.2j Air pollution 
The nature of air pollution has changed over the last fifty years, particularly 
in the Western world. The great smogs of the 1950s in the UK were due to 
the accumulation of fog and air pollution and consisted mainly of black 
smoke and sulphur dioxide. The risk of death following air pollution 
episodes was dramatically demonstrated after the London smog of 1952 
where there were over 4000 excess deaths [123]; many occurred in people 
with what would now be known as COPD. The subsequent ‘Clean Air Acts’ 
led to a move away from burning coal in urban areas, although emissions 
from other sources have increased. Air pollution in Westernised countries 
now consists mainly of nitrogen dioxide, ozone and particles generated by a 
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combination of motor vehicle emissions, burning of fossil fuels and heavy 
industry. Sulphur dioxide contributes to a lesser extent that in the 1950s. 
Current levels of air pollution have detrimental effects on health, both 
chronic effects from long-term exposure and acute effects from air pollution 
episodes. Air pollutants can increase oxidative stress and produce a pro-
inflammatory response in the lungs, increasing airway mucous production 
and impairing ciliary function. 
Chronic exposure to elevated levels of air pollution contributes to all cause 
morbidity and mortality. To what extent chronic exposure influences 
subjects with COPD is less clear. Long-term exposure to high levels of air 
pollution has been associated with factors that may predispose to the 
development of COPD; impaired lung growth in childhood [124], mucus 
hypersecretion, bronchial hyperresponsiveness and low FEV1 [125,126]. 
The ‘Six Cities’ study demonstrated increased mortality in urban areas with 
high levels of air pollution, without showing a specific effect in subjects 
with COPD [127,128]. 
Studies have examined the temporal relationship between air pollution 
episodes, rates of hospitalisation, overall mortality and mortality from 
COPD. Hospital admissions from COPD have risen following air pollution 
episodes [129,130] and fallen after periods of reduced air pollution [131]. 
Air pollution episodes have been associated with increased mortality from 
various causes, including COPD; particulate matter may be particularly 
harmful [132-135]. 
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1.3.2k  Social class and nutrition 
The finding that the prevalence of respiratory symptoms increases with 
lower socio-economic status is likely to be multifactorial, with contributions 
from maternal smoking during pregnancy, increased childhood infections, 
passive smoke, urban air pollution, poor housing and diet.  
In the Copenhagen City Heart Study, the incidence of COPD was greatest in 
subjects with low socio-economic status, with FEV1 and exacerbation rates 
related to educational level and income after adjustment for smoking [136]. 
Unskilled workers had a greater decline in FEV1 over twelve years than 
skilled workers in Paris after adjusting for occupation and smoking [137]. 
Education level has also been related to FEV1, with adults who only had a 
primary school education being 2.9 times as likely to have obstructive lung 
disease than those with a university education after adjusting for age, sex, 
smoking and occupation [138]. 
Several epidemiological studies have examined the role of diet in the 
pathogenesis of COPD. Increased intake of certain vitamins (A, C and E) 
has been associated with improved lung function in some populations 
[139,140]. A diet rich in fresh fruit and vegetables appeared to reduce the 
risk of COPD in one study [141] and high fish and fruit intake was 
associated with reduced COPD mortality in the Seven Countries study [142]. 
Subjects with high dietary intake of fish (n-3 fatty acids) had a reduced risk 
of developing COPD in another study [143].  
None of the dietary studies in COPD have been interventional however and 
it is not known whether poor diet simply reflects poor general health and 
socio-economic status and therefore exposure to other factors that would 
influence these outcomes. 
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1.4 NATURAL HISTORY 
Healthy subjects have maximal lung function between the ages of 20 and 25. 
A relative plateau follows and the FEV1 then gradually declines by around 
30 ml per year. Smokers have a greater mean annual decline in lung 
function than non-smokers, with an average fall in FEV1 of around 40 - 50 
ml per year. Although most smokers have little additional loss of lung 
function, a minority of ‘susceptible’ smokers have an accelerated decline in 
FEV1, with substantial damage occurring more frequently among heavy 
smokers.  
In susceptible individuals, lung function deteriorates over time until 
symptoms of cough, sputum production and dyspnoea develop, often in the 
fifth and sixth decades when the FEV1 has fallen to around 50% of the 
predicted value.  
Symptoms will progress and gradually be accompanied by exercise 
limitation, disability and an impaired quality of life as the lung function 
declines. As COPD becomes more severe, gas exchange is impaired and 
patients develop hypoxaemia. This can lead to increased pulmonary artery 
pressures and the subsequent development of pulmonary hypertension [144-
146]. The pulmonary artery pressure increases by 0.5 – 3.0 mmHg per year 
in severe COPD, causing right ventricular hypertrophy. In the late stages of 
COPD, individuals develop respiratory failure with associated cor 
pulmonale. Once present, the five-year survival is only 30-40%.  
Some patients with severe COPD have significant alveolar hypoventilation 
and will develop chronic type 2 respiratory failure, with hypoxaemia and 
hypercapnia. Secondary polycythaemia occurs as a result of long-term 
hypoxaemia, with an associated increased risk of vascular events. Muscle 
 37 
mass falls as COPD progresses and although this may be due to 
deconditioning, systemic inflammation may also contribute; weight loss 
often occurs and is associated with increased serum levels of tumour 
necrosis factor-alpha (TNF-α) [147]. Peripheral muscle weakness is 
associated with a transition from oxidative to the less energy-efficient 
glycolytic metabolism [148]. A body mass index (BMI) of less than 20 
kg/m2 in the presence of severe COPD is a strong predictor of mortality 
[149].  
Exacerbations with worsening respiratory failure become more frequent as 
COPD deteriorates, with some exacerbations requiring hospitalisation. The 
development of acute type 2 respiratory failure has a poor prognosis, 
particulary when complicated by a respiratory acidosis. Other predictors of 
poor survival include smoking, ischaemic heart disease, chronic mucus 
hypersecretion and male gender. 
Smoking cessation remains the only intervention known to alter the long-
term rate of decline in FEV1 in patients with COPD. Although oxygen can 
benefit some patients with COPD and severe hypoxaemia, it does not affect 
FEV1. Bronchodilators do not appear to change the rate of decline in FEV1, 
but controversy surrounds the relationship between inhaled steroids and rate 
of change in FEV1. The difficulty in formulating a precise conclusion about 
the relationship is highlighted by the conflicting conclusions of two meta-
analyses [150, 151]. Highland et al examined data from six randomised, 
placebo-controlled studies, encompassing 3571 patients with COPD and 
concluded that inhaled corticosteroid use was not associated with the rate of 
FEV1 decline [150]. Sutherland et al used the same data and results from 
two other small studies, but used different methodology and statistical 
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analysis and concluded that inhaled steroids used for over two years slows 
the rate of FEV1 decline in COPD by 7.7 ml per year [151]. 
 
1.5 PATHOLOGY 
The main pathological changes seen in COPD include thickening of the 
airway wall, excessive mucus in the airway lumen and widespread 
emphysema. Inflammation leads to airway remodelling and narrowing, with 
neutrophils, macrophages and T lymphocytes identified as the most 
important inflammatory cells. Numerous techniques including lavage 
samples, induced sputum and bronchial biopsies have been used to identify 
the cells and inflammatory mediators involved in COPD pathogenesis, but 
the results have not always been consistent.  
The central and peripheral airway walls are thickened, particularly the 
cartilaginous bronchi between two and four millimetres in diameter. 
Submucosal gland hypertrophy occurs and the volume and number of goblet 
cells is increased [152,153] and squamous metaplasia leads to fewer ciliated 
epithelial cells with shortened cilia [154,155]. Macrophages and T 
lymphocytes (predominantly CD8+ cells) are seen in the airway wall and 
smooth muscle and as airflow obstruction progresses, the inflammatory cell 
count increases.  
There are increased numbers of macrophages and neutrophils in the airway 
lumen [156,157]. Neutrophils cause mucous metaplasia and luminal 
narrowing and are an important component of the protease/anti-protease 
imbalance implicated in pathogenesis of emphysema. Neutrophils can 
enhance connective tissue destruction through the release of elastase and 
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other inflammatory cytokines. These include matrix metalloproteases 
(MMPs), some of which degrade collagen and elastin in vitro. 
Macrophages are the most prominent inflammatory cells seen in lavage and 
sputum studies and they also produce a range of inflammatory mediators 
(including MMPs). Studies examining the relationship between COPD and 
matrix metalloproteases have produced inconsistent results. Increased 
expression of gelatinase A and B (MMP2 and MMP9) and collagenase 1 
and 2 (MMP1 and MMP8) have been found in BAL fluid from subjects with 
emphysema however [158]. 
CD8+ T cells play an important role in the defence against respiratory 
viruses, but whether they also contribute to COPD development is unclear. 
A positive viral culture can be detected in around 40% of acute 
exacerbations [159,160] and progression of emphysema has been associated 
with increased adenoviral E1A protein expression [161]. The defence 
against viruses may have some detrimental effects; the release of lytic 
agents from CD8+ cells and interactions with other agents could amplify the 
inflammatory response. 
Pulmonary vessels are also infiltrated and thickened by inflammatory cells 
(particularly T lymphocytes) and the intimal thickening increases as airflow 
obstuction progresses [162,163].  
There is limited information on the pathological changes that occur during 
an acute exacerbation of COPD. Bronchial biopsies taken during an 
exacerbation have found an increase in airway wall eosinophils, neutrophils 
and activated T lymphocytes, with increased chemokine activity [164,165].  
The role of pro-inflammatory cytokines in an acute exacerbation remains 
unclear. Although studies have found increases in tumour necrosis factor 
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and interleukin-6 levels, the results for other cytokines (including 
interleukin-8) have been inconsistent [166,167].  
 
 
1.6 PHYSIOLOGY 
 
 
The aim of the respiratory system is to exchange oxygen and carbon dioxide 
in order to meet the metabolic needs of the body. The exchange of O2 and 
CO2 between air and blood is closely regulated and control of ventilation is 
a complex interaction between central controllers within the brain, 
peripheral receptors that sense changes around the body and respiratory 
muscles. The amount of oxygen in inspired air, cardiac output and the 
metabolic demands of the body are important contributors to gas exchange.  
The central respiratory centres are collections of neurones found in the pons 
and medulla, with the dorsal medullary centre mainly involved in inspiration 
and the ventral medullary centre mainly involved in expiration. The 
inspiratory centre generates nervous impulses which are transmitted to the 
diaphragm and other respiratory muscles and a pontine ‘pneumotaxic centre’ 
can inhibit inspiration, regulating rate and inspiratory volume. Inspiratory 
centre output can be further modulated by the vagus and glossopharyngeal 
nerves. Expiratory centres are activated during more forceful breathing and 
are quiescent during passive breathing. Breathing is under voluntary control 
to a degree and the cortex can partially override the brainstem, with other 
parts of the brain influencing breathing during periods of high emotion. 
Central chemoreceptors respond to a change in the chemical make up of the 
blood or surrounding fluid. The most important receptors are on the ventral 
surface of the medulla and respond to a change in pH of brain extracellular 
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fluid, with an increase in H+ concentration stimulating ventilation. The 
blood CO2 level chiefly regulates breathing by its effect on the pH of CSF 
and the cerebral vasodilatation associated with hypercapnia enhances CO2 
transfer from blood to CSF. 
Peripheral chemoreceptors in the carotid and aortic bodies, unlike central 
chemoreceptors, respond to a fall in PaO2 as well as a rise in PaCO2. The 
response to falls in partial pressure of arterial oxygen is very small with a 
PaO2 of over 100 mmHg, but below this point the activity rises sharply. All 
human responses to hypoxaemia are regulated by peripheral 
chemoreceptors, whereas they contribute less to the response to hypercapnia 
than central chemoreceptors. The carotid, but not the aortic chemoreceptors 
also respond to a fall in pH. 
Respiratory gas disturbances are the consequence of an interaction between 
ventilation-perfusion abnormalities, alveolar ventilation, cardiac output, 
oxygen consumption and carbon dioxide production. 
Hypoxaemia occurs if one of four processes occurs: ventilation–perfusion 
mismatch, alveolar hypoventilation, shunt or impaired diffusion, whereas 
the presence of hypercapnia generally reflects alveolar hypoventilation.  
The degree of ventilation-perfusion inequality is the main cause of 
hypoxaemia in disease and can be assessed from an arterial blood gas 
sample by calculating the alveolar-arterial PO2 difference. In a perfect lung, 
ventilation and perfusion are matched. In reality, there are differences in the 
distribution of ventilation and perfusion in the healthy lung, which range 
from some areas of ventilated lungs having no perfusion and some perfused 
areas of lung having no ventilation. Alveoli with no ventilation will have the 
same PaO2 and PaCO2 as mixed venous blood and alveoli with no perfusion 
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have the same PaO2 and PaCO2 as inspired gas. Most alveoli lie between 
these extremes and have a PaO2 and PaCO2 which lie in the range between 
that of inspired gas and mixed venous blood.  
In the healthy lung, most alveoli have a V/Q ratio of 0.5 to 2.0, a range that 
increases with age and disease. While unventilated alveolar units are classed 
as ‘intrapulmonary shunt’, unperfused units are classed as dead space. 
Increased dead space is overcome by an increase in minute volume and 
shunts up to 30% can be overcome by increasing the inspired oxygen 
concentration. 
Cardiac output influences respiratory gas exchange. An increase in cardiac 
output increases pulmonary arterial and venous pressures and leads to 
recruitment and distension of pulmonary capillaries. If perfusion increases 
more than ventilation, V/Q mismatch can increase. Enhanced tissue 
perfusion will follow a rise in cardiac output and the subsequent increase in 
venous return will lead to a flux of CO2 to the lungs which stimulates 
ventilation, a mechanism named ‘cardiodynamic hyperpnoea’.  
It is important to consider the influence of an increased carbon dioxide 
production on PaCO2. The amount of CO2 produced is a function of the 
metabolic rate and the substrate used for fuel. In healthy subjects, the 
absorption and metabolism of carbohydrate loads causes an increase in CO2 
output. Interventions which increase the metabolic rate increase CO2 
production and stimulate ventilation.  
The work of breathing is produced by respiratory muscles stretching the 
elastic tissues of the chest wall and lungs and moving air through the 
respiratory passages. Work is proportional to the pressure change (change in 
transpulmonary pressure needed to overcome the elastic work of breathing 
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and the resistive work of breathing) times the volume change (tidal volume). 
In healthy lungs and during passive breathing, the work of breathing is 
performed by the inspiratory muscles alone. Half of the work is dissipated as 
heat overcoming the frictional forces opposing inspiration and half is stored 
as potential energy in the elastic tissues within the lung and chest wall. 
Stored energy becomes the energy source for expiration and is dissipated as 
heat to overcome the friction resisting expiration. The work of expiration in 
healthy lungs is therefore transferred to inspiratory muscles.  
The work performed by the respiratory muscles is very small in the healthy 
resting subject, with oxygen consumption in the respiratory muscles 
contributing less than 3% of the metabolic rate. In this situation, the 
respiratory muscles are only 10% efficient. The oxygen cost of breathing 
can increase to as much as 30% in a healthy individual during exercise. 
During exercise larger tidal volumes result in increased work of breathing to 
overcome the elastic recoil of the lungs and chest wall during inspiration. 
The lungs are less compliant at high volumes and the elastic recoil of the 
lungs is inward at high thoracic volumes. High airflow rates result in greater 
airway resistance, with turbulence and dynamic airway collapse. Healthy 
adults can increase minute ventilation from 6 L/min to 150 L/min, but 
cardiac output can only increase 4-6 fold. In healthy adults the increase in 
oxygen transport with exercise can be 15-20 times the resting rate. PaO2 
stays constant during exercise, as does PaCO2 until anaerobic threshold is 
reached and lactic acid is produced.  
The work of breathing is increased during disease and efficiency falls as 
minute volume increases. In disease, individuals select a respiratory 
frequency close to the level that minimises respiratory work. 
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Subjects with severe COPD working at maximum exercise capacity can 
only increase oxygen consumption by a factor of 4. The limitation occurs 
because the lungs are unable to match pulmonary O2 uptake and CO2 
elimination to the increased whole body level of O2 consumption and CO2 
production that accompanies exercise. 
In subjects with COPD, more work is required to overcome inspiratory 
frictional resistance as airway obstruction progresses and the oxygen cost of 
breathing is not only much higher at resting minute volumes, but rises 
steeply as ventilation is increased. As maximum ventilation is approached, a 
further increase in ventilation could mean that respiratory muscles are 
consuming more oxygen than is available to the rest of the body. When 
respiratory muscles have been severely stretched, they contract with less 
strength and muscle fatigue is likely to contribute to ventilatory failure. The 
high rate of activity of respiratory muscles makes them more susceptible to 
weakness in the context of reduced oxygen supply.  
In COPD there is increased dead space as a result of alveoli being replaced 
by emphysematous air sacs and the presence of uneven alveolar ventilation 
and perfusion leads to the development of hypoxia. The mismatch between 
ventilation and perfusion is partially ameliorated by a compensatory 
mechanism of hypoxic vasoconstriction and collateral ventilation. The blood 
supply is thus limited in those areas of the lung with low alveolar PaO2, 
minimising the degree of hypoxaemia. Some subjects with severe COPD 
develop a persistent high PaCO2, which may reflect a reduction in the 
sensitivity of peripheral chemoreceptors. 
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A series of scientific breakthroughs in the 20th century led from the concept 
that cells have a “receptive substance” [168] to the identification and 
subdivision of adrenergic receptors and the evolution of pharmacological 
agents specifically directed towards these receptors. This chapter examines 
the nature of the most important pulmonary adrenoceptor; the β2-
adrenoceptor and looks at the pharmacology of β2-agonists. 
 
2.1 THE HUMAN β2-ADRENOCEPTOR  
2.1.1 Background 
 
Bates, an American ophthalmologist, first reported the discovery of a 
substance produced by the adrenal gland in 1886, which was later isolated 
and identified as epinephrine by a Polish physiologist, Cybulski, and a 
research team at the John Hopkins University, Baltimore, led by Professor 
Abel. In 1901 a Japanese chemist, Takamine, isolated the same hormone 
from the adrenal medulla, and called it adrenaline. The German chemist, 
Stolz, synthesized adrenaline in 1904 and over forty years later, the Swedish 
scientist, von Euler, identified the sympathetic neurotransmitter 
noradrenaline. 
The concept that the adrenergic receptor existed in two forms was first 
suggested following experimental work conducted in the 1940s to find a 
drug that relaxed the human uterus. Ahlquist compared the effects of 
catecholamines on a range of target tissues and after finding different 
responses, determined the rank order of potency of adrenaline, noradrenaline 
and isoprenaline (a synthetic derivative of noradrenaline) on each tissue. 
These results led him to propose that distinct adrenergic receptor types 
existed, which he classified as α- and β-receptors [169].  
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Lands and colleagues subdivided the β-receptor into β1- and β2- subtypes 
after correlating the effects of catecholamines on lipolysis and cardiac 
stimulation (β1-effects) and bronchodilatation and vasodepression (β2-
effects). The order of potency was Isoprenaline > Adrenaline = 
Noradrenaline at the β1-receptor and Isoprenaline > Adrenaline > 
Noradrenaline at the β2-receptor  [170].  
β1-receptors predominate in the heart, with β2-receptors found in the lungs, 
heart, skeletal muscle, blood vessels, uterus, bladder and brain. β3-receptors 
have since been identified and although not present in the human lung [171], 
they are found in the heart, adipose tissue, gastrointestinal tract, brain, 
skeletal muscle and urogenital tract. Their main functions appear to be 
lipolysis and thermogenesis. 
2.1.2 Structure/Function  
 
The β-adrenoceptor is a 413 amino acid protein (Figure 2.1), the product of 
a 1242 base pair gene located on the long arm of chromosome five (5q31-
32). Like other members of the G protein-coupled receptor family, the β-
adrenoceptor has an extracellular amino-terminus, seven hydrophobic 
transmembrane-spanning domains and an intracellular carboxy-terminus, 
with three extracellular and three intracellular hydrophilic loops. A fourth 
cytoplasmic loop forms when cysteine at position 341 in the carboxy-
terminus forms a covalent bond with fatty acids in the membrane protein 
(palmitoylation) thus anchoring part of the cytoplasmic tail to the plasma 
membrane. The three β-adrenoceptor subtypes have structural similarities; 
the β2-receptor shares around 54% amino acid sequence homology with the 
β1-receptor and 50% with the β3-receptor. 
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Figure 2.1: The human ȕ2-adrenoceptor. The sites of receptor 
polymorphisms are demonstrated (Ɣ), together with the amino acid residues 
involved in agonist binding (Ɣ). 
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Agonist binding to the β2-adrenoceptor alters the receptor structure, causing 
activation of the guanine nucleotide-binding protein (G protein). Site-
directed mutagenesis studies have determined that the critical sites of 
agonist binding are in a “pocket” between the third and sixth transmembrane 
domains [172]. β2-agonists bind to amino acids on the third (Aspartate 113), 
fifth (Serine 204, 207) and sixth (Asparagine 293) transmembrane domains 
[173,174] (Figure 3.1). The part of the receptor that activates the G protein 
has been localised to part of the third and fourth intracellular loops 
[175](Figure 2.2).  
The β2-adrenoceptor oscillates between active and inactive states, achieving 
equilibrium in resting conditions, with the inactive state in predominance. In 
the active state the receptor is associated with the Į subunit of the G protein 
and the inactive state when the Į subunit is dissociated. 
 
2.1.3  Location 
Autoradiographic localization studies in ferrets and subsequently on human 
lungs have shown numerous β–receptors in all airways. The receptor density 
increases as airways became smaller, with the highest density on the 
smallest bronchioles, with β2-receptors outnumbering β1-receptors by 
approximately 3:1. β2-receptors are present in higher density on airway 
epithelium and submucosal glands than airway smooth muscle, with greatest 
numbers in alveolar walls (90%). 10% of submucosal and 30% of alveolar 
receptors are of the β1–subtype [176,177]. 
In situ hybridisation of human lung tissue showed that the distribution of β–
receptor subtype mRNA was similar to that of binding sites [178]. Large 
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amounts of β2-receptor mRNA are found in airway smooth muscle relative 
to the number of binding sites, which may reflect high receptor turnover and 
protect against the development of bronchodilator tolerance. 
 
2.1.4   Intracellular mechanisms of action  
 
Binding of the adrenoceptor by the β2-agonist activates a G protein, 
changing the G protein conformation, allowing guanosine diphosphate 
(GDP) bound to the α subunit to be replaced by guanosine triphosphate 
(GTP). The activated α subunit then dissociates from the other two subunits 
(ȕȖ), diffuses within the plasma membrane to bind and activate adenylyl 
cyclase. This catalyses the conversion of adenosine triphosphate (ATP) into 
cyclic 3’5’ adenosine monphosphate (cyclic AMP). This intracellular second 
messenger causes airway smooth muscle relaxation through a number of 
protein kinase A (PKA)-mediated mechanisms which include: 
1. Inhibition of inositol phospholipid hydrolysis [179]  
2. Inhibition of myosin light chain phosphorylation [180]  
3. Reduced release of intracellular calcium ions [181] 
4. Increased Na+/K+ adenosine triphosphatase [181]  
5. Stimulation of calcium-activated potassium channels (maxi-K 
channels) [182]  
 
Not all β2-agonist related smooth muscle relaxation is cAMP dependent 
since the G protein α-subunit can open large conductance potassium 
channels (maxi-K channels) in smooth muscle, an effect seen in vitro with 
concentrations of β-agonist that do not cause a rise in cAMP [183]. 
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Protein kinase A can also increase β2-adrenoceptor gene transcription by 
phosphorylating cAMP response element binding protein (CREB) in the 
nucleus, and thus activating cAMP response element (CRE) in the upstream 
promoter region of the β2-adrenoceptor gene. 
 
2.1.5   Desensitisation 
Prolonged exposure to a given dose of β2-agonist in vitro and in vivo leads 
to a reduced response over time (‘desensitisation’). ‘Tachyphylaxis’ refers 
to short-term desensitisation and ‘tolerance’ to desensitisation after 
prolonged exposure. Several mechanisms contribute to these effects (Figure 
2.2), including; 
1) β-arrestin binding. Within seconds of agonist-receptor binding, β-
adrenergic receptor kinase (βARK), a G protein kinase (GRK), anchors to 
the two dissociated G protein subunits (βγ) to phosphorylate sites on the 
carboxy tail [184,185]. Phosphorylation of the receptor by βARK does not 
directly cause desensitisation, but enhances binding of β-arrestin, a protein 
that uncouples the receptor from GĮs protein and limits receptor function. 
cAMP-dependant protein kinases also contribute to desensitisation by 
phosphorylating other parts of the third intracellular loop and carboxy tail.  
2) Receptor internalisation / Sequestration. The β2-adrenoceptor becomes 
internalised to a subcellular compartment within minutes of agonist 
exposure and cannot activate the G protein.
 
The process is maximal around 
30 minutes and is mediated by βARK/β-arrestin and a tyrosine residue in 
the seventh transmembrane domain [186]. Removal of the β2-agonist allows 
the receptor to return to the cell surface ‘resensitised’. 
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Figure 2.2: The third intracellular loop and carboxy terminal of the human 
ȕ2-adrenoceptor. The sites of G-protein coupling and areas involved in 
receptor desensitisation are identified. 
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3) Down-regulation. Longer-term exposure to β2-agonists causes a reduction 
in the levels and stability of receptor mRNA and a decrease in the rate of 
receptor gene transcription. Once receptor degradation has occurred, new 
receptors must be synthesized to restore responsiveness. 
‘Homologous desensitisation’ describes the reduced responsiveness to β-
agonists. Desensitisation of the β2-adrenoceptor to other agonists also occurs 
and is termed ‘heterologous desensitisation’. 
 
2.1.6 Receptor cross-talk 
Stimulation of the β2-adrenoceptor can alter the activity of other receptors 
and similarly, activity at other receptors can influence β2-receptor function. 
The interactions with corticosteroid and muscarinic receptors are of 
particular importance.  
Phosphorylation of the glucocorticoid receptor by ȕ-arrestin-induced 
mitogen-activated protein kinase (MAPK) makes the β2-receptor more 
sensitive to steroid-induced activation. Glucocorticoids can increase ȕ2-
receptor expression in human lung tissue and restore downregulated 
receptors to normal levels, although high ȕ2-agonist concentrations may 
inhibit some of the anti-inflammory effect of glucocorticoids [187]. 
Furthermore, muscarinic M2 receptors have the opposite effect to ȕ2-
agonists on maxi-K channels and, inflammatory mediators such as 
acetylcholine can activate smooth muscle receptors that uncouple and 
downregulate β2-receptors via phospholipase C and protein kinase C. 
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2.1.7 Genetic polymorphism 
Nine single base polymorphisms in the coding region of the β2-adrenoceptor 
gene have been identified. Five are clinically silent because the encoded 
amino acid is unchanged, but four result in a single amino acid change in 
receptor structure. Studies using site-directed mutagenesis and recombitant 
expression suggest that the polymorphisms at positions 16, 27 and 164 may 
alter receptor function, whilst that at position 34 does not.  
The two most common receptor variants are in the extracellular amino 
terminus, characterised by substitution of glycine (Gly) for arginine (Arg) at 
position 16 and glutamic acid (Glu) for glutamine (Gln) at position 27, 
occuring with an allelic frequency of around 60-70% and 40-50% 
respectively.  
The other polymorphisms that alter the ȕ2-receptor amino acid sequence 
occur infrequently. Substitution of threonine (Thr) by isoleucine (Ile) at 
position 164 has an allelic frequency of less than 5%, whilst substitution of 
valine (Val) by methionine (Met) at position 34 occurs in less than 1% of 
subjects [188].  
Cells with the Ile 164 polymorphism have lower affinity for adrenaline and 
noradrenaline [189] and lower adenylyl cyclase levels after agonist 
stimulation [190]. This may relate to the proximity of the polymorphism to 
serine at position 165, which has a role in agonist binding. 
Linkage disequilibrium (when a combination of alleles occur at a higher or 
lower than expected frequency) occurs between the polymorphisms at 
positions 16 and 27. The combination of Arg 16-Glu 27 is rare and when 
individuals have Arg 16 they are likely to have Gln at position 27 [190]. 
Since most individuals are heterozygotes, large populations are required to 
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study the relationship between individual β2-receptor polymorphisms and 
disease phenotypes. 
Three combinations of polymorphisms (haplotypes) at positions 16 and 27 
account for most of the population; Arg-Gly/Gln-Glu (26-33%), Gly-
Gly/Glu-Glu (18-29%) and Gly-Gly/Gln-Glu (15-22%) [191-193].  
Although early studies suggested that the Gly 16 genotype was associated 
with more severe asthma, a recent large study showed no difference in 
distribution of ȕ2-adrenoceptor polymorphisms between the normal 
population and those with airways disease and no relationship with asthma 
prevalence [194]. 
The question of whether ȕ2-adrenoceptor polymorphisms affect the respose 
to ȕ2-agonists has also been studied. In early studies in vitro using 
transfected cell lines or primary airway smooth muscle cells, the Gly 16 
variant cells showed increased downregulation in response to β2-agoinsts 
and the Glu 27 variant demonstrated attenuated downregulation [195,196].  
Numerous studies have examined the association between ȕ2-receptor 
polymorphisms and clinical outcomes among subjects with asthma, and to a 
much lesser extent, chronic obstructive pulmonary disease.   
Early clinical studies found that Gly 16 was associated with increased 
nocturnal symptoms and increased bronchial responsiveness among 
asthmatics [197-201]. 
Studies also showed an association between Gly 16 and desensitisation of 
the bronchodilator response [202,203].  
Results have not been consistent however and retrospective analysis of three 
of the larger studies of subjects with asthma treated with regular salbutamol 
found that those homozygous for Arg 16 had worse outcomes than those 
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homozygous for Gly 16 [204-206]. This was corroborated in a recent 
prospective study, which found that asthmatics with the Gly-Gly 16 
genotype using regular salbutamol had better outcomes than those 
homozygous for Arg 16 [207]. Studies in subjects with asthma found that 
the Gly-Gly/Glu-Glu combination was associated with a larger 
bronchodilator response and smaller systemic effects after β2-agonists than 
those with the Arg-Arg/Gln-Gln combination [208,209].  
Fewer studies have examined β2-receptor polymorphisms among subjects 
with COPD. Recent post hoc analysis of patients in the Lung Health Study 
suggested that heterozygosity at position 27 might confer some protection 
against rapid FEV1 decline [210]. 
 
2.2 β2-AGONISTS 
Ephedrine has been used in the treatment of respiratory diseases for over 
5000 years. Derived from the plant Ephedra and called Ma Huang in 
Chinese medicine, ephedrine is the earliest known bronchodilator. 
Ephedrine was shown to be effective by inhalation in 1910 [211], producing 
bronchodilatation.  
Solis-Cohen, a physician from Philadelphia, first showed that orally 
administered adrenal extract (adrenal substance pills) was beneficial in 
asthma [212]. The direct bronchodilator effect of adrenaline was 
subsequently demonstrated by Kahn in 1907 using precontracted tracheal 
strips in vitro [213]. Subcutaneous adrenaline injection became a widely 
used treatment, particularly for acute exacerbations of asthma. Isoprenaline 
was modified from early adrenergic drugs by German chemists in the 1940s 
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and became the most widely used treatment for asthma. 
The first description of delivering adrenergic agonists by inhalation was by a 
general practitioner who described the efficacy of nebulising an adrenaline 
solution with oxygen in patients with acute exacerbations of asthma [214]. 
Maschberg, an American engineer, designed a special valve in 1956, which 
allowed patients with asthma to self-deliver bronchodilator medications by 
aerosol. 
The discovery of adrenoceptor subtypes led to the development of β2-
agonists, drugs that were highly selective for the β2-receptor and had a 
prolonged duration of action. The short-acting ȕ2-agonist, salbutamol was 
introduced as an inhaled treatment for asthma in 1969 and inhaled β2-
agonists with a long duration of action were introduced in the 1990s. 
 
2.2.1   Chemistry 
All adrenergic agonists have the same basic structure; a benzene ring with 
an attached chain of two carbon atoms linked to an amine group or a 
substituted amine head. Catecholamines are characterised by the presence of 
hydroxyl groups at positions three and four of the benzene ring. 
Modification to the basic catecholamine structure has produced non-
catecholamines that are more selective to the β2-receptor and are 
metabolised more slowly.  
β2-agonist non-catecholamines have a substitution or repositioning of the 
hydroxyl groups that reduces potency, but confers greater metabolic stability 
and resistance to breakdown. Increasing the size of the alkyl substitution on 
 58 
the amine group also reduces potency, reduces drug metabolism and 
increases β2-receptor selectivity. 
All β2-agonists contain at least one asymmetrical carbon which results in the 
molecule existing as a pair of optical isomers (mirror images), the R or S 
enantiomers, in a racemic mixture. Some β2-agonists have two asymmetrical 
centres and four enantiomers, known as RR, SS, RS and SR. Experimental 
data has shown that the R-configuration mediates the beneficial adrenergic 
effects [215], whereas the S-configuration has weaker and often negligible 
effects. These differences may occur because the β-hydroxy group on the R-
enantiomer is orientated downwards and could have a better interaction with 
key amino acids in the adrenoceptor [216]. 
 
2.2.2   Metabolism and elimination 
Endogenous catecholamines are metabolised following active removal 
processes known as uptake-1 and uptake-2. Noradrenaline and adrenaline 
are taken into synaptic storage vesicles in sympathetic nerve terminals 
(uptake-1) where they are metabolised by monoamine oxidase (MAO), 
which inactivates them by cleaving or deaminating the side chain. All 
catecholamines are metabolised by uptake-2 in non-neuronal tissues with 
sympathetic innervation, where the enzyme catechol-O-methyl transferase 
(COMT) terminates their action by methylation of the catechol nucleus. 
Catecholamines have short half-lives due to rapid metabolism by COMT 
and MAO; the breakdown products are then excreted in urine. 
Non-catecholamine β2-agonists do not undergo metabolism via uptake-1 or 
uptake-2. Altering the hydroxyl groups on the catecholamine benzene ring 
creates resistance to COMT breakdown and substitution of the amine head 
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imparts resistance to MAO allowing a longer duration of action. Non-
catecholamine β2-agonists have longer half lives than catecholamines and 
are eliminated by metabolism or renal excretion of unchanged drug. 
Elimination depends on the route of administration; parenteral 
administration leads to most drug being excreted unchanged in urine, 
avoiding the first pass elimination in liver and small intestine seen after 
inhalation and oral administration. 
 
2.2.3   Lipophilicity 
Short acting β2-agonists are generally hydrophilic and access the receptor 
from the extracellular aqueous compartment. Long-acting β2-agonists have 
much greater lipophilicity and are rapidly taken up into the cell membrane, 
before interacting with the receptor. The lipophilicity of long-acting β2-
agonists plays an important role in determining the onset and duration of 
their action.  
Gastrointestinal absorption is also affected by lipophilicity, since absorption 
of lipophilic β2-agonists is almost complete, whereas absorption of 
hydrophilic β2-agonists is generally much lower.  
 
2.2.4   Systemic absorption and drug distribution 
The inhaled route delivers drug directly to the airways, allowing lower doses 
to be given and reducing systemic blood levels. Although β2-agonist 
reaching the lungs is rapidly absorbed, most inhaler devices only deliver 
around 20% of the drug to the lung (Section 2.6.2).  
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Following oral administration of β2-agonists, the bioavailability will be 
reduced by pre-systemic first-pass metabolism, with conjugation to 
sulphates or glucoronides following uptake in the gut wall and liver.  
Lipophilic β2-agonists have high plasma protein binding and hydrophilic 
agents have low protein binding. Although β2-agonists have a large volume 
of distribution, animal experiments have found that only modest amount of 
β2-agonist cross the blood brain barrier [217]. 
 
2.2.5   Efficancy, potency and selectivity  
β2-agonists have variable efficacy (ability to produce the desired effect), 
potency (amount of drug needed to produce an effect) and selectivity for β2- 
versus β1-adrenoceptors (ability to relax airway smooth muscle (β2-effects) 
versus the effect on cardiac β-receptors).  
While a full agonist has high efficacy and an antagonist would have low or 
zero efficacy, most β2-agonists have intermediate efficacy. Partial agonists 
can antagonise full agonists by occupying receptors and reducing the access 
of drugs that have fuller agonist activity. Although β2-agonists have variable 
efficacy in studies in vitro, the bronchodilator efficacy of β2-agonists in 
human studies shows little difference between drugs. 
A highly selective β2-agonist drug produces more beneficial airway effects 
and fewer positive inotropic and chronotropic effects than a non-selective 
drug. Although the short- and long-acting inhaled β2-agonists in current use 
have similar selectivity and are more selective than isoprenaline, some 
inhaled β2-agonists, including fenoterol, are less β2-selective and are no 
longer widely used. 
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2.3 PHARMACOLOGY OF SPECIFIC β2-AGONISTS 
Differences in β2-agonists relate to a combination of characteristics and of 
the many examples, only four are frequently prescribed to patients with 
COPD. Here I have summarised the pharmacology of the short-acting β2-
agonists, salbutamol and terbutaline, and the long-acting β2-agonists, 
salmeterol and formoterol (Figure 2.3). 
 
2.3.1    Salbutamol  
Salbutamol is a saligenin, with a –CH2OH replacing the 3-hydroxy group 
and protecting the molecule from COMT. It has a N-tertiary butyl 
substituent side chain preventing MAO breakdown and conferring β2-
selectivity and exists as a mixture of R- and S- enantiomers.  
Salbutamol is hydrophilic, so penetration of the lipid bilayer is poor and the 
drug accesses the ȕ2-adrenoceptor from the extracellular aqueous 
compartment. Inhaled salbutamol has a rapid onset of action, with 
bronchodilation occuring within five minutes, peak bronchodilation 
occurring around 60 minutes and the effect maintained for up to six hours. 
A proportion of inhaled salbutamol is delivered to the oropharynx and 
subsequently to the gut after swallowing, with only negligible buccal 
absorption and a variable amount reaching the lungs. Salbutamol delivered 
to the lungs is rapidly absorbed and excreted unchanged by the kidneys. 
Salbutamol is almost completely absorbed from the gastrointestinal tract, 
with around half undergoing first-pass metabolism.  Sulphate conjugation in 
the gastrointestinal mucosa and liver produces a virtually inactive 
metabolite, with renal excretion accounting for 60% of the total clearance of 
salbutamol and its 4,O-sulphate conjugate.  
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Figure 2.3: The chemical structure of the main ȕ2-agonists used in COPD. 
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Blood levels are low after inhaled salbutamol, reaching a peak between five 
and fifteen minutes post inhalation, with a half-life of four to six hours [218-
220]. 
Differences have been found in the bioavailability of R- and S-enantiomers 
after inhaling racemic salbutamol and although results have been 
inconsistent [221,222], there is some evidence of preferential gut 
metabolism of the more pharmacologically active R-enantiomer [223]. 
 
2.3.2   Terbutaline 
Terbutaline has the same amine side chain substitution as salbutamol, with 
hydroxyl groups at positions three and five of the benzene ring, and exists as 
a pair of optical isomers. 
Terbutaline is highly hydrophilic with poor lipid bilayer penetration, acting 
directly on the ȕ2-adrenoceptor. The rapid onset and duration of action is 
similar to that of salbutamol. Of the terbutaline that is swallowed following 
inhalation, around half is absorbed from the gastrointestinal tract and two-
thirds of the absorbed drug undergoes first pass metabolism in the gut wall 
and liver. It is conjugated with sulphuric acid and excreted as sulphate 
conjugate, with no active metabolites formed. 
Peak serum concentrations of terbutaline are recorded 30-60 minutes after 
inhalation. Terbutaline and its metabolites are mainly excreted in urine and 
it has a plasma half-life of almost six hours. 
 
2.3.3   Salmeterol 
Salmeterol is a saligenin derivative of phenylethanolamine with a large, 
eleven-atom, aliphatic side chain.  
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It is a highly potent relaxant of human bronchial airway smooth muscle in 
vitro, with β2:β1 selectivity of 2800. However, in vivo salmeterol is a partial 
agonist and has a lower efficacy on airway smooth muscle than salbutamol.  
Salmeterol is highly lipophilic, with a slower onset of action than 
salbutamol, but a long duration of action. Neutron diffraction studies show 
that salmeterol diffuses rapidly and completely into the lipid bilayer and 
then slowly binds to an exosite found on β2- but not the β1-adrenoceptor, in 
addition to the normal binding sites. The exosite, located at a relatively 
hydrophobic section of the fourth transmembrane regulator domain by 
sequence mutagenesis [224], binds to the long hydrophobic side chain of 
salmeterol preventing dissociation from the receptor and allowing the 
saligenin head of the molecule to engage repeatedly with the active receptor 
site and prolonging the drugs duration of action [225].  
Salmeterol is well absorbed from the lung and gut and is metabolised by 
hydroxylation in the liver. The majority of the drug is eliminated within 72 
hours, 23% in urine and 52% in faeces [226]. 28-36% of the systemic effects 
produced by inhaled salmeterol are caused by drug absorption from the 
gastrointestinal tract [227].  
 
2.3.4    Formoterol 
Formoterol, a formanilide-substituted phenoethanolamide, is a highly potent 
relaxant of human bronchial airway smooth muscle in vitro, with β2:β1 
selectivity of 200-400. Formoterol is a fuller agonist than salbutamol, 
terbutaline and salmeterol [228].  
Following inhalation, formoterol has a rapid onset and long duration of 
action. It is moderately lipophilic, which enables the drug to dissolve into 
 65 
the cell membrane lipid bilayer, to diffuse and bind to traditional ȕ2-receptor 
binding sites. Some drug remains in the aqueous phase and reacts directly 
with the receptor, accounting for the rapid duration of action [228]. The 
onset of bronchodilatation after inhaled formoterol is similar to that seen 
with salbutamol [229]. Despite being lipophilic, absorption is poor after oral 
ingestion of formoterol. Oral formoterol does not produce high 
concentrations of drug in the lipid bilayer and it does not produce the long-
acting effects seen with inhaled formoterol.  
Formoterol is well absorbed from the lung and exhibits a biphasic serum 
concentration after inhalation with an initial peak after fifteen minutes and a 
smaller peak after ninety minutes. Formoterol is largely metabolised by 
hepatic conjugation with glucuronic acid and the metabolites are mainly 
excreted in urine. The mean plasma half-life of inhaled formoterol is around 
two hours and twelve hours after inhalation, 24% of the drug has been 
excreted in urine [230].  
The clinical efficacy of these four inhaled β-agonists in subjects with 
chronic obstructive pulmonary disease is reviewed in chapter 3. 
 
2.4 AIRWAY EFFECTS OF β2-AGONISTS 
β2-agonists have a range of effects that can contribute to airway obstruction. 
2.4.1    Airway smooth muscle 
β2-agonists relax airway smooth muscle and are functional antagonists in 
that they inhibit or reverse the airway response to bronchoconstrictor stimuli 
[231]. β2-agonists have also been shown to inhibit smooth muscle 
proliferation after exposure to different agents, including epidermal growth 
factor [232,233]. 
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2.4.2    Blood vessels  
β2-agonists cause vasodilatation and increase blood flow in the pulmonary 
circulation [234]. They reduce airway microvascular leakage induced by 
inflammatory mediators in animal airways [235,236] and formoterol 
reduced histamine-induced plasma exudation in the induced sputum of 
healthy subjects [237].  
 
2.4.3    Mucus secretion and mucociliary clearance  
β2-agonists increase ciliary beat frequency in human and mammalian airway 
epithelial cells, enhancing mucus clearance [238-240]. Although β2-agonists 
stimulate mucus secretion in animal models, consistent effects have not been 
demonstrated in human airways and their effect on human epithelial goblet 
cells is unclear [241-243]. β2-agonists may prevent airway closure by 
stimulating the release of surfactant lipids from Clara cells [244]. 
 
2.4.4 Epithelial protection 
β2-agonists may counteract some of the detrimental effects of bacterial 
infection and may help to protect the airway epithelial barrier. Salmeterol 
has been associated with reduced pseudomonas aeruginosa and haemophilus 
influenzae induced epithelial damage [245,246]. The beneficial effect is 
likely to relate to improved structural integrity of the epithelium rather than 
a direct antibacterial effect. Evidence in this area is limited, but salmeterol 
also increased the expression of tight junction proteins in human airway 
epithelial cells; proteins which are important in preserving the epithelial 
barrier [247]. 
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2.4.5 Inflammation and mediator release 
Some studies in vitro have found that β2-agonists have anti-inflammatory 
effects. Not all studies have demonstrated an effect however and some 
effects are only seen in high doses [248]. β2-agonists have been associated 
with inhibited release of thromboxane, leukotrienes and eosinophil-
activating cytokines from airway smooth muscle cells [249,250]. 
Although β2-agonists have demonstrated in vitro anti-inflammatory 
properties, data from bronchial biopsy studies does not suggest that long-
term treatment has a beneficial effect on chronic inflammation [251]. 
 
2.5 SYSTEMIC EFFECTS OF β2-AGONISTS 
 
Inhaled β2-agonists are absorbed into the systemic circulation and cause 
adverse effects directly relating to the stimulation of β2-adrenoceptors. 
These effects are summarised below and are opposed by β-receptor 
antagonists. 
 
2.5.1    Tremor 
β2-agonists produce tremor by stimulating receptors on extrafusal fibres and 
spindles of skeletal muscle [252]. The tremor increases in a dose-dependant 
manner in healthy subjects and patients with asthma and COPD [253-256]. 
It is more apparent after oral administration of β2-agonists and with high 
doses delivered via a nebuliser [257]. Tremor is reported by around 2 – 4% 
of patients with asthma taking a regular β2-agonist [258]. Mann et al (1996) 
found that 1 in 296 asthmatics discontinued inhaled salmeterol because of 
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tremor. Blunting of the tremor response has been demonstrated among 
subjects taking regular inhaled β2-agonists [259]. 
2.5.2    Hypokalaemia  
Stimulation of β2-receptors on skeletal muscle activate the Na+/K+ ATPase 
‘pump’, which increases sodium efflux, hyperpolarazing the cell and 
causing flux of potassium ions into cells and reducing extracellular and 
plasma potassium concentrations [260,261]. Plasma potassium falls in a 
dose related manner after inhaled short- and long-acting β2-agonists among 
both healthy volunteers and subjects with asthma and COPD [262-266]. The 
degree of hypokalaemia is reduced after prolonged use of inhaled β2-
agonists [267,268]. Studies involving healthy subjects have found that 
inhaled β2-agonists reduce the plasma potassium by between 0.3 and 1.12 
mmol/L, even when doses well above recommended levels are used [262-
264]. Inhaled β2-agonists appear to produce a similar or lesser degree of 
hypokalaemia when equivalent doses are administered to subjects with 
asthma and COPD.  
 
2.5.3    Cardiac effects  
β2-agonists relax vascular smooth muscle and cause peripheral 
vasodilatation, with reflex cardiac stimulation leading to tachycardia; direct 
stimulation of cardiac β1- and β2- adrenoceptors also contributes to an 
increase in heart rate and contractility. Radioligand studies have 
demonstrated that β2-receptors constitute around 35% of atrial and 25% of 
ventricular β-adrenoceptors  [269,270]. 
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β2-agonists can cause T wave changes and a prolonged QTc interval on the 
electrocardiograph. In a recent study nebulised salbutamol enhanced AV 
node conduction and reduced the AV nodal, atrial and ventricular refractory 
period, changes that were independent of heart rate and could contribute to 
the generation of arrhythmias [271].  
Inhaled β2-agonists cause a dose related increase in heart rate and systolic 
blood pressure, a fall in diastolic blood pressure and prolongation of the QTc 
interval in healthy volunteers and patients with asthma and COPD 
[253,254,272-274]. Like other systemic effects, tolerance has been 
demonstrated for the acute cardiovascular effects, with a reduction in the 
change in heart rate, QTc interval and T wave response after long-term 
inhaled β2-agonist use [275,276]. 
 
2.5.4    Hypoxaemia 
Inhaled β2-agonists transiently reduce the partial pressure of arterial oxygen 
(PaO2) in patients with asthma and COPD. A fall in PaO2 was originally seen 
in patients receiving intravenous aminophylline, but similar changes were 
noted in asthmatic patients with inhaled isoprenaline and salbutamol [277-
279]. The fall in PaO2 is mainly attributed to a β2-agonist mediated increase 
in ventilation-perfusion mismatch. The effect is generally small and returns 
to normal within thirty minutes [280].  
The distribution of ventilation throughout the lung is more variable in 
COPD than in normal lungs and the variability increases as COPD becomes 
more severe. The mismatch between ventilation and perfusion in the lungs 
of a subject with COPD is partially ameliorated by an adaptive mechanism 
of hypoxic vasoconstriction in poorly ventilated areas of the lung.  
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β2-agonists cause vasodilatation in the hypoxic areas of lung without 
equivalent brochodilatation, worsening ventilation-perfusion mismatch and 
reducing the partial pressure of arterial oxygen. 
β2-agonists can increase minute ventilation and although the exact 
mechanism of this action is unclear, potential mechanisms include 
stimulation of central or peripheral receptors. β2-agonists increase oxygen 
consumption and carbon dioxide production and the subsequent flux of 
carbon dioxide to the lungs may directly stimulate ventilation 
(cardiodynamic hyperpnoea)[281,282].  
 
2.5.5    Other effects 
β2-agonists can cause agitation, irritability and headaches. This has been 
attributed to stimulation of receptors in the central nervous system, with β2-
receptors most abundant in the cerebellum and hippocampus [283].  
Other metabolic changes after administration of β2-agonists include an 
increase in serum insulin, plasma glucose and lactate. The rise in insulin 
levels may result from direct stimulation of pancreatic islet cell β2-receptors 
and would also contribute to the fall in plasma potassium [268,284]. Blood 
glucose levels increase with inhaled short- and long-acting β2-agonists as a 
result of hepatic glycogenolysis and gluconeogensis [227,285]. β2-agonists 
also increase muscle glycogenolysis and produce lactate [286]. It is unclear 
whether long-term β2-agonist use attenuates the metabolic effects [268]. 
β2-agonists are used in obstetrics as a tocolytic agent, when relaxation of the 
uterine smooth muscle can suppress contractions and delay the onset, or halt 
the progress, of labour. 
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2.5.6 Safety 
Questions surrounding the safety of β2-agonists date back to the 1960s, 
when it was suggested that a sharp increase in asthma deaths, particularly 
among young people, may be due to overuse of inhaled sympathomimetics 
[287,288]. Adrenergic agents can cause areas of myocardial necrosis when 
infused into animals, and similar lesions have been demonstated in humans 
who died from asthma [289,290]. 
A number of theories have been suggested to explain the association 
between asthma deaths and sympathomimetic use, including one that the 
introduction of isoprenaline ‘forte’ was responsible for the asthma epidemic. 
Isoprenaline is a poorly selective β2-agonist and the dose of ‘forte’ was five 
times the standard dose. Drug sales showed a temporal relationship with 
asthma deaths and mortality increased in countries where the ‘forte’ 
preparation was used [288, 291]. As a result of the concerns, bronchodilator 
aerosols became available by presciption only in the United Kingdom. 
It was also proposed that the freons found in fluorocarbon propellants might 
sensitise the heart to asphyxia-induced arrhythmias, but studies with placebo 
inhalers could not replicate the high blood levels of freon required to cause 
cardiotoxic effects in animals [292].  
The safety of β2-agonists was brought into question again a decade later 
after an increase in asthma deaths occurred in New Zealand and three case-
control studies showed an association between use of inhaled fenoterol and 
an increased risk of death in young patients with severe asthma [293-295]. A 
Canadian case-control study noted that the odds ratio of death or near death 
from asthma was high with the regular use of inhaled β2-agonists, 
particularly fenoterol [296].  
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Concerns remain about the safety of regular inhaled β2-agonists in asthma 
and have extended to long-acting β2-agonists. A recent large-scale 
surveillance study looking at the safety of regular inhaled salmeterol was 
halted prematurely after an increase in asthma-related deaths was identified 
in the active limb [297]. 
Debate about the safety of inhaled β2-agonists in patients with COPD has 
followed on from concerns raised in patients with asthma. Cardiovascular 
safety is particularly relevant in patients with COPD, since a significant 
proportion of patients have co-existing, or subclinical, ischaemic heart 
disease [298]. The risk of developing a cardiac event (ischaemia or 
arrhythmia) may be particularly high in the presence of hypoxaemia, 
hypercapnia and acidosis and if concomitant drugs that also stimulate the 
myocardium (eg theophyllines) and cause hypokalaemia are used. The 
potential for risk may be increased further if β2-agonists cause tachycardia, 
hypokalaemia and worsening of hypoxaemia. The effect of inhaled β2-
agonists on cardiovascular outcomes (heart rate, QTc, peripheral vascular 
resistance) are greater during hypoxaemic conditions [299,300]. The 
presence of hypoxia and hypercapnia can be particularly pro-arrythmogenic 
for subjects with COPD; in this situation, correction of hypoxia can shorten 
an already prolonged QTc interval [301].  
Few studies have concentrated on the cardiovascular safety of inhaled β2-
agonists in COPD, with most safety data extracted from meta-analyses and 
prospective studies designed to assess effectiveness, many of which exclude 
patients with ischaemic heart disease.  
Conradson et al concluded that patients with COPD and no evidence of 
ischaemic heart disease were not at increased risk of arrhythmia after 
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inhaled β2-agonists [302]. Suissa et al (1996) used subjects from the 
Saskatchewan health insurance database to examine the relationship 
between bronchodilator use and acute cardiac death, but found no associated 
increased risk with the use of inhaled β2-agonists in patients with cardiac 
disease [303]. A meta-analysis of seven long-term studies found no 
difference in cardiovascular events or death rates between patients with 
COPD treated with salmeterol 50 µg bd and those treated with placebo, even 
after stratifying by age or known cardiovascular disease [304]. A 
community-based study with a cohort of over 12000 subjects found that the 
use of short-acting inhaled β2-agonists by subjects with COPD was not a 
risk factor for myocardial infarction [305]. 
Some studies have found an association between β2-agonist use and adverse 
outcomes in COPD. Au et al (2000) conducted two case-control studies in 
North America and found an increased risk of myocardial infarction among 
subjects recently commenced on an inhaled β2-agonist [306] and an 
increased risk of acute coronary syndrome among subjects with COPD 
filing a prescription for an inhaled β2-agonist [307].  Although one meta-
analysis concluded that β2-agonist use in obstructive airways disease 
increased the risk of adverse cardiovascular events [308], major flaws in the 
methodology and analysis were identified [309]. Cazzola et al compared the 
effect of a single dose of salmterol 50 µg, formoterol 12 µg and 24 µg on 
electrocardiography in twelve subjects with COPD, hypoxaemia and 
previous cardiac dysrhythmia. Each dose increased the heart rate and caused 
a fall in serum potassium levels, but the effect was greatest with the higher 
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dose of formoterol and one third of subjects developed paired or multiform 
ventricular beats. 
In the recent TORCH (Towards a Revolution in COPD Health) study [310], 
over 1500 subjects with COPD were randomised to receive salmeterol 50 µg 
twice daily for three years. The study found no difference between placebo 
and salmeterol for all-cause mortality rates or COPD-related deaths, with 
fewer subjects discontinuing salmeterol than placebo. Subjects randomised 
to salmeterol had fewer moderate or severe exacerbations, required fewer 
systemic corticosteroids and had fewer hospitalizations. Adverse events 
were similar in the placebo and salmeterol groups and there was no evidence 
of an increase in cardiac events in the salmeterol limb. 
 
2.6 FACTORS AFFECTING DRUG DEPOSITION  
Inhaler devices have the advantage of delivering high drug concentrations 
directly to the disease site, achieving a similar or superior therapeutic effect 
at a lower dose than is required with systemic administration.  
 
2.6.1 Particle size 
The deposition and distribution of inhaled drugs within the lung depends on 
several factors, including particle size. Fine particles are distributed in 
peripheral airways at low levels of drug per unit surface area, while large 
particle aerosols are deposited at higher density on central airways [311]. 
Inhaled drugs usually consist of particles of varying size, with the size 
calculated using mass median diameter (When 50% of particle mass appears 
above and below this point) and aerodynamic diameter (The diameter of a 
sphere of unit density that has the same settling velocity as the particle 
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regardless of shape or density). The mean mass aerodynamic diameter 
(MMAD) is calculated from a cumulative distribution curve of the different 
particle sizes and volumes and geometric standard deviation (GSD) 
measures the variability of particle sizes within the aerosol [312]. 
Lung deposition occurs by inertial impaction (>5µm), gravitational 
sedimentation (0.4-5µm) or diffusion (<0.4µm), with the majority of 
particles with a diameter of 5-10 µm deposited in the large conducting 
airways. In the alveoli there is negligible air velocity and deposition occurs 
by sedimentation and diffusion [313]. Particles > 10 µm are generally 
deposited in the oropharyngeal region and subsequently swallowed, while 
particles <3 µm have an 80% chance of reaching the lower airways with 50-
60% being deposited in the alveoli [314].  
 
2.6.2   Delivery device. 
Various devices are available to deliver inhaled drugs including nebulisers, 
metered-dose inhalers (MDI) and dry-powder inhalers (DPI). Each has 
advantages and disadvantages. 
There are two main types of nebuliser device. The jet nebuliser uses the 
Bernoulli principle, with compressed air passing through a narrow orifice to 
produce an area of low pressure, drawing drug solution from a fluid 
reservoir and producing shattered droplets. Ultrasonic nebulisers use a high 
frequency vibrating crystal to generate a fountain of small droplets.  
Nebulisers do not require patient co-ordination or a specific inhalation 
technique, but the majority of nebulised drug deposits within the apparatus 
or is released into the environment. Small amounts are deposited in the 
oropharynx and often only around 10% of the drug reaches the lungs [315]. 
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Nebuliser solutions with a low pH and/or hypo-/hyper-osmolality can cause 
bronchoconstriction and hence alter drug deposition [316,317].  
Metered-dose inhalers are compact and portable, with the drug aerosol 
driven by chlorofluorocarbons (CFC) or hydrofluoroalkanes (HFAs) through 
a nozzle at a velocity of over 30 metres per second. Even with effective 
delivery (good hand-mouth coordination and an appropriate inspiratory flow 
rate), only around 10-20% of emitted drug reaches the lung with many 
inhalers, with approximately 50-80% delivered to the oropharynx due to the 
large particle size and velocity of delivery [318]. Although effective use of 
the MDI requires good hand-mouth co-ordination, over 50% of subjects 
were unable to manage this in one study [319]. The inspiratory flow rate is 
an important variable for drugs with a MMAD of 1-5 µm, since very high 
flow rates reduce total lung deposition and peripheral penetration, since 
more drug is deposited by inertial impaction in the conducting airways and 
oropharynx [320]. With slow inhalation and an increase in tidal volume, 
deposition in the peripheral regions of the lung is enhanced [321-323], while 
a ten-second-breath hold reduces the immediate exhalation of drug 
deposited in the peripheries.  
The addition of a holding chamber or spacer device to a MDI can decrease 
the proportion of drug deposited in the oropharynx (reducing the mean 
particle size and slowing aerosol velocity) and can increase peripheral drug 
deposition [324]. 
Dry powder inhalers were designed to eliminate the need for hand-mouth 
co-ordination and have the environmental advantage of not using 
chlorofluorocarbon propellants. Various devices are available, producing 
variable lung deposition (12-40%), with around a quarter of the drug being 
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retained in the device [325-327]. Lung delivery is enhanced by a rapid 
inspiratory rate, since airflow through the inhaler provides the required 
turbulence to separate drug from carrier particles and produce particles 
small enough to be carried into the lower airways [328]. Poor deposition can 
relate to slow inspiration rates or factors (high humidity, changes in 
temperature) that impair the deaggregation of drug particles from larger 
carrier particles. Modern dry powder inhlers are breath actuated and require 
an inspiratory flow rate of 30-130 L/min to achieve an aerosol in the 
appropriate range [329]. 
 
2.6.3   Pulmonary factors.  
2.6.3a Drug deposition 
Pulmonary factors including airway narrowing and inflammation can affect 
the deposition of an inhaled drug. Airway obstruction increases turbulence 
and disturbs the normal laminar flow, with inhaled aerosols directed towards 
unobstructed airways and less drug delivered to obstructed areas. Airway 
obstruction is associated with central deposition of the inhaled drug, with 
deposition depth correlating with FEV1 [322,330]. Severe obstruction causes 
a heterogeneous central distribution, unlike the uniform and peripheral 
distribution seen in normal lungs. 
 
2.6.3b Drug clearance 
Various factors protect the lung against inhaled particles, including airway 
geometry, humidity and clearance mechanisms. The complex airway 
branching system with progressively smaller airways encourages particles to 
deposit by impaction [331]. The high relative humidity ensures that 
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hygroscopic particles increase in size (upto five fold) as they move from an 
area of low temperature and humidity into the airways, encouraging central 
distribution within the lung [332-334].  
Following deposition, inhaled drugs are degraded, absorbed into the 
systemic circulation or cleared from the lungs. Within conducting airways, 
most drug is cleared by ciliated epithelia which stretch from the trachea to 
terminal bronchioles. Particulate matter is trapped in the mucus layer and 
beating of the cilia generates upward movement of the particles towards the 
pharynx and subsequently, the gastrointestinal tract. Mucociliary function is 
usually impaired with airflow obstruction, with secretions and particulate 
matter removed by coughing. Despite this, there is an inverse relationship 
between FEV1 and drug clearance [335].  
Some soluble particles are absorbed, with lipophilic molecules passively 
transported through airway epithelium and hydrophilic molecules crossing 
extracellular pathways or being actively transported into the circulation or 
lymphatics [336]. Alveolar drug particles are either phagocytosed by 
macrophages and slowly cleared from the lungs or absorbed into the 
pulmonary circulation [337]. Drug metabolism within the lung plays a minor 
role in drug clearance; although metabolising agents are found throughout 
the airways and alveoli, more than 95% of inhaled proteins are absorbed 
intact [338]. 
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Patients with COPD have limited reversibility of airflow obstruction and 
therefore limited capacity to respond to pharmacological interventions. 
Inhaled ȕ2-agonists are frequently prescribed to patients with COPD and this 
chapter examines the balance between benefits and risks with long-term use. 
 
 
3.1 EFFICACY OF REGULAR SHORT-ACTING ȕ2-AGONISTS IN 
PATIENTS WITH COPD 
 
Inhaled short acting bronchodilators have a rapid onset of action and are the 
first line treatment for patients with symptomatic COPD. Inhaled ȕ2-agonists 
are used by millions of patients with COPD throughout the world but very 
few studies have examined the long-term effects of regular treatment.  
The limited data from studies that have compared regular inhaled 
salbutamol or terbutaline taken at recommended doses with placebo, inhaled 
muscarinic receptor antagonists and oral theophyllines has been reviewed. 
Only studies that have been conducted over at least two weeks’ duration 
have been included (Table 3.1).  
 
3.1.1 Studies comparing short-acting ȕ2-agonists with placebo 
3.1.1a Lung function 
Regular inhaled short-acting ȕ2-agonists have been shown to cause 
bronchodilatation in subjects with COPD, improving morning FEV1 [339-
342], FVC [339,341,343] and PEFR [339,341].  
 
3.1.1b Symptoms and quality of life 
Salbutamol 200 µg, inhaled four times a day, has reduced breathlessness 
compared to placebo [340], although other authors have concluded that 
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regular salbutamol is no more effective than placebo at reducing symptoms 
among subjects with COPD [341,342]. 
Only two studies have examined the effect of regular inhaled short-acting 
ȕ2-agonists on quality of life. One study found that salbutamol 200 µg taken 
four times daily for two weeks had a beneficial effect on quality of life 
compared to placebo, improving the physical and emotional function 
domains of the Chronic Respiratory Disease Questionnaire [339]. The other 
study found that salbutamol 200 µg four times daily and placebo had 
comparable effects on health related quality of life (HRQOL) [342]. 
 
3.1.1c Effect on exacerbations  
No published data exists to determine whether regular long-term inhaled 
short-acting ȕ2-agonists have a beneficial or detrimental effect on 
exacerbation rates in subjects with COPD. 
 
3.1.1d Exercise tolerance  
Two studies have compared the effect of two weeks of treatment with 
salbutamol or placebo on walk distance and obtained conflicting results. 
Regular salbutamol 200 µg four times daily increased six-minute walk 
distance in one study, with a corresponding reduction in exertional dyspnoea 
scores [339]. The second study found that the same dose of inhaled 
salbutamol and placebo had the same effect on twelve-minute walk distance 
[342]. 
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Study No of 
subjects 
Duration 
SAȕA 
(weeks) 
SAȕA 
qid dose 
(µg) 
Mean FEV1 
% predicted 
Control 
Versus placebo 
Guyatt et al   
1987 
19 XO 2 Sb 200 1.02 La Placebo 
T bid 
Sb 200 + T bid 
Guyatt et al 
1989 
24 XO 2 Sb 200 34 Placebo 
T bid 
Sb 200 + T bid 
Jaeschke et al 
1991 
24 XO 2 Sb 200 34 Placebo 
T bid 
Sb 200 + T bid 
Thomas et al 
1992 
12 XO 2 Sb 200 1.09 La Placebo 
T bid 
Sb 200 + T bid 
Sansores et al 
2003 
20 XO 2 Sb 200 38 Placebo 
IB 80 µg qid 
Sb 200 + IB 80 µg 
qid 
Versus other bronchodilators 
COMBIVENT 
study group 
1994 
534 PG 12 Sb 200 37 IB 42 µg qid 
Sb 200 + IB 42 µg 
qid 
Man et al 
1996 
20 XO 2 Sb 200 1.18 La T bid 
 
Campbell 
1999 
357 PG 4 Sb 200 36 Sb 200 + IB 40 µg 
qid 
D’Urzo et al 
2001 
172 XO 3 Sb 200 51 F 12 bid 
Cook et al 
2001 
53 XO 13 Sb 200 34 Sb 200 ‘as required’ 
 
 
FEV1 = forced expiratory volume in one second; a Mean FEV1 (% predicted 
not given); SAȕA = short-acting ȕ2-agonist; XO = crossover; PG = parallel 
group; Sb = salbutamol; IB = ipratropium bromide; T = theophylline; F = 
formoterol; bid = twice daily; qid = four times daily. 
 
 
 
Table 3.1: Controlled studies of >2 weeks’ duration in adults with chronic 
obstructive pulmonary disease (COPD) in which the clinical response to 
regular short-acting ȕ2-agonist was compared with placebo or other 
bronchodilators. 
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3.1.2 Comparison with other bronchodilators 
3.1.2a Long-acting ȕ2-agonists 
The only comparison of short- and long-acting β2-agonists in patients with 
COPD is a three-week study in which all patients were taking ipratropium 
bromide 40 µg four times daily [344]. The addition of formoterol 12 µg 
twice daily caused a greater improvement in FEV1 over six hours, pre-
treatment morning FEV1, symptom scores and the symptoms component of 
the St George’s Respiratory Questionnaire compared with the addition of 
salbutamol 200 µg four times daily. 
 
3.1.2b Muscarinic receptor antagonists 
Short-acting muscarinic receptor antagonists 
Only two trials of reasonable duration have compared regular inhaled 
β2-agonists with regular inhaled ipratropium bromide in subjects with 
COPD. Both had the primary objective of comparing the combination of 
salbutamol and ipratropium bromide with each individual agent and found 
no appreciable difference between regular inhaled salbutamol and 
ipratropium bromide for spirometric measurements [342,345], dyspnoea 
scores [342,345] or walk distance [342]. A shorter study conducted over one 
week had similar findings, with no difference between salbutamol and 
ipratropium for spirometry, dyspnoea scores or walk distance [346]. 
Long-acting muscarinic receptor antagonists 
Although clinical studies have compared tiotropium bromide with placebo, 
ipratropium bromide and long-acting β2-agonists in patients with COPD, no 
published studies have compared tiotropium bromide and regular short-
acting inhaled β2-agonists. 
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3.1.2c Theophylline 
After two weeks of treatment with inhaled salbutamol 200 µg four times 
daily or an appropriately titrated dose of twice-daily oral theophylline, there 
was no difference between treatments for FEV1, FVC or PEFR, symptom 
scores or side effects [341]. In a comparison of once-daily sustained release 
theophylline and inhaled salbutamol 200 µg four times daily, the main 
outcome was the effect of the two drugs on sleep quality. Results favoured 
theophylline for nocturnal hypoxaemia, symptoms, early morning FEV1 and 
FEV1/FVC ratio, but there were no differences between treatments for sleep 
quality [347]. 
 
3.1.3 Effect of adding short acting ȕ2-agonists to other bronchodilators 
Regular inhaled salbutamol has been compared with ‘as required’ use in 
subjects with COPD already taking regular inhaled ipratropium bromide and 
corticosteroids. There were no clinically important differences between the 
two groups and the authors concluded that regular inhalation doubled the 
amount of salbutamol use without providing any significant physiological 
benefit [348].  
The combination of a short-acting inhaled ȕ2-agonist and inhaled 
ipratropium bromide has been compared with inhaled salbutamol alone in 
three studies. The combination improved FEV1 in two studies [345,349], 
symptom scores in one study [349] and exertional dyspnoea but not walk 
distance in the third study [342]. All the studies concluded that there were 
no additional adverse effects with the combination compared to salbutamol 
alone. A retrospective analysis, concluded that the combination might have 
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a beneficial effect on exacerbation rates compared to inhaled salbutamol 
alone [350].  
Regular inhaled salbutamol taken with oral theophylline has produced 
additional improvements in spirometry and symptom scores than that seen 
with either individual drug [339,341]. The combination of the two drugs 
also produced a small improvement in six-minute walk distance, but this did 
not translate to a beneficial effect on quality of life measures [339]. Neither 
study reported differences in the adverse effects produced by salbutamol 
alone and the combination of inhaled salbutamol and oral theophylline. 
 
3.1.4 Effect of different doses 
All of the studies have examined a single dose of inhaled ȕ2-agonist, so no 
published data has looked at the effect of different doses over a period of at 
least two weeks. 
 
3.2 EFFICACY OF REGULAR LONG-ACTING β2-AGONISTS IN 
PATIENTS WITH COPD 
 
Few studies have looked at the longer-term effects of long-acting 
β2-agonists in patients with COPD and the results have been inconsistent.  
Studies comparing long-acting β2-agonists with placebo, muscarinic 
receptor antagonists and oral theophyllines, and of more than four weeks’ 
duration, are detailed in table 3.2. The studies have involved between 29 and 
6184 subjects and have lasted up to three years. 
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Study No of 
subjects 
(No on 
LAȕA) 
Duration 
LAȕA 
(weeks) 
LAȕA 
bid 
dose 
(µg) 
Mean 
FEV1  
% 
predicted
% on 
ICS 
Control 
Versus placebo 
Ulrik 
1995 
66  XO 4 S 50 45 0 Placebo 
Grove et 
al 1996 
29 XO 4 S 50 42 83 Placebo 
Boyd et al 
1997 
674 
(447) 
16 S 50 & 
100 
46 60 
(5) 
Placebo 
Jones & 
Bosh1997 
283 
(188) 
16 S 50 & 
100 
46 71 
(16) 
Placebo 
Weiner et 
al 2000 
30 (24) 6 S 50 33 NR Placebo 
Chapman 
et al 2002 
408 
(201) 
24 S 50 45 61 Placebo 
Aalbers et 
al 2002 
692 
(430) 
12 F 4.5, 
9 & 18 
54 NR Placebo 
Stockley 
et al 2006 
634 
(316) 
52 S 50 46 54 Placebo 
Mahler et 
al 2002 
691 
(160) 
24 S 50 41 25 Placebo 
FP 500 µg bid 
FP 500 µg bid 
plus S 50 bid 
Szafranski 
et al 2003 
812 
(201) 
52 F 9 36 26 Placebo 
BUD 400 µg 
bid 
BUD 320 µg 
bid plus F 9 bid 
Calverley 
et al 
2003a 
1465 
(372) 
52 S 50 45 51 Placebo 
FP 500 µg bid 
FP 500 µg bid 
plus S 50 bid 
Calverley 
et al 
2003b 
1022 
(255) 
52 F 9 36 48 Placebo 
BUD 400 µg 
bid 
BUD 320 µg 
bid plus F 9 bid 
Hanania 
et al 2003 
723 
(177) 
24 S 50 42 20 Placebo 
FP 500 µg bid 
FP 500 µg bid 
plus S 50 bid 
O’Donnell 
et al 2006 
185 (59) 8 S 50 1.21 La 0 Placebo 
FP 250 µg bid 
plus S 50 bid 
Calverley 
et al 2007 
6184 
(1521) 
156 S 50 44 9 Placebo 
FP 500 µg bid 
FP 500 µg bid 
plus S 50 bid 
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Study No of 
subjects 
(No on 
LAȕA) 
Duration 
LAȕA 
(weeks) 
LAȕA 
bid 
dose 
(µg) 
Mean 
FEV1 % 
predicted 
% on 
ICS 
Control 
Versus ipratropium bromide or tiotropium bromide and placebo 
Mahler et al 
1999 
411 
(135) 
12 S 42 40 NR Placebo 
IB 36 µg qid 
Rutten-van 
Molken et al 
1999 
144 (47 
S) (47 
S+IB) 
12 S 50 44 77 Placebo 
S 50 + IB 40 
µg qid 
Van Noord 
et al 2000 
144 (47 
S) (47 
S+IB) 
12 S 50 44 77 Placebo 
S 50 + IB 40 
µg qid 
Dahl et al 
2001 
780 
(386) 
12 F 12 & 
24 
45 52 Placebo 
IB 40 µg qid 
Rennard et 
al 2001 
405 
(132) 
12 S 42 1.27 La NR Placebo 
IB 36 µg qid 
Wadbo et al 
2002 
183 (61) 12 F 18 33 71 Placebo 
IB 80 µg tid 
Donohue et 
al 2002 
623 
(213) 
26 S 50 40 66 Placebo  
TB 18 µg od 
Versus theophylline 
Di Lorenzo 
et al 1998 
178 
open 
label 
(91) 
52 S 50 2.0 La 17 T bid 
ZuWallack 
et al 2001 
943 
open 
label 
(310) 
12 S 42 41 37 S 42 + T bid 
T bid 
Rossi et al 
2002 
854 
(425) 
52 F 12 & 
24 
47 47 Placebo 
T bid 
 
FEV1 = forced expiratory volume in one second; a Mean FEV1 (% predicted 
not given); LAȕA = long-acting ȕ2-agonist; NR = not reported; XO = 
crossover; PG = parallel group; S = salbutamol; F = formoterol; IB = 
ipratropium bromide; T = theophylline; BUD = budesonide; FP = 
fluticasone propionate; ICS = inhaled corticosteroid ; TB = tiotropium 
bromide;  OD = once daily; bid = twice daily;  tid = three times daily; qid = 
four times daily. 
 
 
Table 3.2: Controlled studies of >4 weeks’ duration in adults with chronic 
obstructive pulmonary disease (COPD) in which the clinical response to 
salmeterol or formoterol was compared with placebo or other 
bronchodilators. 
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All seventeen studies of salmeterol (presented in nineteen papers) have 
looked at the 50 µg twice daily dose and one of the studies (two papers 
[351,352]) also looked at the 100 µg twice daily dose. Of the six studies of 
formoterol, five have looked at 12 µg twice daily, four at 24 µg twice daily 
and one at 6 µg twice daily. The main findings in these studies can be 
summarised as follows. 
 
3.2.1 Studies comparing long-acting β2-agonists with placebo 
3.2.1a  Lung function 
Salmeterol and formoterol when taken twice daily have been shown to cause 
bronchodilatation in patients with COPD when compared to placebo. There 
is usually an increase in pre-treatment morning peak flow [353-364], pre-
treatment morning FEV1 [351,354,355,358-361,363-368] and FEV1 twelve 
hours after drug administration [356,360]. Four studies found salmeterol or 
formoterol to be more effective than placebo at increasing evening peak 
flow [354,358,359,362] whilst two found no difference [353,357]. The 
increase in morning PEFR has been marginally greater than the increase in 
evening PEFR. 
In the study in which salmeterol 50 µg and 100 µg were included, the 
bronchodilator response to both doses was greater than the response to 
placebo but there was no difference between the two doses [351]. In the 
three studies comparing formoterol 12 µg and 24 µg there was also no 
difference in change in FEV1 or PEFR between the two doses, although 
again both doses differed from placebo [356,361,365]. The response to the 
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formoterol 6 µg dose produced a similar response to the other two doses in 
the study by Aalbers et al [365]. 
 
4.2.1b  Symptoms and quality of life 
Twice daily treatment with salmeterol and formoterol has reduced rescue 
medication use [351,353-356,358-362,366,368,369] and most studies have 
shown a beneficial effect on daytime or nocturnal symptoms compared with 
placebo [351-354,356,358,365,366,368,369]. In the three studies 
[356,361,365] comparing formoterol 12 µg and 24 µg with placebo, 
symptom scores were lower with both doses of formoterol compared to 
placebo, although this was not significant in one study [361] and was only 
significant for the 24µg dose in another [365]. The reduction in symptom 
scores for the 12 µg and 24 µg doses were almost identical in two of the 
studies, whereas in the third, which included the 6 µg dose, there was a 
dose-related reduction in symptom-free days [365].  
Salmeterol and formoterol have generally shown a trend towards a 
beneficial effect on quality of life compared with placebo, irrespective of the 
tool used to measure quality of life. The beneficial effects have not always 
reached the level considered to be clinically important, however, and have 
not always been statistically significant. Of the twelve studies comparing 
quality of life after administration of salmeterol 50µg twice daily or placebo, 
three showed a significant improvement with salmeterol [352,368,369], 
seven showed an improvement that was not statistically significant 
[310,355,357,359,360,363] and two studies showed no difference [364,370].  
Five studies have looked at the effect of formoterol on quality of life. In the 
two that included the 12 µg and 24 µg twice-daily doses, both showed an 
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improved quality of life compared to placebo, although the greater benefit 
was seen with the lower 12 µg dose in one study [356], and with the higher 
dose in the other [361]. Quality of life did not differ between the 24 µg 
twice daily dose and placebo in a third smaller study [358], while in the final 
two studies [362,366] the 12 µg twice-daily dose was superior to placebo, 
although the significance was only stated for one [362]. 
 
3.2.1c  Effect on exacerbations 
The effect of salmeterol on exacerbations of COPD has been assessed in 
some of the larger studies. Salmeterol 50 µg twice daily increased the time 
to first exacerbation in one study [369] and reduced the exacerbation rate in 
another [363] (1.3 versus 1.04 exacerbations per patient per year for placebo 
and salmeterol, respectively). The largest study found that salmeterol 50 µg 
twice daily reduced moderate and severe exacerbation rates and the number 
of exacerbations requiring systemic corticosteroids [310]. It did not cause a 
significant reduction in exacerbation rates in the other five studies, however, 
and although the trend was in favour of salmeterol in all the studies, the 
differences were small [351,354,355,357,359,368].  
The effect of formoterol on exacerbations has also been rather variable. 
Formoterol 12 µg and 24 µg reduced mild exacerbations and the 24 µg dose 
reduced more severe exacerbations in one study [361]. However, neither the 
frequency of exacerbations nor use of additional therapy for exacerbations 
was reduced by twice daily treatment with either dose in a second study 
[356] or by the 12 µg dose in a further two studies [362,366]. 
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3.2.1d  Exercise tolerance and respiratory muscle strength 
When compared with placebo, twice-daily salmeterol 50 µg reduced Borg 
scores for perceived exertion in a four-week study [371] and breathlessness 
scores in a sixteen week study [351], although the six-minute walk distance 
was unchanged in both studies.  
When respiratory muscle strength and endurance were studied there was no 
change after six weeks of treatment with salmeterol 50 µg twice daily 
compared with placebo [372]. There was no change in exercise time after 
eight weeks treatment between placebo and salmeterol 50 µg twice daily, 
although the long-acting ȕ2-agonist produced a beneficial effect on some 
physiologic responses to exercise [367]. 
 
3.2.2  Comparison with other bronchodilators 
3.2.2a  Muscarinic receptor antagonists 
Three studies have compared ipratropium bromide 40 µg four times daily 
with recommended doses of formoterol or salmeterol [355,356,369] and, 
although differences were not always statistically significant, the benefit has 
generally been in favour of the long-acting β2-agonist. In a twelve-week 
study in which formoterol 12 µg and 24 µg twice daily were compared with 
ipratropium bromide 40 µg administered every six hours, both doses of 
formoterol were more effective at increasing pre-treatment morning PEFR, 
increasing the FEV1 over 12 hours and reducing symptoms, rescue 
medication use and improving quality of life [356].  Two studies comparing 
salmeterol 50 µg twice daily and ipratropium 40 µg four times daily did not 
show any difference in morning FEV1 or FEV1 over twelve hours at the end 
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of the studies [355,369], but salmeterol was associated with a reduction in 
nocturnal breathlessness and increased the time to first exacerbation in one 
study [369]. 
When formoterol 12 µg twice daily was compared with a higher dose of 
ipratropium bromide (80 µg three times daily) there were no differences in 
spirometric outcomes, symptoms or overall quality of life [358]. 
A large study has compared salmeterol with once daily tiotropium bromide 
in 623 patients. Tiotropium bromide 18 µg daily was more effective than 
salmeterol 50 µg twice daily at increasing pre-treatment morning FEV1, 
mean FEV1 over twelve hours (measured as area under the curve) and 
evening PEFR. This was in part due to a greater initial response to 
tiotropium bromide and in part because the bronchodilator response to 
salmeterol fell over the course of the study, whereas the response to 
tiotropium bromide was maintained [359,373]. Tiotropium bromide also 
caused a greater improvement in the St George’s Respiratory Questionnaire 
total score and in the number of patients achieving a four-point change in 
score, although only the latter differed significantly from the finding with 
salmeterol [359]. 
 
3.2.2b  Theophylline 
Three studies have compared a long-acting β2-agonist with individually 
titrated oral theophylline, one with formoterol 12 µg and 24 µg twice daily 
[361] and two with salmeterol 50 µg twice daily [374,375]. For most 
endpoints the long acting β2-agonists were superior to theophylline, 
although not all differences were statistically significant. Significant 
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differences in favour of the long acting β2-agonist in at least one of the 
studies included morning PEFR and the twelve-hour change in FEV1 [361], 
pre-treatment morning FEV1, symptoms and rescue medication use [374], 
number of ‘bad days’ experienced [361] and satisfaction with treatment 
[375]. No consistent differences in quality of life measures were seen after 
long-term treatment with salmeterol or formoterol compared with 
theophylline despite the increased adverse events seen with theophylline 
[370,374,375]. Whether this is due to increased withdrawals with 
theophylline is unclear. 
 
3.2.3  Effect of adding long-acting β2-agonists to other bronchodilators 
Combining salmeterol 50 µg twice daily with ipratropium 40 µg four times 
daily improved lung function (FEV1, airway conductance and evening 
PEFR) more than salmeterol alone, although the combination was no more 
effective than salmeterol alone at improving symptoms, rescue medication 
use, morning PEFR or exacerbation rate [354]. The combination of 
ipratropium bromide and salmeterol caused a greater improvement in certain 
quality of life measures, namely the total score, emotional domain and 
proportion of patients improving by the four points considered to be 
clinically useful on the Chronic Respiratory Questionnaire, and the 
symptoms component but not total score of the St George’s Respiratory 
Questionnaire [370]. 
When combined with orally titrated doses of theophylline, salmeterol caused 
greater bronchodilatation than was seen with either drug alone, with 
improved dyspnoea scores and salbutamol-free days. Other outcomes 
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favoured the combinations, although there was no difference in the rate of 
exacerbation between salmeterol and combined treatment [375]. 
 
3.2.4  Effect of different doses 
No consistent bronchodilator dose response effects have been seen with 
formoterol doses ranging from 6 to 24 µg twice daily [356,361,365], 
although the lower dose was more effective among patients with more 
reversible airflow obstruction in the study by Rossi et al [361]. The effect on 
symptom scores has also been broadly similar when formoterol 12 µg and 
24 µg doses have been compared. There was, however, a dose-response 
effect for reduction in symptom-free days for the three doses of formoterol 
[365] but no differences between doses for the six-minute walk distance, 
rescue medication use or exacerbation rates [356,361,365]. Formoterol 12 
µg and 24 µg twice daily produced similar changes in quality of life in one 
study [361], while the lower dose caused greater improvements in the total 
score and all three domains of the St George’s Respiratory Questionnaire in 
another [356]. 
For salmeterol, no difference was seen between the 50 µg and 100 µg twice 
daily doses in terms of effect on FEV1, symptom scores, rescue medication 
use or exacerbation rates [351]. For several end points the lower 50 µg dose 
had the greater effect, including reduction in breathlessness score at the end 
of a six-minute walk, total score and impacts component of the St George’s 
Respiratory Questionnaire. In the short form health survey (SF-36), the 
lower dose of salmeterol improved health score in four of the eight 
components while the higher dose caused deterioration in these components 
[351,352]. 
 95 
Thus, neither drug has shown a bronchodilator dose-response effect in 
patients with COPD. The finding that lower doses caused a greater 
improvement in quality of life than higher doses in some studies is 
interesting and presumably relates to the balance between the relatively 
small bronchodilator effect in these patients and increased adverse effects 
with the higher doses. A similar phenomenon was observed in a study of 
increasing doses of salbutamol ranging from 400 µg to 4 mg in patients with 
COPD [253]. In this study there was a dose related increase in PEFR and 
FEV1, but the incremental effects were small and higher doses were 
associated with a progressive increase in heart rate and tremor and a fall in 
oxygen saturation. Patients preferred the middle dose (1mg) where 
presumably the benefits from bronchodilatation were not outweighed by 
excessive adverse effects. The fact that the quality of life measures favoured 
the lower dose of the long-acting β2-agonist suggests that this dose achieves 
the optimum balance between beneficial and adverse effects. 
 
3.3 SAFETY OF REGULAR LONG-ACTING β2-AGONISTS IN 
COPD 
 
The safety of long-acting β2-agonists is an important consideration. Concern 
about the safety of regular short-acting β2-agonists in the management of 
asthma has recently extended to long-acting β2-agonists. Mann et al 
reviewed three studies (one in children) and found an increased number of 
severe asthma exacerbations among patients receiving formoterol 24 µg 
twice daily compared with formoterol 12 µg twice daily [376]. A 
randomised 28-week study was set up at the request of the FDA to 
determine the safety of salmeterol in a post-marketing context. The study 
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was halted prematurely after an interim analysis showed that salmeterol was 
associated with an increased risk of life-threatening asthma episodes or 
asthma-related deaths [297].  
The adverse effect profile of β2-agonists is well recognised, particularly at 
higher doses and although the systemic response to β2-agonists may show 
tolerance with regular use, both salmeterol and formoterol have the potential 
to cause systemic adverse effects when used in the management of COPD. 
To assess the safety of long-acting β2-agonists in the management of COPD 
i have reviewed the adverse effects reported in long-term prospective studies 
of effectiveness. I have also discussed a small prospective study designed 
specifically to look at cardiovascular safety of long-acting β2-agonists in 
COPD. 
Most of the prospective studies that have assessed the effects of salmeterol 
and formoterol in patients with COPD were designed primarily to look at 
efficacy but have also reported the adverse effects relating to β2-agonists. It 
is important to consider that most long-term studies conducted in patients 
with COPD excluded those individuals with a history of cardiac problems. 
The predictable adverse effects were reported in most studies and although 
there was not usually a difference between the treatment groups and 
placebo, the incidence of adverse effects was greater in some studies when 
the higher doses of salmeterol and formoterol were used [351,365].  
None of the studies identified a difference between placebo and either 
salmeterol or formoterol in terms of effect on cardiovascular endpoints, with 
no increase in the rate of dysrhythmias. Occasional patients in the studies 
have developed a dysrhythmia with long-acting β2-agonists, but it is not 
clear whether these were due to the drug itself or simply occurred by 
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chance. Two individuals developed atrial fibrillation with formoterol 12 µg 
twice daily [356,365] and one study found an increase in the rate of non-
sustained ventricular tachycardia with salmeterol 50 µg twice daily [355]. 
A published meta-analysis of seven studies of salmeterol 50 µg twice daily 
covering 1443 patients with COPD found no difference in cardiovascular 
events or deaths compared with placebo, even when patients were stratified 
by age >65 years or known cardiovascular disease [304]. In this study 40% 
of patients had a cardiac problem and a serious cardiovascular adverse event 
occurred in 38 patients (2.6%) taking salmeterol and in 27 patients (1.9%) 
taking placebo. 
A small single-dose study looked specifically at the effect of a long-acting 
β2-agonist in patients with COPD who had experienced a previous cardiac 
dysthythmia and hypoxaemia. Formoterol 12 µg and 24 µg and salmeterol 
50 µg were compared in 12 patients with continuous electrocardiography. 
All three doses caused an increase in heart rate and a fall in serum potassium 
levels. The effects were most marked with the higher dose of formoterol and 
four of these patients developed paired or multiform ventricular beats [377]. 
The TORCH (Towards a Revolution in COPD Health) study was 
established to assess the effect of inhaled corticosteroids and inhaled long 
acting β2-agonists on mortality in the management of COPD [310]. The 
combination of inhaled fluticasone propionate and salmeterol was compared 
with inhaled salmeterol alone, inhaled fluticasone alone and placebo, with 
each subject randomised to a three-year study. Over 1500 subjects with 
COPD (mean FEV1 44% predicted) were randomised to receive salmeterol 
50 µg twice daily and 960 of these subjects completed the study.  
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This study covered a greater period of time than previous published studies 
of long-acting β2-agonists in subjects with COPD and randomised the 
largest number of patients, so important safety data relating to the long-term 
use of salmeterol was obtained. The study found no difference between 
placebo and salmeterol for all-cause mortality rates or COPD-related deaths 
after three years. There was a large dropout rate in the study, but fewer 
subjects discontined salmeterol than placebo over the three years. Drug-
related adverse events were similar in the placebo and salmeterol groups and 
there was no evidence of an increase in cardiac events in the salmeterol 
limb. 
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Chapter Four 
 
 
 
 
Determining the optimum dose of nebulised 
salbutamol in acute exacerbations of Chronic 
Obstructive Pulmonary Disease 
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4.1 AIMS 
This study was designed to examine the effect of nebulised salbutamol on 
arterial blood gas tensions during an acute exacerbation of COPD. We 
wished to test the hypothesis that increased carbon dioxide production and 
flux of carbon dioxide to the lungs following high doses of ȕ2-agonists could 
cause an increase in arterial carbon dioxide tension and thus worsen 
respiratory failure in some subjects with COPD.  
Unfortunately the study had to be abandoned since we were only able to 
recruit five patients in eighteen months. Because this is an important clinical 
question and we have detailed information on the five patients, I am 
presenting the data in this chapter without a formal analysis. 
 
4.2 INTRODUCTION 
Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a 
major cause of hospital admissions and patients with hypercapnia have 
particularly high mortality rates [378]. The response to treatment during 
acute admissions has been little studied and guidelines are unable to provide 
clear dose recommendations for bronchodilator treatment. Patients with 
severe COPD have a limited ability to bronchodilate, particularly during an 
acute exacerbation. In this situation high doses of β2-agonists are often 
given although the bronchodilatation they produce is often minimal. The 
adverse effects following the high doses could then outweigh the limited 
beneficial effects as was seen in the study by Vathenen et al [253], where 
subjects with severe airflow obstruction and limited reversibility were given 
a range of doses of salbutamol and preferred a modest dose.  
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One potential problem with high dose β2-agonists in patients with severe 
COPD could arise as a result of an increase in carbon dioxide output 
(VCO2). Carbon dioxide output rose by 20% after healthy subjects inhaled 
salbutamol, with a direct relationship between dose and VCO2 [277]. The 
increase has been attributed to a combination of factors, including an 
increase in CO2 production as tremor increases and an increase in flux of 
CO2 to the lungs as cardiac output increases [281,282,379]. The normal 
response to the increase in CO2 flux to the lungs would be to increase 
ventilation (cardiodynamic hyperpnoea), but during an acute exacerbation 
patients with severe COPD and limited reversibility may not have the 
capacity to do this, in which case the PaCO2 would rise. In addition, inhaled 
β2-agonists have been shown to cause transient hypoxaemia in patients with 
asthma and COPD, an effect that has been attributed to an increase in 
ventilation/perfusion mismatching. 
We wished to examine the effect of a range of doses of nebulised salbutamol 
in patients during an acute exacerbation of COPD. We gave ipratropium 
bromide to the control subjects to try to avoid the need for additional 
bronchodilators during the study period and to avoid the bronchoconstriction 
that can occur with nebulised normal saline [380].   
We planned a double blind study in which patients admitted to Nottingham 
City Hospital with an acute exacerbation of COPD received five doses of 
nebulised salbutamol or ipratropium, with each dose given an hour apart. 
The main endpoint was the change in partial pressure of carbon dioxide 
(PaCO2) from baseline. 
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4.3 SUBJECTS AND METHODS 
4.3.1  Subjects 
Patients aged 40 to 85 admitted to Nottingham City Hospital with an acute 
exacerbation of COPD were eligible to participate in the study. Subjects 
were required to have a smoking history of more than 20 pack years, no 
history of asthma or atopy, a previous diagnosis of COPD and a documented 
forced expiratory volume in one second (FEV1) of less than 70% predicted. 
Exclusion criteria included the presence of another significant acute medical 
problem, radiographic evidence of pneumonia, anticoagulation, hypotension 
(<100/60 mmHg), hypokalaemia (<3.5 mmol/l) or a history of glaucoma. 
Nottingham City Hospital Ethics Committee approved the study and written 
informed consent was obtained on the day prior to the study day.  
4.3.2 Measurements 
PaCO2, PaO2 and pH were measured using standard electrodes on a blood 
gas analyser (Rapidlab 840, Bayer, Leverkusen, Germany), which calibrates 
automatically. One-point calibration with a reagent of known concentration 
occurs every 30 minutes and two-point calibration occurs every 120 minutes 
by measuring the response to two reagents of known concentration. 
The electrocardiograph was recorded on a central monitor (Dynascope DS-
5100E, Fukuda Denshi, Japan) and heart rate was calculated as mean of six 
consecutive beats.  
4.3.3 Protocol 
This was a double blind, single centre randomised study performed on 
patients within 48 hours of admission to Nottingham City Hospital with an 
acute exacerbation of COPD. Subjects were required to withhold all short-
acting bronchodilators from 2200 on the night before the study and all long-
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acting bronchodilators for at least 24 hours. Patients abstained from caffeine 
containing foods and beverages from midnight on the day before the study 
and following a light breakfast at 0700, abstained from eating throughout 
the study period. 
Prior to randomization and after hand circulation has been assessed by 
‘Alan’s test’, an arterial cannula (FloSwitch, Becton Dickinson, Swindon, 
UK) was inserted into the radial artery to allow blood sampling. Three chest 
leads were attached to the subject, who was then placed on bed rest for 30 
minutes. The subject received continuous oxygen, delivered at 28% via 
Venturi mask.  
Subjects were randomised to receive one of two treatment options at a ratio 
of 3:1 with the treatment determined by computer-generated random 
sequence; the majority received five doses of salbutamol sulphate (Steri-
Neb, Baker Norton, UK), delivered via a nebuliser, at hourly intervals from 
0800 to 1200. A quarter of the patients acted as the control group and 
received five doses of nebulised ipratropium bromide (Steri-Neb, Baker 
Norton, UK) at the same time points. Resting heart rate and arterial blood 
gas tensions were recorded at ten-minute intervals for 30 minutes after 
insertion of the arterial cannula. The first dose of medication was given 
around 0800 when the heart rate, PaCO2 and PaO2 had reached a stable state. 
This was defined as two consecutive resting heart rates within ten beats per 
minute and consecutive mean PaCO2 and PaO2 readings within 0.5 kPa, with 
the baseline calculated as the mean of these two values. Two one ml blood 
samples were taken sequentially from the arterial cannula to measure PaCO2 
and PaO2 (mean value recorded).  
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The subject was given either salbutamol sulphate, two doses of 1.25mg in 
2.5ml, one dose of 2.5mg in 2.5ml and two doses of 5mg in 2.5ml or five 
doses of ipratropium bromide 125µg diluted to 2.5ml with normal saline. 
Each dose was delivered one hour apart, over six minutes via a nebuliser 
(IEC 601-1, Medic-Aid, Pagham, UK) driven by air at 5 litres per min. 
Duplicate one ml samples of arterial blood were taken 10, 15, 20, 30, 45 and 
60 minutes after starting drug delivery to determine PaCO2 and PaO2 and 
followed at each time point by heart rate measurement. Sixty minutes after 
starting the first nebulisation the second dose was delivered and 
measurements repeated over the next hour. Five doses were given in total at 
hourly intervals and once the final blood sample was taken, the arterial 
cannula was removed.  
4.3.4  Analysis 
With twenty patients having salbutamol and assuming a SD of 0.3 kPa for 
change in PaCO2 and PaO2, we had >90% power to find a 1 kPa change in 
PaCO2 or PaO2 from baseline. The primary endpoint was change in PaCO2 
from baseline and secondary endpoints were change in PaO2 and heart rate.   
 
4.4 RESULTS 
In the eighteen months between June 2002 and December 2003, we 
approached 121 patients, but only ten subjects were suitable and willing to 
give consent, of which five completed the study. Among the five subjects 
who were not randomised, two withdrew consent next morning, two were 
unable to manage overnight without bronchodilators and an arterial cannula 
could not be inserted in one person. In view of the small numbers we have 
not carried out any statistical analysis on the data. 
 105
Demographic data for the five subjects (two women) who completed the 
study is shown in table 5.1. The subjects had severe disease (mean FEV1 
28% predicted), were ex-smokers (mean 29 pack years) and used inhaled β2-
agonists on a regular basis. Three had stable ischaemic heart disease. 
Subject three received ipratropium bromide whilst the other four received 
salbutamol. 
4.4.1   Changes with salbutamol 
4.4.1a Partial pressure of arterial carbon dioxide  
Individual changes in PaCO2 with increasing doses of salbutamol are shown 
in figure 5.1. There were small fluctuations in PaCO2 over the five-hour 
study period. No subject showed a clear dose related increase in PaCO2, nor 
was any single dose associated with a change in the PaCO2 of more than 1 
kPa. Subject five, who had the highest baseline PaCO2 of 7.1 kPa, showed a 
short-lived increase in PaCO2 after the highest doses of salbutamol (5 mg) at 
180 and 240 minutes. Subject one had short-lived increases in PaCO2 after 
four of the five doses of salbutamol. 
4.4.1b  Partial pressure of arterial oxygen  
Individual changes in PaO2 with increasing doses of salbutamol are shown in 
figure 5.2. The subjects experienced a fall in PaO2 after most doses of 
salbutamol, but the magnitude of change does not appear to be greater when 
higher doses were delivered. Although three subjects (one, four and five) 
had a fall in PaO2 of over 1 kPa after some doses, the decrease was not 
sustained. 
4.4.1c Heart rate  
Individual changes in heart rate with increasing doses of salbutamol are 
shown in figure 5.3. All four subjects had a rise in heart rate over the five-
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hour study period (area under the time response curve). Changes were 
modest however, although subject two had a short period of sinus 
tachycardia sixty minutes after the first dose of salbutamol. 
4.4.2 Changes with ipratropium bromide. 
Subject three received ipratropium and there were only modest, inconsistent 
effects on PaCO2 and heart rate. The PaO2 fell transiently after each dose of 
ipratropium bromide. 
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Table 4.1: Demographic data for the five subjects 
 
 
 Sex Age FEV1 
(L) 
FEV1/
FVC 
(%) 
Baseline 
PaCO2 
Baseline 
PaO2 
Pack 
yrs 
Regular β2-
agonists 
 
1 
 
M 
 
70 
 
0.7 
 
56 
 
5.6 
 
11.72 
 
24 
 
Salbutamol 
 
2 M 78 0.65 30 5.37 9.34 40 Salbutamol  
Salmeterol 
3 M 75 0.8 40 5.26 10.17 35 Salmeterol 
 
4 F 67 0.7 47 4.89 9.95 21 Salbutamol 
Salmeterol 
5 F 76 0.6 48 7.1 9.99 25 Salbutamol 
Salmeterol 
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Figure 4.1: Individual changes in PaCO2 (kPa) after five doses (∧) of 
bronchodilator. 
 
 109
 
Figure 4.2: Individual changes in PaO2 (kPa) after five doses (∧) of 
bronchodilator. 
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Figure 4.3: Individual changes in heart rate (bpm) after five doses (∧) of 
bronchodilator. 
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4.5 DISCUSSION 
This study was designed to address an important clinical question, namely 
can high doses of nebulised salbutamol have a detrimental effect on arterial 
carbon dioxide tension and worsen respiratory failure in subjects admitted 
with an acute exacerbation of COPD?  
The study was carefully planned and the admission rate of patients with 
COPD to Nottingham City Hospital (15 per month, Royal College of 
Physicians Audit, 2001) appeared to offer a ready supply of potential 
candidates. I made daily visits to the medical admissions ward and 
respiratory base wards to identify appropriate subjects, I enrolled the 
hospital COPD nurses to highlight or identify admissions from known 
patients and asked the junior medical staff to liaise with members of the 
research team when potential study subjects were admitted. 
We were however only able to recruit five patients over eighteen months. 
The main barriers to recruitment were that patients; 
a) Were too well. 
Some patients seen on the admissions unit with a mild exacerbation were 
deemed to be too well for hospital admission and had an early supported 
discharge. 
b) Were too unwell.  
A proportion of patients were too unwell to participate in the study. Some 
individuals required non-invasive ventilation; others were unable to manage 
for long periods without bronchodilators and some felt too ill to consider 
taking part in a research study. 
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c) Had other co-morbidities.  
The presence of other medical conditions or the potential that other events 
had precipitated the admission led to many patients being excluded. 
Evidence of pneumonia on the chest radiograph, the need for the admitting 
team to exclude a myocardial infarction and co-existing left ventricular 
failure were common reasons for exclusion.  
d) Had issues with consent.  
Consent provided another source of difficulty, with some subjects having a 
degree of confusion and being unable to give informed consent. Others were 
unwilling to give consent because of concerns about the study duration, the 
need to abstain from bronchodilators overnight and/or the need for arterial 
cannulation. 
Although our data are insufficient for statistical analysis, some conclusions 
can be drawn from the results we obtained. Changes in PaCO2 were small 
and there was no evidence of a dose response relationship between 
salbutamol and PaCO2. The subject with the highest baseline PaCO2 had a 
transient increase in PaCO2 after the 5mg doses of salbutamol. Since the 
increase in PaCO2 was small and only seen in one person, the significance is 
uncertain. The change is in keeping with our hypothesis and would support 
further investigation in patients with chronic type 2 respiratory failure.  
An initial fall in PaO2 after salbutamol has been demonstrated before and 
attributed to an increase in ventilation/perfusion mismatching. The 
magnitude of the changes in PaO2 we saw is similar to that seen previously 
in subjects with COPD [280].  
High dose salbutamol caused a modest increase in heart rate among the four 
subjects. The absence of a larger increase in heart rate may represent 
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tolerance to the systemic effects of the drug, since all participants used ȕ2-
agonists on a regular basis. 
The hypothesis that salbutamol can cause an increase in PaCO2 when 
delivered to patients with COPD during an acute exacerbation is based on 
the presumption that high dose ȕ2-agonists will produce a rise in carbon 
dioxide production and flux of CO2 to the lungs. The absence of a consistent 
rise in PaCO2 after salbutamol suggests that the increase in VCO2 was not as 
large as expected or that patients are able to increase ventilation in response 
to the rise in VCO2 during an acute exacerbation.  
The increase in VCO2 after salbutamol may be less marked in patients who 
inhale ȕ2-agonists on a regular basis, due to the development of tolerance to 
the systemic effects of the drug. This is supported by the modest changes in 
heart rate. Patients admitted acutely with a severe exacerbation of COPD 
who present with hypoxaemia and hypercapnia may be at particular risk of 
developing worsening respiratory failure with salbutamol if they are ȕ2-
agonist-naïve.  
Subject 5 had the highest baseline partial pressure of arterial carbon dioxide 
and the increase in PaCO2 that they experienced after the highest doses of 
salbutamol offers some support to our hypothesis.  
 
4.6 CONCLUSION 
Semi-invasive studies in an acute exacerbation of COPD are very difficult to 
conduct. We were only able to recruit five subjects over an eighteen-month 
period, of which four were randomized to receive a series of doses of 
nebulised salbutamol. There was no evidence of a dose response effect of 
salbutamol on PaCO2 in these subjects. 
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Chapter Five 
 
Effects of salbutamol on arterial blood gases in 
patients with stable hypercapnic Chronic Obstructive 
Pulmonary Disease 
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5.1 AIMS 
 
In view of the problems we encountered recruiting subjects during an acute 
exacerbation, this study was designed to examine the effect of nebulised 
salbutamol on arterial blood gas tensions in patients with stable COPD and 
chronic or intermittent hypercapnia. As in chapter five, we tested the 
hypothesis that high dose salbutamol could cause a rise in the partial 
pressure of arterial carbon dioxide and worsen respiratory failure among 
some subjects with severe COPD. 
 
5.2 INTRODUCTION 
Patients with COPD and long-standing hypercapnia have chronic alveolar 
hypoventilation. If high dose salbutamol causes an increase in carbon 
dioxide production, these subjects may not be able to increase ventilation in 
response to the flux of carbon dioxide to the lungs and the PaCO2 may rise 
further (see section 4.2).  
We wished to examine the effect of high dose nebulised salbutamol in 
patients with severe stable COPD and chronic hypercapnia. We chose to 
give a low dose of salbutamol as the control rather than normal saline to 
reduce the possibility that patients would require treatment to relieve 
breathlessness during the study and to try to avoid bronchoconstriction from 
inhalation of normal saline [380].   
We report the changes in arterial blood gas tensions from a crossover study 
in which fourteen patients with stable COPD, documented hypercapnia and 
limited reversibility received 10mg or 400µg nebulised salbutamol on 
separate days, both given in two doses an hour apart.  
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5.3        SUBJECTS AND METHODS 
5.3.1 Subjects 
Patients aged 40 to 85 with a clinical diagnosis of COPD were recruited if 
they had a forced expiratory volume in one second (FEV1) below 50% 
predicted and a FEV1/forced vital capacity (FVC) ratio of less than 70%. 
Subjects had to have an increase in FEV1 of not more than 200ml and 15% 
ten minutes after inhaling 200µg salbutamol. Subjects were required to have 
had an arterial carbon dioxide tension (PaCO2) of greater than 6 kPa on two 
occasions when clinically stable or have developed hypercapnia (PaCO2 > 
6kPa) during assessment for long term oxygen. 
Exclusion criteria were other causes of respiratory failure, an additional 
unstable medical condition, an acute exacerbation of COPD requiring oral 
corticosteroids within the last four weeks and regular medication with a β2-
adrenoceptor antagonist or anticoagulant. Nottingham City Hospital 
Research Ethics Committee approved the study and written informed 
consent was obtained at least 24 hours before the first study day. 
5.3.2 Measurements 
PaCO2, PaO2 and pH were measured using standard electrodes on a blood 
gas analyser (Rapidlab 840, Bayer, Leverkusen, Germany), which was 
calibrated daily (See section 4.3.2).  
The electrocardiograph was recorded on a central monitor (Dynascope DS-
5100E, Fukuda Denshi, Japan) and heart rate was calculated as mean of six 
consecutive beats. 
5.3.3 Protocol 
This was a randomised, double blind, crossover study performed on two 
non-consecutive days, not more than five days apart. Subjects were required 
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to withhold short-acting bronchodilators for at least ten hours, and 
theophylline, tiotropium and long acting β2-agonists for at least 24 hours 
before each study day; inhaled and oral corticosteroids and non-pulmonary 
medications were taken as usual. Subjects using home oxygen discontinued 
this 30 minutes before leaving home.  After an early breakfast without 
caffeine-containing beverages, subjects came to the hospital by taxi, were 
escorted to the laboratory by wheelchair and rested in a reclining chair for 
ten minutes. Three chest leads and the fingertip pulse oximeter were 
attached and Alan’s test performed on the radial and ulnar arteries to 
confirm the adequacy of local circulation. A cannula (FloSwitch, Becton 
Dickinson, Swindon, UK) was inserted into the radial artery under local 
anaesthetic and attached to the transducer. Two one ml blood samples were 
taken sequentially from the arterial cannula to measure pH, PaO2 and PaCO2 
(mean value recorded) and these were repeated at ten-minute intervals until 
consecutive mean PaO2 and PaCO2 readings were within 0.5 kPa. 
Consecutive heart rate readings also had to be within 5 beats per minute, 
without an increase in rate. Baseline values for all variables were taken as 
the mean of the last two results. 
On each day the patient was given salbutamol sulphate (Steri-Neb, Baker 
Norton, UK), either two doses of 5mg in 2.5ml an hour apart or two doses of 
200µg diluted to 2.5ml with normal saline an hour apart, with the order 
determined by computer-generated random sequence. Each dose was 
delivered over six minutes via a nebuliser (IEC 601-1, Medic-Aid, Pagham, 
UK) driven by air at 5 litres per min. Duplicate one ml samples of arterial 
blood were taken 10, 15, 20, 30, 45 and 60 minutes after starting the first 
dose of drug to determine PaCO2 and PaO2 and followed at each time point 
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by heart rate, blood pressure and oxygen saturation measurements in that 
order. Sixty minutes after starting the first nebulisation the second identical 
dose of salbutamol was delivered and the measurements repeated over the 
next hour. Subjects received the alternative dose of salbutamol on the 
second study day, using an identical protocol, except that the cannula was 
placed in the contralateral radial artery. 
The primary endpoint was the difference in change in PaCO2 between the 
two study days. 14 patients provided > 90% power to find a mean difference 
of 0.5 kPa.h-1, assuming a standard deviation of 0.2 kPa.h-1. Secondary 
outcome measures were differences in change in PaO2 and heart rate 
between the two study days.  
5.3.4 Analysis 
Change in mean PaCO2, PaO2 and heart rate for each dose of salbutamol was 
plotted against time and area under the time-response curves (AUC for 0-
120 minutes) calculated by trapezoid integration. T-tests were conducted to 
exclude carry-over and period effects between baseline readings [381] and 
paired t-tests to determine differences in AUC measurements between 
doses. Within subject change in PaCO2 (AUC) following high dose 
salbutamol was related to change in PaO2 (AUC) and heart rate (AUC) and 
to baseline measures of PaCO2, PaO2 and heart rate using Pearson’s 
correlation.
 
Analyses were carried out using the statistical software program, 
SPSS version 11 (SPSS inc, Chicago, USA), with statistical significance 
accepted at p<0.05. I conducted all the statistical analysis after advice from 
Dr Sarah Lewis  
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5.4       RESULTS 
Of the fifteen subjects who agreed to participate, one was withdrawn after 
the first study day following a fall at home. Mean demographic data for the 
fourteen patients (three women) who completed the study is found in table 
5.1. Twelve patients had had a PaCO2 above 6 kPa on two previous 
occasions and two had developed hypercapnia in response to oxygen (2 
L/min) during assessment for long-term domiciliary treatment. 
 
Baseline measurements 
Baseline PaO2 ranged from 6.0 to 10.1 kPa (mean 7.9 kPa) and showed a 
negative correlation with baseline PaCO2 (r = -0.6, p = 0.02) and a positive 
correlation with baseline FEV1 (r = 0.6, p = 0.02). The baseline PaCO2 
ranged from 5.31 to 8.3 kPa (mean 7.0 kPa), the baseline FEV1 ranged from 
0.26 to 1.1 L (mean 0.71 L (27 % predicted)) and cigarette consumption was 
high (mean 53 pack years).  
 
Comparison of the two study days 
There was no carry-over or period effect for the two study treatments. 
5.4.1 Mean changes with salbutamol (figure 5.1, table 5.2) 
Mean PaCO2 for the fourteen patients fell gradually over the study period 
following both high and low doses of salbutamol. There was no difference 
between the study days for AUC PaCO2 (0.03 kPa.h-1; 95% CI 0.02,0.04, p = 
0.57). The mean fall in PaCO2 after 120 minutes was 0.32 and 0.29 kPa for 
the high and low doses of salbutamol respectively.   
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There was a progressive fall in mean PaO2 on both study days, with a greater 
fall after high dose salbutamol. The difference between study days for AUC 
PaO2 was significant (0.1 kPa.h-1; 95% CI 0, 0.2, p=0.04). The reduction at 
120 minutes was 0.57 and 0.24 kPa for the high and low doses respectively.  
There was a greater rise in mean heart rate with the high dose compared to 
the low dose (difference in AUC HR 1.1 bpm.h-1; 95% CI 0.4, 1.8, 
p=0.005); the heart rate increase at 120 minutes in the two groups was 4.9 
and 1.1 beats per minute.  
 
5.4.2 Within subject changes with high dose salbutamol (figure 5.2) 
The change from baseline PaCO2 120 minutes after high dose salbutamol 
ranged from + 0.8 kPa to - 0.82 kPa, with 11 of the 14 subjects showing a 
fall in PaCO2. Patients showing a rise in PaCO2 were more likely to have a 
lower baseline PaCO2 and a smaller rise in heart rate with salbutamol i.e. 
PaCO2 AUC showed a negative correlation with baseline PaCO2 (r = - 0.6, p 
= 0.04) and heart rate AUC (r = - 0.6, p = 0.02). There was no significant 
correlation between PaCO2 AUC and PaO2 AUC (r = 0.2, p = 0.44) or other 
baseline measures (PaO2 r = 0, FEV1 r = 0.4, reversibility r = 0).  
Patients with the largest falls in PaO2 had higher baseline FEV1 and PaO2 
values and a greater rise in heart rate; ie PaO2 AUC showed a negative 
correlation with FEV1 (r = - 0.6, p = 0.04), baseline PaO2 (r = -0.7, p = 0.01) 
and heart rate AUC (r = - 0.53, p = 0.05).  
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Age (years) 66 (7) 
FEV1 (L) 0.71 (0.3) 
BMI (kg m-2) 28 (6) 
Cigarette consumption (pack years) 53 (34) 
Reversibility (ml) 109 (57) 
PaCO2 (kPa) 7.9 (1.0) 
PaO2 (kPa) 7.2 (1.3) 
Number of subjects taking respiratory medication 
       -short-acting β2-agonists 13 
       -long-acting β2-agonists 9 
       -inhaled corticosteroids 9 
       -short-acting anti-muscarinics 9 
       -long-acting anti-muscarinic 0 
       -oral theophylline 2 
       -home oxygen 8 
 
 
Table 5.1: Mean (SD) baseline demographic data for the fourteen subjects. 
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Figure 5.1: Mean change in heart rate, arterial carbon dioxide (PaCO2) 
and oxygen (PaO2) tension over 120 minutes after high (Ŷ—Ŷ) and low dose 
(Ÿ• • •Ÿ) nebulised salbutamol (n=14). 
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 Figure 5.2:  The effect of high dose salbutamol on PaCO2 and PaO2 for 
each patient (n=14), comparing baseline reading with the 
reading at 120 minutes post-dose. 
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PaCO2 AUC  
Difference (high v low) 0.03 kPa.h-1 (0.02, 0.04), p = 0.57 
PaO2 AUC  
Difference (high v low) 0.1 kPa.h-1   (0, 0.2), p = 0.04 
Heart rate AUC  
Difference (high v low) 1.1 bpm.h-1 (0.4, 1.8), p = 0.005 
 
 
 
 
 
 
 
Table 5.2:  Between dose comparisons of mean AUC for PaCO2, PaO2 
and heart rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 125
5.5       DISCUSSION 
We examined the effects of high and low dose nebulised salbutamol on 
arterial blood gas tensions in patients with stable COPD who had limited 
bronchodilator reversibility and either resting hypercapnia or a raised PaCO2 
in response to oxygen therapy. The higher dose of salbutamol produced a 
greater fall in mean PaO2 and increase in heart rate, although the differences 
between the high and low doses were small. Neither dose of salbutamol 
caused a rise in mean PaCO2, although three subjects showed a small 
increase in PaCO2 with high dose salbutamol. 
β2-agonists have reduced PaO2 in previous studies in patients with less 
severe COPD
 
and the changes were attributed to an increase in 
ventilation/perfusion mismatching [280,382,383]. Although these studies 
have not shown a rise in PaCO2, other studies have documented an acute 
increase in CO2 output of over 25% in response to modest salbutamol doses 
in normal subjects and patients with asthma [281,384]. This increase in 
VCO2 has been attributed to increased CO2 flux to the lungs, due to 
increased cardiac output, and increased CO2 production as metabolic rate 
and skeletal muscle tremor increase. We hypothesized that PaCO2 might rise 
following higher doses of salbutamol in patients with severe COPD, 
hypercapnia and limited bronchodilator reversibility due to an inability to 
increase ventilation in response to an increase in VCO2. After the difficulties 
we experienced studying patients during an acute exacerbation, we chose to 
test the hypothesis on patients with severe COPD in a stable condition in 
whom previous episodes of hypercapnia suggests limited ability to further 
increase ventilation.  
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The mean PaCO2 in our patients fell after high dose salbutamol, suggesting 
that either VCO2 did not rise for most subjects or that ventilation increased 
appropriately in response to an increase in VCO2 despite severe airflow 
obstruction and hypercapnia. We did not measure VCO2 since it was 
important that patients were as relaxed as possible.  All but one of our 
subjects was taking regular β2-agonists and they may therefore have 
developed tolerance, thus reducing the increase in tremor and cardiac output 
following salbutamol. Tolerance has been shown for the increase in CO2 
production with β2-agonists in normal subjects [385] and it would also 
explain the relatively small increase in heart rate following salbutamol in 
our study.  
There was some variation in change in PaCO2 in response to the high dose of 
salbutamol and a rise in PaCO2 was seen in three of the 14 subjects. 
Contrary to our expectations, patients showing a rise in PaCO2 were more 
likely to have had low baseline PaCO2 values and they also had a smaller 
increase in heart rate. This could reflect relaxation during the study although 
we went to some lengths to ensure that subjects were relaxed and that 
baseline measurements were stable before giving salbutamol.  Nevertheless 
patients who were less relaxed would have a lower PaCO2 and higher heart 
rate prior to treatment, and these would tend to increase and decrease 
respectively during the study. We considered whether salbutamol might 
potentiate the effects of hypoxaemia on chemoreceptor stimulation and also 
contemplated the direct effect of salbutamol on respiratory drive. β-
adrenoceptors may exist on central chemoreceptors and there is evidence 
that while β2-agonists can increase respiratory drive, β-antagonists can have 
the opposite effect [386,387].  
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The changes in the partial pressure of arterial carbon dioxide 120 minutes 
after 10 mg nebulised salbutamol were small (maximum 0.8 kPa) and the 
rise in PaCO2 seen in the three subjects was unlikely to produce a clinically 
significant adverse outcome. Some of the change in PaCO2 we found can be 
explained by regression to the mean and by subjects not being completely 
relaxed at the start of the study. There will always be some variability in the 
results as a consequence of the repeatability of blood gas measurements. 
This was minimised by using the same machine for the whole study, which 
was calibrated every thirty minutes and had a quoted agreement between 
PaCO2 results of 0.09 kPa in healthy subjects and hypoxaemic patients.   
Change in PaCO2 did not correlate with either baseline PaO2 or change in 
PaO2 however, which may reflect differences between patients in their 
ability to increase ventilation, in the extent to which tolerance to β2-agonists 
had developed and/or the presence of different β2-adrenoceptor 
polymorphisms within the group. 
 
5.6       CONCLUSION 
Whatever the mechanism behind these changes, our findings confirm that 
10mg nebulised salbutamol reduces PaO2 and suggest that an increase in 
PaCO2 following a high dose of salbutamol is uncommon in patients with 
stable severe COPD who take β2-agonists regularly.  
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Chapter Six 
 
Systemic and bronchodilator effects of formoterol in 
Chronic Obstructive Pulmonary Disease: a dose 
response study 
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6.1 AIMS 
This study was designed to determine whether higher doses of inhaled 
formoterol produce systemic adverse effects that outweigh the limited 
bronchodilator benefit seen in subjects with COPD. We performed this 
study to determine whether high doses were well tolerated and to establish 
whether formoterol may have the potential to be used ‘as required’ by 
symptomatic patients with COPD. 
 
6.2 INTRODUCTION 
Bronchodilators are widely used by patients with symptomatic chronic 
obstructive pulmonary disease (COPD). Short-acting agents are used for 
symptom relief, but long-acting β2-agonists have additional benefits 
[344,356] and management algorithms recommend their introduction if 
symptoms persist [388]. 
Formoterol, a selective β2-agonist with a twelve-hour duration of action at 
conventional doses, has been shown to improve lung function and reduce 
symptoms when inhaled twice daily by patients with COPD [356,365]. It 
has a rapid onset of bronchodilatation within five minutes, similar to that of 
short-acting β2-agonists [229,389] and when used “as-required” by patients 
with asthma, was more effective than terbutaline, in terms of lung function 
and prolonging the time to the first severe exacerbation [390].  
A similar strategy has been suggested for patients with COPD [391], but the 
balance of beneficial and adverse effects may be different since additional 
bronchodilatation with higher doses may be minimal in these patients whilst 
the potential for adverse effects will continue to increase. In a previous 
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salbutamol (1mg) rather than the highest dose (4mg), presumably because 
the lower dose offered the best balance between beneficial and adverse 
effects [253]. The main safety concern with high dose formoterol relates to 
cardiovascular adverse effects. This is an important consideration among 
patients with COPD, who may have co-existing ischaemic heart disease and 
hypoxaemia, both risk factors for cardiac arrythmia. 
We therefore carried out a randomised, crossover, dose-response study to 
compare the efficacy, systemic effects and subject satisfaction following 
single doses of inhaled formoterol (6, 12, 24 and 48µg) and placebo in 
twenty patients with symptomatic COPD. 
6.3 SUBJECTS AND METHODS 
6.3.1 Subjects 
Subjects aged 40 to 85 with a clinical diagnosis of COPD were recruited if 
they had exertional breathlessness, limited reversibility to inhaled 
salbutamol, a forced expiratory volume in one second (FEV1) below 70% 
predicted and a FEV1/forced vital capacity (FVC) ratio of less than 70%.  
Patient characteristics on entry to the study are shown in table 6.1. Subjects 
were excluded if they were current smokers [392] or had an exhaled carbon 
monoxide level above ten parts per million on study days (Smokerlyzer, 
Bedfont Scientific, UK), had experienced an acute exacerbation of COPD 
within the last four weeks, a myocardial infarction or unstable angina in the 
last three months, had an unstable medical condition or were taking β-
adrenergic antagonists. Nottingham City Hospital Research Ethics 
Committee approved the study and written informed consent was obtained 
from each subject at least 24 hours before the first study day. 
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Subject Age  Sex FEV1 
(L) 
FEV1  
% pred 
FEV1/ 
FVC 
β2-agonists Other respiratory 
medications 
1 72 M 0.75 25 44 Formoterol 
Salbutamol 
Budesonide 
Ipratropium 
2 75 F 1.05 58 62 Salbutamol 
 
 
3 54 F 1.4 51 54 Salmeterol 
Salbutamol 
Fluticasone 
Ipratropium 
4 59 M 1.64 48 52 Salmeterol 
Salbutamol 
Fluticasone 
Ipratropium 
5 75 F 0.88 49 53 Salbutamol 
 
Ipratropium 
6 67 M 0.5 18 28 Salbutamol 
 
Ipratropium 
7 71 M 0.74 30 44 Salbutamol 
 
Beclomethasone 
Ipratropium 
8 62 F 1.22 53 53 Formoterol 
Salbutamol 
Budesonide 
Ipratropium 
9 77 M 0.82 31 32 Salmeterol 
Salbutamol 
Fluticasone 
Ipratropium 
10 71 M 0.95 51 51 Salbutamol 
 
 
11 66 M 1.4 44 49 Salmeterol 
Salbutamol 
 
Fluticasone 
Ipratropium 
Theophylline 
12 64 M 1.95 56 65 Formoterol 
Terbutaline 
Budesonide 
13 63 F 0.95 41 44 Salmeterol 
Salbutamol 
Fluticasone 
Tiotropium 
14 60 M 2.65 69 63 
 
 
Tiotropium 
15 62 F 1.37 59 58 Salmeterol 
Salbutamol 
Fluticasone 
Ipratropium 
16 60 M 0.75 23 25 Formoterol 
Salbutamol 
Budesonide 
Tiotropium 
17 77 M 1.4 55 50 Salmeterol 
Terbutaline 
 
Fluticasone 
Ipratropium 
Theophylline 
18 75 M 1.28 42 49 Salmeterol 
 
Fluticasone 
Ipratropium 
19 52 M 2.52 68 53 Terbutaline 
 
Tiotropium 
20 67 M 2.11 63 54 Salmeterol 
 
Ipratropium 
 
Table 6.1: Subject characteristics on entry into formoterol dose-response 
study. 
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6.3.2 Measurements 
a)  Oxygen saturation 
Oxygen saturation was measured using a fingertip pulse oximeter (Minolta 
Pulsox-7, Tokyo, Japan). 
b) Cardiovascular measures 
The electrocardiograph was recorded by three-lead ambulatory monitor 
(DMS 300-7, Numed Cardiac Diagnostics, Sheffield, UK) and heart rate 
was calculated as the mean of ten consecutive beats. Blood pressure 
measurements were taken by electronic sphygmomanometry (HEM-705CP, 
Omron, Japan).  
c) Dyspnoea 
Dyspnoea was measured using a 100 millimetre visual analogue scale 
(VAS) ranging from “no breathlessness” to “worst possible breathlessness”. 
d) Tremor 
Tremor was measured in two ways. Subjective tremor was measured using a 
100 millimetre visual analogue scale (VAS) ranging from “no tremor” to 
“worst possible tremor”. Tremor amplitude was measured for one minute, 
using an accelerometer (Bruel and Kjaer 4367, Naerum, Denmark) fitted to 
the terminal phalanx of the right middle finger with the forearm supported 
and the hand outstretched. The waveform was amplified and filtered to 
remove frequencies above 50 Hz, before five-second samples were 
subjected to Fourier analysis to calculate acceleration (Pulse Platform, Bruel 
and Kjaer, Naerum, Denmark). The machine was calibrated prior to each 
study day by measuring the tremor amplitude of the accelerometer at rest. 
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e) FEV1 
Spirometry was performed with the patient seated using a dry bellows 
spirometer (Vitalograph, Buckingham, UK), taking the better of two 
successive measurements of FEV1 within 100ml. Each spirometer was 
calibrated once every two months with a one-litre Vitalograph® syringe; six 
litres of air were injected into the spirometer in one litre increments and the 
observed readings were required to be within +/- 0.05 litres of the volume 
inserted. In addition each spirometer was checked for air leaks once a 
fortnight by attaching a one-way valve to the mouthpiece, instilling air and 
ensuring that the recording pen did not drift downwards over the following 
two minutes. 
f)     Plasma potassium 
Plasma potassium concentration was measured by flame photometry 
(Olympus AU5000, Olympus Optical Co. Ltd, Eastleigh, UK).  
g)  Six-minute walk test 
A six-minute walk test was performed according to American Thoracic 
Society guidelines with standardised verbal encouragement [393] and 
breathlessness was measured on a Borg scale before and after exercise. 
Subjects carried out two six-minute familiarisation walk tests before 
randomisation [394].  
h) Satisfaction 
Overall satisfaction with each drug/dose was measured on a 200 mm visual 
analogue scale from “completely dissatisfied, side effects outweigh any 
benefit” to “completely satisfied, benefit outweighs any side effects”.  
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6.3.3 Protocol 
This was a randomised, double blind, crossover study performed on five 
days within a two-week period and with each visit commencing at the same 
time of day. Subjects were required to withhold short-acting bronchodilators 
for at least ten hours and theophylline, tiotropium and long-acting β2-
agonists for at least 24 hours before each study day. Inhaled corticosteroids 
and non-pulmonary medications were taken as usual unless they were 
deemed likely to affect any of the study outcomes. After an early breakfast 
with a maximum of one cup of tea or coffee, subjects attended the 
laboratory at 0800 and rested in a comfortable chair for twenty minutes. 
After checking exhaled carbon monoxide levels, the ambulatory cardiac 
monitor was attached and baseline measures of SpO2, heart rate, blood 
pressure, breathlessness, tremor (accelerometer and VAS) and FEV1 were 
taken. Blood was then taken for plasma potassium measurement and 
followed by a six-minute walk test, with pre- and post-test measures of 
breathlessness. After a ten-minute rest, subjects inhaled formoterol (6, 12, 
24 or 48 µg) or placebo, with the dose and order determined by randomised 
computer generated sequence. On each day and under independent 
supervision, subjects took four inhalations at one-minute intervals from 
identical Turbohalers®. Three inhalers were used, containing placebo, 
formoterol 6 µg or 12 µg, with each device being removed from the subject 
between inhalations in order to ensure blinding. Subjects remained seated 
for the next four hours with repeat measures of oxygen saturation, heart rate, 
blood pressure, breathlessness, tremor and FEV1 in that order at 30, 60, 120, 
180 and 240 minutes post inhalation. Every 60 minutes, subjects were 
asked, “Have you felt any adverse effects that may relate to inhaling the 
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medication”. At four hours, a further blood sample was taken for plasma 
potassium assay and the subject was asked to record overall satisfaction with 
the treatment. The six-minute walk test was then repeated.  
We were most interested in the patients overall satisfaction with each 
treatment, as a balance between beneficial and adverse effects, but with no 
data on which to base the power calculation, we randomised twenty subjects 
to provide 80% power to detect a 160ml change in FEV1 [395]. Twenty 
subjects would also allow us to assess systemic effects of interest [396]. 
 
6.3.4 Analysis  
The area under the curve for all variables measured at intervals over the four 
hours was calculated for each subject and treatment. Shapiro-Wilks testing 
was performed to confirm that the results were normally distributed (p>0.05 
for all tests). The difference between placebo and formoterol was assessed 
using repeated measures ANOVA for individual AUC values and the dose-
response assessed by statistical significance of the linear contrast with 
increasing formoterol dose.  Change in plasma potassium and six-minute 
walk distance between baseline and four hours after treatment was assessed 
using repeated measures ANOVA, followed by post test analysis to assess 
for linear trend with increasing dose. The difference in mean ectopic beat 
rate between placebo and each formoterol dose and the dose-response 
relationship was assessed by repeated measures ANOVA. Mean satisfaction 
scores for each formoterol dose and placebo were compared using a t-test. 
Statistical analyses were performed using SPSS Version 12 (SPSS Inc, 
Chicago, USA) after advice from Dr Sarah Lewis, and statistical 
significance was accepted as p<0.05. 
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6.4 RESULTS 
All twenty subjects (six women) completed the study. Their mean age was 
66 years, mean cigarette consumption was 42 pack years, BMI 26 kg/m2 and 
FEV1 1.32 L (47% predicted) with a mean increase in FEV1 of 33 mL (range 
0-160 ml) following salbutamol 200µg.  
Thirteen of the twenty participants used inhaled corticosteroids and only 
four used tiotropium bromide. Nineteen subjects used inhaled β2-agonists on 
a daily basis, with thirteen taking a long-acting β2-agonist twice-daily and 
six further subjects taking short-acting β2-agonists four times a day. Eleven 
subjects used both short- and long-acting β2-agonists.  
Data were available for all time points, except for three plasma potassium 
levels due to blood clotting. There were no significant differences in 
baseline FEV1 values between study days and no crossover effects. 
 
6.4.1 Spirometry (figures 6.1 and 6.3, table 6.2) 
FEV1 increased from baseline with all doses of formoterol and the effect 
was sustained over four hours. AUC FEV1 was higher after all doses of 
formoterol compared to placebo and showed a significant dose-response 
relationship with increasing doses of formoterol. The largest AUC FEV1 
(626.6 ml.h) was seen with the highest dose of formoterol and reflects a 
mean increase in FEV1 of around 157 ml across the four hour time period. 
There was no correlation between the AUC FEV1 and baseline FEV1 (r = 
0.7, p = 0.2). 
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6.4.2 Oxygen saturation (figures 6.2 and 6.4, table 6.2) 
There was an initial fall in mean SpO2 after each dose of formoterol with the 
maximum fall occurring between 30 and 60 minutes. The mean fall from 
baseline was less than 1% after all doses however, and there was no 
difference between placebo and any formoterol dose and no dose-response 
relationship for AUC SpO2. 
 
6.4.3 Breathlessness (figures 6.1 and 6.3, table 6.2) 
All doses of formoterol and placebo were associated with a fall in dyspnoea 
score and this was sustained over the four hours. There was no difference 
between placebo and any formoterol dose and no dose related effect of 
formoterol. 
 
6.4.4 Cardiovascular responses (figures 6.1, 6.2, 6.3, 6.4, 6.5, table 7.2) 
There was an initial fall in mean heart rate after the three lowest doses of 
formoterol, but a small rise with the highest dose and AUC heart rate for the 
48 µg dose was greater than that for placebo (p = 0.02). There was no 
difference between placebo and other formoterol doses and no dose 
response relationship. 
Systolic blood pressure fell initially following all formoterol doses and 
placebo and then increased gradually whilst diastolic blood pressure showed 
a small rise over the four hours. There were no difference between placebo 
and any formoterol dose and no dose response relationship for either systolic 
or diastolic blood pressure.  
There was no difference between any formoterol dose and placebo and no 
dose response relationship for mean hourly rate of supraventicular or 
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ventricular ectopics, although formoterol 48 µg was associated with the 
highest ectopic rate. 
 
6.4.5 Tremor (figures 6.1, 6.2, 6.3 and 6.4, table 6.2) 
Tremor measured by accelerometer increased with the two highest 
formoterol doses compared to placebo and AUC tremor showed a dose-
response effect. Tremor measured by VAS was more variable. Although 
there were no differences between individual doses and placebo, a dose 
response relationship was evident.  
 
6.4.6 Walking distances (figure 6.5) 
Changes in six-minute walk distance were trivial, with no difference 
between placebo and any formoterol dose and no dose-response 
relationship. The maximum change in six-minute walk distance between 
placebo and any dose of formoterol was around fifteen metres, which is less 
than 5% of the mean baseline walk distance of 360 metres. 
 
6.4.7 Exertional dyspnoea (figure 6.6) 
Formoterol produced no change in pre- or post-walk Borg dyspnoea scores 
compared to placebo and no dose response relationship was present.  
 
6.4.8 Plasma potassium (figure 6.5) 
At four hours mean plasma potassium had changed by less than 0.1 mmol 
from baseline for all doses, with no difference between placebo and 
individual formoterol doses and no dose-response effect. 
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6.4.9 Satisfaction scores (figure 6.5) 
Each formoterol dose produced higher satisfaction scores than placebo, but 
with no dose-response relationship. 
6.4.10 Adverse events 
No serious adverse effects were reported during the study. Two individuals 
reported headache after placebo and formoterol 6 µg respectively and one 
reported light-headedness two hours after formoterol 6 µg. 
 
6.5 DISCUSSION 
In subjects with moderately severe, symptomatic COPD, formoterol 
produced a dose dependent increase in FEV1 without a corresponding 
improvement in dyspnoea or walk distance. Tremor also increased in a dose 
dependent manner whilst heart rate only increased significantly after the 
highest formoterol dose. Formoterol had no significant effect on plasma 
potassium, blood pressure, oxygen saturation or ectopic beat rate. All doses 
of formoterol produced higher satisfaction scores than placebo, although no 
dose response relationship was evident. 
Satisfaction with any treatment depends on a balance of beneficial and 
adverse effects. This is particularly relevant in COPD where the largely 
irreversible nature of the disorder will limit the beneficial effects seen with 
higher drug doses whilst adverse effects can continue to increase. The 
increase in FEV1 in this study was small and of similar magnitude to that 
seen in other studies in subjects with COPD [397], but was not associated 
with a dose related decrease in dyspnoea scores or an increase in exercise 
tolerance. Formoterol [365] and salmeterol [351] have failed to produce a 
dose related effect on dyspnoea or walk distance in previous longer term  
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Figure 6.1: Mean values over 240 minutes for FEV1(L), dyspnoea VAS 
(mm), heart rate (bpm) and tremor acceleration (m/s/s) after formoterol 6 
(7), 12 (8), 24 (♦) and 48 (•) µg and placebo ( e ). 
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Figure 6.2: Mean values over 240 minutes for SpO2 (%), tremor VAS (mm), 
systolic and diastolic blood pressure (mmHg) after formoterol 6 (7), 12 
(8), 24 (♦) and 48 (•) µg and placebo ( e ). 
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Figure 6.3: The relationship between log dose formoterol (µg) and mean 
area under the curve for FEV1 (ml.h), dyspnoea VAS (mm.h), heart rate 
(bpm.h) and tremor acceleration (m/s/s.h) with placebo (P) shown for 
comparison ( e ). 
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Figure 6.4: The relationship between log dose formoterol (µg) and mean 
area under the curve for SpO2
 
(%.h), tremor VAS (mm.h), systolic and 
diastolic blood pressure (mmHg.h) with placebo (P) shown for comparison ( 
e ). 
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Figure 6.5: The relationship between log dose formoterol (µg) and change in 
six-minute walk distance (m), change in plasma potassium concentration 
(mmol/l), mean rate of ventricular (Ÿ) and supraventricular (>) ectopic 
beats and mean satisfaction scores (mm), with placebo (P) shown for 
comparison ( e ). 
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Figure 6.6: The relationship between formoterol 6 (7), 12 (8), 24 (♦) and 
48 (•) µg and placebo ( e ) and the pre- and post-walk Borg dyspnoea 
scores. 
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AUC values 
SBP DBP 
 
FEV1 
 
(ml.h) 
SpO2 
 
(%.h) 
Dyspnoea 
 
(mm.h) 
HR 
 
(bpm.h) 
Tremor 
 
(m/s/s.h) 
VAS 
tremor 
(mm.h) 
 
(mmHg.h) 
 
Placebo 
 
- 104.3 
 
0.5 
 
- 25 
 
- 8.9 
 
- 0.42 
 
- 3.2 
 
- 21 
 
- 6.7 
 
6   µg 
 
225.3† 
 
1.2 
 
- 46.0 
 
- 2.8 
 
- 0.26 
 
- 4.6 
 
- 3.3 
 
1.5 
 
12 µg 
 
362† 
 
0.3 
 
- 38.2 
 
- 2.5 
 
- 0.12 
 
- 20.7 
 
- 4.1 
 
3.1 
 
24 µg 
 
510.8† 
 
- 1.0 
 
- 46.2 
 
- 6.3 
 
0.57† 
 
0.6 
 
8.2 
 
3.6 
 
48 µg 
 
626.6† 
 
1.1 
 
- 44.3 
 
0.6† 
 
0.85† 
 
1.5 
 
3.9 
 
8.4 
 
p value 
 
0.04ä 
 
0.69 
 
0.98 
 
0.65 
 
<0.001ä 
 
0.04ä 
 
0.6 
 
0.68 
 
ä p = <0.05 for dose response trend 
      †   p = <0.05 for individual formoterol dose versus placebo 
 
Table 6.2: Mean area under the time response curve (AUC) for FEV1 
and the systemic measurements made at intervals over 240 
minutes for each formoterol dose. 
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studies, suggesting that these may be less sensitive outcome measures for 
evaluating the dose response effect of long-acting β2-agonists and reflecting 
the relatively small increases in FEV1 seen in patients with COPD.   
The adverse systemic effects of β2-agonists are well known, but in this study 
only tremor and heart rate increased significantly with high doses of 
formoterol. Moderate doses of formoterol have been shown to increase heart 
rate, systolic blood pressure and QT interval,
 
and to reduce plasma 
potassium and diastolic blood pressure in healthy volunteers [264,398,399]. 
The effects have been less marked in subjects with asthma [399-404], 
perhaps reflecting the development of tolerance to β2-agonists for systemic 
effects [267,405,406]. Tolerance could explain the limited systemic effects 
and lack of reported adverse effects in our study since most subjects were 
using β2-agonists regularly.  
We summarized our findings as mean values, and as area under the curve 
for the measurements that were made on several occasions. Outliers may not 
be apparent with this approach but could be important in relation to adverse 
effects. Checking individual data showed that the data was homogenous and 
that there were no worrying outlying results. We limited the study to four 
hours so that responses would not be affected by meals, as in previous 
studies. The greatest pharmacodynamic changes are known to occur within 
four hours so it is unlikely that we missed additional effects after this time 
period [264].  
The dose response curve produced by the accelerometer suggests that this 
may a better way than the visual analogue scale to determine the presence of 
tremor. Subjects did not perceive the symptoms to be troublesome or 
significant. Again, since most individuals used β2-agonists on a daily basis, 
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tolerance may have limited the physiological tremor and the tremor 
produced may almost be considered normal by those who experience the 
symptom on a daily basis.  
Rather than seeing the bronchodilator response plateau with high doses, 
there was a dose-related rise in AUC FEV1. The increase in FEV1 and the 
limited systemic effects would support the suggestion that inhaled 
formoterol may have a role as rescue medication in COPD. However, 
concerns do exist about the adverse effects produced by high dose β2-
agonists, particularly among patients with pre-existing cardiovascular 
disease. As discussed in chapter four, a small study of subjects with COPD 
who had had a cardiac arrhythmia suggested that formoterol 12 µg offered a 
higher safety margin than the 24 µg dose since it had less effect on heart 
rate, plasma potassium, supraventricular and ventricular premature beats 
[377]. There was a trend towards increased ectopic beats with higher doses 
in our study, but a larger long-term study would be needed to fully assess 
the safety of higher doses in these patients. Adverse cardiovascular effects 
and dysrhythmias are particularly important for patients with COPD due to 
the increased incidence of cigarette smoking and risk factors such as 
hypoxaemia, hypokalaemia and prolonged QT interval [405], which are 
likely to increase further during an exacerbation [299].  
Assessing the balance between beneficial and adverse effects is difficult and 
asking about overall satisfaction with the drug after each study day was an 
attempt to address the patients’ perception of this balance. Satisfaction 
scores are difficult to validate but formoterol produced greater subject 
satisfaction than placebo in keeping with its effect on FEV1. A similar 
approach had face validity in a previous study that compared different doses 
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of salbutamol in subjects with COPD and produced a bell shaped response 
for satisfaction, in that subjects preferred a modest dose of salbutamol (1mg) 
to both placebo or the highest dose of salbutamol (4mg), presumably 
because the 1mg dose offered the best balance between beneficial and 
adverse effects [253]. Satisfaction improved with all doses of formoterol in 
our study however, suggesting that the perceived adverse effects of 
formoterol 48 µg did not exceed the perceived benefit.  
 
6.6 CONCLUSION 
In our subjects with moderate to severe COPD, single doses of inhaled 
formoterol produced a dose-dependent improvement in FEV1. The lack of 
serious systemic adverse effects with high doses was reassuring and 
suggests that further studies designed to explore the role of formoterol as a 
rescue medication in COPD are warranted. 
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7.1 DISCUSSION 
Determining the optimum use of inhaled β2-agonists in chronic obstructive 
pulmonary disease is important. COPD is very common, worldwide 
prevalence is increasing and β2-agonists are widely used. Patients are often 
elderly and often have co-morbidities, including an increased incidence of 
the cardiovascular diseases associated with cigarette smoking. COPD is 
progressive and much of the pathology is irreversible, with limited 
reversibility to bronchodilators being a distinguishing feature of the disease. 
This means that high doses of inhaled β2-agonists could produce adverse 
systemic effects that outweigh the limited beneficial bronchodilator effects 
in some patients with COPD. 
The adverse systemic effect profile of inhaled β2-agonists is well known and 
includes headaches, agitation, tachycardia, palpitations, muscle cramps, 
tremor, a reduction in serum potassium and a fall in the partial pressure of 
arterial oxygen. Although the adverse effects are generally mild and well 
tolerated, there are concerns that a fall in PaO2 and serum potassium and an 
increase in heart rate could precipitate a serious cardiac event in some 
patients with COPD, particularly if the patient already has hypoxaemia, 
hypokalaemia or cardiac problems. The risk of a serious adverse event may 
be increased further if the patient is taking drugs that can stimulate the 
myocardium (theophyllines) or cause hypokalaemia (diuretics and 
corticosteroids) as these patients often are. 
Concerns about the safety of using regular short-acting inhaled β2-agonists 
in the management of asthma have been present for some time and more 
recently these concerns have extended to long-acting β2-agonists. A large-
scale surveillance study comparing the safety of regular inhaled salmeterol 
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with placebo was halted prematurely after an increase in asthma-related 
deaths and life-threatening experiences was identified amongst subjects 
receiving salmeterol [297]. Concerns also exist about the safety of relatively 
high doses, after Mann et al found that the 24 µg twice-daily dose of 
formoterol was associated with more frequent serious asthma exacerbations 
than placebo, an effect not seen with the 12 µg twice-daily dose [376]. 
Although widely used in the management of COPD, few studies have 
concentrated on the safety of inhaled β2-agonists in these patients. Placebo-
controlled studies that examined the efficacy of regular short-acting inhaled 
β2-agonists in COPD did not report an increase in adverse effects with β2-
agonists, but each study only examined a low (200 µg qds) dose of 
salbutamol. The placebo-controlled studies that examined the efficacy of 
formoterol and salmeterol in COPD generally found a beneficial effect on 
lung function and symptoms without an increase in adverse systemic effects 
(Chapter Four). The three studies in this thesis have examined aspects of the 
safety of higher doses of inhaled β2-agonists used in the treatment of 
patients with COPD.  
In the management of COPD, the highest doses of inhaled β2-agonists are 
given as rescue medication during an acute exacerbation and similar doses 
are given on a regular basis as part of the domicilary care of some patients 
with severe COPD. These may be two situations when high doses of β2-
agonists are particularly hazardous since both are associated with more 
severe hypoxaemia, which heightens the cardiovascular risk with β2-agonist 
use. If inhaled β2-agonists produce a further fall in PaO2 and a reduction in 
plasma potassium the potential hazard may become clinically important. 
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The reduction in potassium level can be less marked after chronic use of an 
inhaled β2-agonist in COPD, a situation where tachyphylaxis could be 
helpful for the individual patient.  
Inhaled β2-agonists increase carbon dioxide output. A number of 
mechanisms have been suggested, including an increase in carbon dioxide 
flux to the lungs as a result of the increase in cardiac output and an increase 
in CO2 production as tremor increases [379]. The rise in carbon dioxide 
output was demonstrated to be over 20% after healthy subjects inhaled 
salbutamol at a dose of 1.2 mg [281]. Since subjects increase the work of 
breathing in response to the metabolic demands during acute exacerbations 
of COPD we hypothesized that some patients would be unable to increase 
ventilation in response to a β2-agonist mediated rise in CO flux to the lungs, 
causing a rise in PaCO2 and worsening respiratory failure. The work of 
breathing of subjects with severe COPD at rest is much higher than age 
matched healthy subjects, but the increase in VCO2 after inhaled β2-agonists 
would be less metabolically demanding than moderate exercise. For a β2-
agonist to cause a rise in PaCO2 via the proposed mechanism, the subject 
would need to be approaching their physiological limit and unable to 
increase their work any further, for example during a severe exacerbation.  
In the first study (chapter 5) we tried to examine the effects of high dose 
salbutamol on arterial blood gas tensions during an acute exacerbation of 
COPD. Due to major problems with recruitment, the study was abandoned 
and instead we examined the effect of high dose salbutamol on arterial 
blood gas tensions among fourteen patients with stable severe COPD and 
chronic or intermittent hypercapnia (chapter 6).  
Our main findings in the five patients studied during an exacerbation were: 
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• There was no evidence that high dose nebulised salbutamol had a 
dose response effect on arterial carbon dioxide (PaCO2) or oxygen 
tension (PaO2). 
• The individual with the highest baseline PaCO2 had a transient rise in 
PaCO2 after the highest doses of salbutamol. 
• Semi-invasive studies during an acute exacerbation of COPD are 
difficult to conduct. 
Our main findings in the fourteen patients with COPD and evidence of a 
raised PaCO2 were: 
• High dose salbutamol caused a small fall in mean PaCO2 and mean 
PaO2. 
• Three individuals had a small rise in PaCO2 120 minutes after 10mg 
salbutamol. 
• A rise in PaCO2 after 10 mg salbutamol was associated with a low 
baseline PaCO2. 
Thus there was no evidence of a sustained or consistent rise in PaCO2 after 
high dose nebulised salbutamol in either study and no evidence that 
salbutamol worsened respiratory failure to any extent in most of the subjects 
we studied with moderate to severe COPD. The fact that most subjects had 
no increase in PaCO2 suggests that either there was no major increase in CO2 
flux to the lungs after inhaled salbutamol or most patients were able to 
increase ventilation in response to the CO2 flux. We have considered the 
likely mechanisms underlying the mean findings in our studies and assessed 
why three subjects had a small rise in PaCO2 in the second study. 
1) The increase in VCO2 was too small to cause an increase in PaCO2. 
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As described earlier there was a mean rise in VCO2 of more than 20% when 
healthy subjects inhaled a modest dose of salbutamol [281]. The study had 
demonstrated a dose related increase in VCO2 and we had anticipated that 
the higher doses of nebulised salbutamol would produce a similar, or 
greater, increase in carbon dioxide output in subjects with COPD. Possible 
reasons for a lower increase in VCO2 include: 
a) Transient increase in VCO2 
The rise in VCO2 may not have been sustained at a sufficiently high level 
for long enough to cause a rise in PaCO2 in our patients. VCO2 was found to 
be at its peak five minutes after inhalation of salbutamol by Amoroso et al 
[281]. Although VCO2 was still high 60 minutes after inhalation, the 
increase was only 10% higher than baseline for the last 30 minutes.  
b) Downregulation of β2-adrenoceptors 
Regular use of inhaled β2-agonists can lead to downregulation of systemic 
response to β2-agonists  [267,406,407]. Most patients in studies one and two 
were taking inhaled β2-agonists regularly prior to being studied, so the effect 
of salbutamol on VCO2 may have been lower than that demonstrated by 
Amoroso et al [281] The absence of a large rise in heart rate in both studies 
suggests that the increase in cardiac output was modest thus reducing any 
increased flux of CO2 to the lungs. Downregulation of tremor would lead to 
a smaller increase in metabolic rate and reduce the anticipated increase in 
carbon dioxide production.  In keeping with downregulation, Wilson et al 
showed that the acute effect of a single dose of salbutamol on VCO2 was 
attenuated by the regular inhalation of β2-agonists for two weeks [385]. 
c) β2-adrenoceptor polymorphisms  
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Little is known about the clinical relevance of β2-receptor polymorphisms in 
COPD. The polymorphisms may affect downregulation and could explain 
some of the variation in the VCO2 response to high dose inhaled salbutamol. 
2) Most subjects can increase ventilation in response to a rise in VCO2. 
Most subjects did not have a rise in PaCO2 after high dose salbutamol even 
when they are experiencing the increased metabolic demands of an acute 
exacerbation of COPD. The majority of patients with COPD and a history of 
hypercapnia (evidence of chronic alveolar hypoventilation) did not have a 
rise in PaCO2 after high dose salbutamol either. This suggests that most 
subjects with COPD have the ventilatory reserve to respond to a flux of CO2 
to the lungs, even if they have severe disease, chronic hypoventilation or are 
experiencing an acute exacerbation.  
The fact that three individuals had a small rise in PaCO2 after high dose 
salbutamol in the second study could provide some support for our 
hypothesis or could reflect heterogeneity of biological response. The 
association between a low baseline PaCO2 and a subsequent rise in PaCO2 
could be due to regression to the mean or anxiety at the start of the study 
causing hyperventilation and an inappropriately low baseline PaCO2 for that 
patient. The rise in PaCO2 might then be due to the patient relaxing over the 
two hours, rather than a salbutamol induced rise in carbon dioxide 
production. This would be consistent with the rise in PaCO2 being associated 
with a smaller rise in heart rate (which would tend to fall as the individual 
became less anxious).  
The results from the two studies were broadly reassuring. We cannot 
exclude the possibility that a more marked or prolonged rise in PaCO2 may 
occur with higher doses of β2-agonists e.g. if high doses are delivered via 
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‘back-to-back’ nebulisers at frequent intervals, or during a more severe 
exacerbation, or in patients with higher PaCO2 tensions. Individuals who 
have not taken regular inhaled β2-agonists may also be at risk of a larger rise 
in PaCO2 after high dose β2-agonists since these patients would not have the 
downregulation of systemic effects seen after regular use of inhaled β2-
agonists.  
Inhaled β2-agonists reduce PaO2 in subjects with COPD by causing 
vasodilatation in poorly ventilated parts of the diseased lung and increasing 
V/Q mismatch. A recent small study found that the detrimental effect of 
salbutamol on PaO2 was not present during an acute exacerbation of COPD. 
Polverino et al examined the effect of salbutamol 5mg on gas exchange 
during an acute exacerbation of COPD and repeated the investigations three 
months later. Salbutamol had no effect on the mean PaO2, alveolar-arterial 
PO2 gradient or PaCO2 during an exacerbation, but did reduce the mean PaO2 
and increase the mean (A-a) gradient when the same subjects were studied 
three months after the exacerbation [408].  
The authors proposed a number of possible explanations for this unexpected 
finding, suggesting that the vasodilator response to salbutamol may be less 
marked during acute severe hypoxia, the effect of salbutamol on 
inflammatory mediator release may reduce vasodilatation and/or the 
bronchodilators administered earlier in the admission had already caused 
vasodilatation.  
During the acute exacerbation part of the study, 30 minutes after salbutamol 
there was a mean rise in cardiac output of 12% and a mean rise in heart rate 
of 10%, without a corresponding rise in PaCO2. Although the effect of 
salbutamol on VCO2 was measured, the results were not reported in the 
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paper [408]. The finding that salbutamol has a different effect on PaO2 
during an acute exacerbation of COPD is contrary to our results and merits 
further attention. 
The inhaled long-acting β2-agonists formoterol and salmeterol are used 
twice-daily as maintenance therapy by subjects with COPD and they have 
been shown to reduce symptoms and improve lung function [248]. 
Formoterol has the advantage of producing rapid bronchodilatation, with a 
similar onset of action as the short-acting β2-agonists. This has led to the 
idea that inhaled formoterol could have a dual role in the management of 
COPD, with the potential to be used ‘as required’ to relieve symptoms as 
well as being used twice daily as maintenance therapy. Using formoterol ‘as 
required’ may lead to inhalation of considerably higher doses of formoterol 
than are used with maintenance therapy. We hypothesized that the adverse 
systemic effects would counter the limited beneficial bronchodilator effects 
if subjects with COPD use formoterol in high doses. 
The third study (chapter 7), a dose-response study of inhaled formoterol in 
twenty subjects with COPD, examined the systemic and bronchodilator 
effects and patient satisfaction with a range of formoterol doses up to 48 µg. 
We assessed whether high dose inhaled formoterol was well tolerated by 
subjects with COPD and tried to determine whether the higher doses 
produced systemic adverse effects that might outweigh the beneficial 
bronchodilator effects. The main findings were: 
• Inhaled formoterol caused a dose-related increase in FEV1. 
• There was no associated improvement in breathlessness scores, 
walking distance or patient satisfaction. 
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• The systemic adverse effects associated with inhaled formoterol 
were modest and did not compromise patient satisfaction, even in 
high doses. 
The dose-related improvement in FEV1 did not translate into an 
improvement in exercise tolerance or symptoms, presumably because the 
improvements in FEV1 were too small. Previous studies have concentrated 
on lung function as a marker of efficacy in COPD and obtained similar 
results to this study [310,356]. Our findings suggest that FEV1 alone may 
not be a good way to measure the benefit of a drug in COPD and future 
studies need to concentrate on outcome measures that are clinically relevant 
[409-411]. 
The systemic effects after single doses of inhaled formoterol were modest 
and even the 48 µg dose was well tolerated. All but one subject used inhaled 
β2-agonists on a regular basis and are likely to have developed tolerance to 
the extra-pulmonary effects of formoterol.  
Satisfaction scores did not increase in a dose-related manner, but were 
similar with all doses of formoterol, and higher than the scores produced by 
placebo. We had expected high dose formoterol to produce adverse systemic 
effects that would outweigh the beneficial bronchodilator effects and hence 
compromise satisfaction. The absence of a decline in satisfaction with high 
doses is interesting and although the scale has not been fully validated, this 
approach provides a different way of assessing the efficacy of treatments in 
COPD and merits further attention. 
The dose response effect on FEV1 and lack of adverse effects suggest that 
further studies are justified to determine whether inhaled formoterol may 
have a role as rescue medication in the management of subjects with COPD, 
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despite the lack of effect on exercise tolerance and symptoms. We examined 
the effect of single inhaled doses of formoterol and there may be different 
outcomes if high doses are taken in quick succession. If formoterol were 
used ‘as required’ it would be important to establish a ceiling dose for a 24-
hour period to reduce the likelihood of using excessive doses. Our data 
covers patients who were taking β2-agonists regularly and the results cannot 
be extrapolated to subjects who do not use β2-agonists on a regular basis and 
who would not have developed tolerance to the systemic effects of inhaled 
β2-agonists.  
This thesis has discussed three studies designed to determine whether the 
systemic adverse effects produced by high doses inhaled β2-agonists could 
outweigh the beneficial bronchodilator effects when subjects with COPD are 
in certain clinical situations. All three studies demonstrated that the systemic 
effects produced by high dose inhaled β2-agonists were generally modest 
and well tolerated in patients who use β2-agonists regularly. Individuals 
using inhaled β2-agonists on a regular basis are likely to develop 
downregulation of β2-receptors which could allow high doses to be 
administered without producing excessive adverse systemic effects.  
 
 
 
 
 
 
 
 
 
 161
7.2 UNANSWERED QUESTIONS 
1) Although our results were broadly reassuring there is still a question 
as to whether high dose nebulised β2-agonists could increase PaCO2 and 
precipitate respiratory acidosis in some patients with COPD. This may only 
be clinically relevant when a subject approaching their physiological 
extreme (during a severe exacerbation with type two respiratory failure) is 
exposed to very high doses of β2-agonist in quick succession. 
 
2) Further work is required to assess whether inhaled formoterol is a 
safe and effective treatment when used ‘as required’ in the management of 
COPD. 
 
3) Although inhaled β2-agonists are generally safe in recommended 
doses when used by subjects with COPD, some individuals may be at 
particular risk of developing adverse effects with high doses, including 
subjects with certain β2-adrenoceptor polymorphisms and those who are β2-
agonist naive. 
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Sample patient letter 
 
 
 
 
 
 
 
Dear 
 
We are trying to improve and develop the treatments available for patients 
who have Chronic Obstructive Pulmonary Disease (COPD), and we have 
designed a number of studies to try and improve our understanding of the 
treatment of this condition. 
I am writing to you because it would appear that you would be ideally suited 
to participate in one of our studies. If you could spare the time we would be 
grateful if you could come to City Hospital to see our research fellow, Dr 
Chris Whale, who would tell you more about the study and explain what it 
involves. 
 
Dr Whale will give you a call in the next few days to see if you would be 
interested. I have enclosed a copy of an information sheet about the study 
for your interest. We would be happy to arrange a taxi to pick you up and 
take you home to reduce any inconvenience. 
 
Best Wishes 
 
Yours sincerely, 
 
 
 
Prof AE Tattersfield 
Professor of Respiratory Medicine 
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Sample GP letter 
 
 
 
 
 
 
 
Dear Dr 
 
RE:  Name: 
 Address: 
 DOB: 
 
The above named patient has agreed to help with a research project we are 
carrying out here at City Hospital looking at the effects of bronchodilators 
on blood gases in patients admitted with an acute exacerbation of Chronic 
Obstructive Pumonary Disease. There is some evidence to suggest that high 
doses of nebulised salbutamol may have some detrimental effects on oxygen 
consumption and carbon dioxide production, and this is what we are 
interested in. 
 
The study will take place on one morning as soon as possible after being 
admitted with an acute exacerbation of COPD. It will involve having five 
nebulised doses of Ventolin or Atrovent, given in a double blinded fashion. 
On completion of the study, the patient will revert to their normal treatment, 
and follow up will be arranged as normal. 
 
If you have any further queries regarding the trial please do not hesitate to 
contact me on 0115 9691169 ext 34757. 
 
Many thanks, 
 
 
 
Dr Chris Whale 
Clinical Research Fellow 
Department of Respiratory Medicine 
Nottingham University 
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Information Sheet for Adults 
 
Determining the optimum dose of nebulised salbutamol in acute 
exacerbations of Chronic Obstructive Pulmonary Disease. 
Professor AE Tattersfield, Dr TW Harrison, Dr CI Whale, Dr R Mahajan, 
Dr MP Sovani. 
 
1. Invitation to take part in the study 
 
You are being invited to take part in a research study. Before you 
decide it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you want to take 
part. 
 
2. What is the purpose of the study? 
 
The overall aim of this work is to try and find out which dose of 
salbutamol (Ventolin) given by nebuliser to people with your 
condition is most helpful. 
 
3. Why have I been chosen to take part in the study? 
 
You have been admitted to hospital because you have an 
exacerbation or flare up of your lung problem, which is known as 
COPD (Chronic Obstructive Pulmonary Disease). In this situation, it 
is usual to give certain drugs by nebuliser to help the airways open 
up. The drug that is usually given is called salbutamol (Ventolin), 
often with another drug called ipratropium (Atrovent). It is common 
to give quite a high dose of the nebulised Ventolin, although there is 
some evidence that patients like you might be better on a lower dose. 
We are carrying out a study therefore to try and find out which dose 
of Ventolin is best for patients in your condition. We are asking 
whether you would consider helping us with this study. 
 
4. Do I have to take part? 
 
This is a research study and you do not have to take part. Whether 
you take part or not is voluntary. You may refuse to take part or stop 
at any time. This would not affect the care you would receive in any 
way. You should read all the information before deciding whether 
you wish to take part.  
 
5. What will happen to me if I take part? 
 
If you agree to take part in the study it will take place over six hours 
on one morning. All your treatment would continue as usual, apart 
from your nebulised drugs (Ventolin, and Atrovent if it has been 
prescribed); these will be stopped at 10 pm on the day before. On the 
morning of the study day we will give you a series of nebulisers, 
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every hour from 8am until Noon. The nebuliser would deliver either 
Ventolin, in slowly increasing doses similar to the ones you would 
normally receive, or repeated small doses of Atrovent. 
We will measure the oxygen and carbon dioxide levels in the blood 
before and for one hour following each of the nebulisers. So that we 
can do this accurately and don’t have to do repeat blood tests, we 
would put a cannula into a small artery in the wrist. This would be 
inserted in the morning and would stay in place until around 1pm. 
Insertion of the cannula may be a little uncomfortable, but we will 
use some local anaesthetic to reduce any pain. After a nebuliser we 
will take 10 samples of blood over the course of each hour. Each 
sample will be a small volume, so that during the study we will take 
125 mL of blood in total. The cannula will be attached to a monitor 
that will measure your heart rate. We will ask you to breath oxygen 
through a mask and rest on the bed during the study period. 
We will ask if you have noticed any side effects from the nebuliser 
and we will also ask you to mark a scale to say how breathless you 
are at intervals before and after each of the nebulisers. 
 
6. What do I have to do? 
 
If you consent to take part in the study we would probably do the 
study tomorrow. A cannula will be inserted into the wrist at 7.30am, 
and over the course of the day blood samples will be taken from it. 
Your nebuliser treatment will be given every hour from 8am until 
noon. You will be asked to breathe oxygen through a mask during 
the study period. All other drugs, except those given by nebuliser, 
will be given as normal. Once the study has ended, you will return to 
your normal medication. 
We will arrange for a light breakfast at 7am and then ask you to 
abstain from eating and drinking (apart from water) during the study. 
 
7. What is the drug that is being tested? 
 
The main study drug is called salbutamol (Ventolin). It is routinely 
used worldwide for the treatment of COPD, at the same doses as you 
will receive. It is a drug that aims to open up your airways since you 
are short of breath. 
The other drug ipratropium bromide (Atrovent) is also used routinely 
throughout the world. It is another drug to open up the airways, but it 
works in a different way to Ventolin. 
 
8. Are there other ways of treating my condition? 
 
Treatment options are quite limited in this condition, but this study 
will not prevent you receiving the other medications that are 
available such as antibiotics. 
 
9. What are the side effects of the study treatment? 
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Ventolin can cause some twitchiness and palpitations and we will be 
asking you about these during the study. These usually settle 
gradually over half an hour to an hour. Atrovent may cause some 
dryness of the mouth. 
 
10. What are the possible disadvantages and risks of taking part? 
 
Salbutamol has been shown to be a very safe drug. If, however, you 
experience unpleasant side effects at any point you may wish to stop 
participating in the study. 
We would not normally insert an arterial cannula in your wrist 
although they are used in patients with severe breathing problems to 
allow oxygen and carbon dioxide levels to be monitored closely. 
Complications from an arterial cannula are rare although infections, 
bleeding and obstruction of the artery have occurred very rarely in ill 
patients requiring the cannula to be in place for many days. Since the 
cannula will only remain in place for 6 hours, we do not expect any 
complications. The cannula will be inserted by an experienced 
doctor who will monitor it carefully during the study and take 
measures to minimise any potential risk of complications. It is 
possible, but unlikely, that a further cannula may be needed if there 
is a problem with the first one. 
 
11. What are the possible benefits of taking part? 
 
It is unlikely that taking part in this study will directly help your 
medical condition. The information we get from this study may help 
us improve future treatment for patients with your condition. 
 
12. What if new information becomes available? 
 
Since Ventolin has been used very widely for a long time it is 
unlikely that new information will become available during the 
course of the study. Should new information become available, the 
study doctor will tell you about it, and will discuss whether you wish 
to remain in the study. 
If the doctor decides that it is in your best interests to withdraw you 
from the study they will explain the reasons for this and arrange for 
your care to continue. 
 
13. What happens when the research study stops? 
 
At the end of the study period around 1pm, you will return to your 
normal medications, which is likely to include Ventolin and 
Atrovent. 
 
14. What if something goes wrong? 
 
You should inform the study doctor of any side effects you 
experience. You may withdraw from the study at any time you wish. 
Your medical care will not be affected if you do this. Your doctor 
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will withdraw you from the studies if they feel it is in your best 
interest. 
If taking part in the study harms you, there are no special 
compensation arrangements. If you are harmed because someone has 
made a mistake, then you may be able to take legal action but you 
may have to pay for it. If you want to complain about the way you 
have been approached or treated during this study, the normal 
National Health Service complaints mechanisms may be available to 
you. 
 
15. Will my taking part in this study be kept confidential? 
 
All information collected about you will be kept strictly confidential. 
Any information from the study will have your name removed so 
you cannot be identified and your name will not be disclosed outside 
the hospital or appear in any study results unless we are obliged to 
do so by law. 
Your GP will be told that you have taken part in the study.  
 
16. What will happen to the results of the research study? 
 
Findings will be published in a medical research journal. Of course, 
this would be anonymous. 
 
17. Who is organising and funding the research? 
 
This is being organised and funded through Nottingham University 
Division of Respiratory Medicine. 
 
18. Who has reviewed this study? 
 
Two independent doctors have reviewed this study. 
 
19. Contact for further information? 
 
If you would like further information, please contact the following 
person: 
Name:                         Dr Chris Whale 
Telephone Number:    0115 9691169 ext 34757 
 
20. What do I do now? 
 
If there are any questions, or there is anything you do not 
understand, then please ask the study doctor. Please take your time to 
decide if you want to take part. You are free to discuss the study with 
your family or friends before you make your decision. 
If all your questions have been answered and you agree to take part 
in the study, you will be asked to sign a consent form. You will be 
given a copy of this information and a copy of the consent form for 
you to keep. 
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If you agree to take part, you can still change your mind at any time, 
even if you have started the study. 
 
We would like to thank you for taking the time to read this 
information. 
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Patient Information Sheet 
 
 
Study to determine the effect of high dose nebulised salbutamol on 
stable hypercapnic chronic obstructive pulmonary disease patients. 
 
Professor AE Tattersfield, Dt TW Harrison, Dr CI Whale, Dr R Mahajan, Dr 
MP Sovani 
 
1. Invitation to take part in the study 
 
You are being invited to take part in a research study. Before you make a 
decision it is important for you to understand why the research is being done 
and what it will involve. Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide 
whether or not you want to take part. 
 
2. What is the purpose of the study? 
 
Breathlessness is a major problem for people with Chronic Obstructive 
Pulmonary Disease (COPD) and it can lead to an increase in carbon dioxide 
levels in the blood. Nebulised drugs are given to try to open up the airways 
and the most commonly administered drug, salbutamol (Ventolin), is often 
given at high doses, although there is some evidence that patients like you 
might be better on a lower dose. We are carrying out a study to determine 
whether high or low doses of Ventolin are better for patients with COPD. 
We are asking whether you would consider helping us with this study which 
will involve visiting the hospital for about 3 hours on two mornings. 
 
3. Why have I been chosen to take part in the study? 
 
We aim to study 14 people, like yourself, who are known to have COPD and 
who have some increase in their blood carbon dioxide levels. 
 
4. Do I have to take part? 
 
This is a research study and you do not have to take part. Whether you take 
part or not is voluntary. You may refuse to take part or withdraw at any 
time. This would not affect the care you would receive in any way. You 
should read all the information before deciding whether you wish to take 
part. 
 
5. What will happen to me if I take part? 
 
If you agree to take part in the study it will take place over two three-hour 
periods, on separate mornings, within a few days of each other. 
On each study day, after a light breakfast at home and before you have taken 
any of your morning inhalers or nebulisers, we will arrange for a taxi to 
bring you to hospital. 
 178
After a short rest, we will attach leads to your chest and place aprobe on 
your fingertip, to measure your heart rate and oxygen levels. We will ask 
you to remain on bed rest during each study day. We will then place a small 
cannula into an artery in the wrist to measure oxygen and carbon dioxide 
levels more accurately. This avoids us having to use a needle each time 
further samples are required. The cannula stays in place for around three 
hours and although insertion of the cannula may be a little uncomfortable, 
we will use local anaesthetic to reduce any pain. 
When the blood tests are stable, we will give you two doses of nebulised 
Ventolin an hour apart, taking 6 blood samples over the course of the hour 
following each drug. Each sample will be a small volume, so that on each 
study day we will take about an egg cup full of blood (a maximum of 50 
mL). The cannula will be connected to a monitor to allow measurement of 
blood pressure throughout the study. On one study day you will receive two 
low doses of salbutamol and on the other day two higher doses. Neither you, 
nor the doctor, will know which dose you are receiving on a particular day. 
During the study we will ask you whether you have experienced any side 
effects and we will ask you to rate your degree of breathlessness using a 
simple scale. The cannula will be removed about two and a half to three 
hours after it was inserted, and we will arrange a taxi to take you home. 
 
6. What do I have to do? 
 
If you consent to take part in the study we would arrange for the two visits 
to take place on convenient days. 
For each study day we will ask you to avoid caffeine-containing food and 
drinks from midnight, and avoid taking certain inhalers and nebulisers prior 
to each visit. On the study day, you can have a light breakfast at around 8am 
before coming to the hospital and we will then ask you to abstain from 
eating and drinking (apart from water) during the study. You will receive 
two doses of nebulised medication, an hour apart and all your other drugs, 
except for those that open up the airways, will be taken as normal. When the 
study has ended, you will continue your normal medication. 
 
7. What is the drug that is being tested? 
 
Salbutamol (Ventolin) is routinely used worldwide for the treatment of 
COPD at the same doses that you will receive in the study. It is a drug that 
aims to prevent breathlessness and open up your airways when you are short 
of breath. 
On one study day you will receive the higher doses of salbutamol twice, and 
on the other day you will receive the low dose twice. 
 
8. What are the side effects of the study treatment? 
 
Ventolin can cause some twitchiness and palpitations and we will be asking 
you about these during the study. These usually settle gradually over half an 
hour to an hour and many people are not troubled at all. 
 
9. What are the possible disadvantages and risks of taking part? 
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Salbutamol has been shown to be a very safe drug. If, however, you 
experience unpleasant side effects at any point you may wish to stop 
participating in the study. Arterial cannulae are used in patients with severe 
breathing problems to allow oxygen and carbon dioxide levels to be 
monitored closely. Complications from an arterial cannula are rare, although 
infections, bleeding and obstruction of the artery have occurred in seriously 
ill patients who required the cannula to be in place for many days. Since the 
cannula will only remain in place for 3 hours, we do not expect any 
complications. The cannula will be inserted by an experienced doctor, who 
will monitor it carefully during the study, taking measures to minimise the 
risk of complications. It is possible, but unlikely, that a further cannula may 
be needed if there is a problem with the first one. 
 
10. What are the possible benefits of taking part? 
 
The study may not be of direct benefit to you. It is unlikely that taking part 
in this study will directly help your medical condition. The information we 
get from this study may help to improve future treatment for patients with 
COPD. 
 
11. What if new information becomes available? 
 
Since Ventolin has been widely used for a long time it is unlikely that new 
information will become available during the course of the study. 
 
12. What happens when the research study stops? 
 
At the end of the study period and between the two study days you will 
return to your normal medications. 
 
13. What if something goes wrong? 
 
If you want to complain about the way you have been approached or treated 
during this study, the normal National Health Service complaints 
mechanism is available to you. 
You should inform the study doctor of any side effects you experience. You 
may withdraw from the study at any time you wish and your medical care 
will not be affected. Your doctor will withdraw you from the studies if they 
feel it is in your best interest. 
If taking part in the study harms you, there are no special compensation 
arrangements. If you are harmed because someone has made a mistake, then 
you can take legal action but you may have to pay for it. 
 
14. Will my taking part in this study be kept comfidential? 
 
All information collected about you will be kept strictly confidential. Any 
information from the study will have your name removed so you cannot be 
identified and your name will not be disclosed outside the hospital or appear 
in any study results unless we are obliged to do so by law. 
Your GP will be told that you have taken part in the study. 
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15. What will happen to the results of the research study? 
 
Study results will be published in a medical research journal without 
mentioning the names of participants. 
 
16. Who is organising and funding the research? 
 
This is being organised and funded through Nottingham University Division 
of Respirtory Medicine. 
 
17. Who has reviewed this study? 
 
Two independent doctors have reviewed this study. 
 
18. Contact for further information? 
 
If you would like further information, please contact the following person: 
Name:   Dr Chris Whale 
Telephone Number: 0115 840 4757 
 
19. What do I do now? 
 
If there are any questions, or there is anything you do not understand, then 
please ask the study doctor. Please take your time to decide if you want to 
take part. You are free to discuss the study with your family or friends 
before you make your decision. 
 
If all your questionshave been answered and you agree to take part in the 
study, you will be asked to sign a consent form. You will be given a copy of 
this information sheet and a copy of the consent form to keep. 
 
If you agree to take part, you can still change your mind at any time,even if 
you have started the study. 
 
 
 
 
We would like to thank you for taking the time to read this information.  
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PATIENT INFORMATION SHEET 
 
The effect of different doses of formoterol in patients with COPD 
 
(A study of the systemic, metabolic and bronchodilator dose-response 
effects of inhaled formoterol in chronic obstructive pulmonary disease.) 
 
1. Invitation paragraph 
We are inviting you to take part in a research study.  Before you decide whether to take part 
or not, it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it with 
others if you wish.  Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
2. What is the purpose of the study? 
 
The aim is to assess the effects of four different doses of formoterol, a drug used to open up 
the airways of patients with COPD. We aim to determine which dose of formoterol 
provides the best balance between beneficial and adverse effects. We will do this by 
monitoring the general effects of the drug, and how it affects your lung function. 
 
3. Why have I been chosen? 
 
You have been chosen because you have chronic obstructive pulmonary disease. We aim to 
study 20 patients in total. 
 
4. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form.  If you decide 
to take part you are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the care you 
receive in any way. 
 
5. What will happen to me if I take part? 
 
The study will take place on five separate mornings over two weeks. On each morning we 
will arrange for a taxi to pick you up and bring you to Nottingham City Hospital for 8am. 
You can have a light breakfast before attending if you wish.  
Each morning will be similar, and will start with a 20-minute rest. We will then check your 
lung function (simple blowing tests), take a small blood sample (2ml), check your heart rate 
and blood pressure, measure any tremor and take a reading of your oxygen level with a 
fingertip probe. We will then measure the distance you can walk. 
After a further 20-minute rest period, we will ask you to inhale a dose of formoterol or 
placebo from a device called a Turbohaler. You will take four inhalations from designated 
inhalers, and they will give you placebo (a dummy drug with no active ingredients) or one 
of the four doses of formoterol (6, 12, 24 or 48µg). To reduce bias, you will not know 
which dose you will receive on a given day. The schedule for doses will be determined by 
computer. 
We will then ask you to rest on a comfortable chair, and will take measurements at set 
intervals. At 30, 60, 120, 180 and 240 minutes after inhaling the drug, we will repeat the 
measurements of lung function, tremor, heart rate and oxygen saturation. Also after 240 
minutes, we will ask how you feel, then repeat the blood test and six-minute walk test. 
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Once this is done, the study day is complete and we will arrange for a taxi to take you 
home, at around 1pm.   
 
6. What do I have to do? 
 
The study would not interfere with your daily life. However, we would ask you to limit 
consumption of tea or coffee to one cup only prior to attending on the morning of each visit. 
The study will not affect your regular medications, although we may require you to abstain 
from taking some of your normal inhalers prior to attending on each of the five mornings.   
 
7. What is the drug or procedure that is being tested? 
 
Inhaled formoterol is widely used to open airways in patients with asthma and COPD. 
We aim to assess the effects of different doses of formoterol in COPD via a Turbohaler. We 
plan to assess the effect of different doses of formoterol on your heart rate, breathing tests, 
oxygen levels, tremor and walking distance. 
We will ask you to inhale a dose of formoterol or placebo (dummy drug) on each of the five 
study days. For the study period (less than 2 weeks), you will be given a small card (like a 
credit card) with details of the trial, which you will be asked to carry at all times. 
 
8. What are the alternatives for diagnosis or treatment? 
 
The study will not interfere with other medications you need to take. 
 
9.  What are the side effects of taking part? 
 
Formoterol is a β-agonist like Ventolin but with a longer action. It can cause certain 
recognised side effects, the main ones are tremor and more occasionally palpitations, 
muscle cramps and headaches. 
 
10.   What are the possible disadvantages and risks of taking part? 
 
Formoterol is considered to be a safe drug, and the side effects (tremor, fast heart rate, 
muscle cramps and headaches) are well recognised. We will monitor these effects at 
intervals on each study day and ask you to tell us if you experience any discomfort during 
the visits. The highest dose (48µg) of formoterol may cause some of these side effects to be 
more noticeable than you have experienced before with your Ventolin inhaler. 
We will take two blood samples on each study day, which may be a little uncomfortable 
and you will experience some breathlessness during the walk tests. 
A doctor will be present throughout each visit. 
 
11.   What are the possible benefits of taking part? 
 
This study is not intended to provide benefit to individual patients. 
The information we get from this study may help us to treat future patients with COPD 
better. 
 
12.   What if the new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the drug that is being studied.  If this happens, your research doctor will tell you 
about it and discuss with you whether you want to continue in the study. If you decide to 
withdraw your research doctor will make arrangements for your care to continue.  If you 
decide to continue in the study you will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in your 
best interests to withdraw you from the study.  He/she will explain the reasons and arrange 
for your care to continue. 
 
13.   What happens when the research study stops? 
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The drug may be available to you after completing the study, at the discretion of your 
consultant and general practitioner.  
 
14.   What if something goes wrong? 
If you are harmed in any way by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to individual negligence, then you may 
have grounds for a legal action but you may have to pay for it.   
If you wish to complain about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanisms 
should be available to you. 
 
15.   Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research 
will be kept strictly confidential.  Any information about you which leaves 
the hospital will have your name and address removed so that you cannot be 
recognised from it. 
 
If you agree, your own GP will be notified of your participation in the trial.  
 
16.   What will happen to the results of the research study? 
 
We would aim to publish the results anonymously in a respiratory medicine journal. 
We will let you know the findings once the study is completed. 
 
17.  Who is organising and funding the research? 
 
University of Nottingham, Division of Respiratory Medicine. 
 
19.  Contact for further information 
 
Dr Chris Whale  
0115 8404757 
chris.whale@nottingham.ac.uk 
 
 
 
 
 
 
 
 
 
 
Many thanks for taking the time to read this information sheet 
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Modified Borg scale for perceived dyspnoea 
 
 
Scale Severity 
0 No breathlessness at all 
0.5 Very very slight (just noticeable) 
1 Very slight 
2 Slight breathlessness 
3 Moderate 
4 Somewhat severe 
5 Severe breathlessness 
6  
7 Very severe breathlessness 
8  
9 Very very severe (almost maximum) 
10 Maximum 
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Protocol for six minute walk test 
 
“The object of this test is to walk as far as possible for six minutes. You will 
walk back and forth in this hallway. Six minutes is a long time to walk, so 
you will be exerting yourself. You will probably get out of breath or become 
exhausted. You are permitted to slow down, to stop, and to rest as necessary. 
You may lean against the wall while resting, but resume walking as soon as 
you are able. 
 
You will be walking back and forth around the cones. You should pivot 
briskly around the cones and continue back the other way without hesitation. 
Now I’m going to show you. Please watch the way I turn without 
hesitation.” 
 
Walk one lap. Walk and pivot around a cone briskly. 
 
“Are you ready to do that? I am going to use this borad to keep ttack of the 
number of laps you complete. I will tick it each time you turn around at this 
starting line. 
 
Remember that the object is to walk AS FAR AS POSSIBLE for 6 minutes, 
but dobn’t run or jog. 
 
Start now, or whenever you are ready.” 
 
1st minute “You are doing well. You have 5 minutes to go.” 
 
2nd minute “Keep up the good work. You have 4 minutes to go.” 
 
3rd minute “You are doing well. You are halfway done.” 
 
4th minute “Keep up the good work. You only have 2 minutes left.” 
 
5th minute “You are doing well. You only have 1 minute to go.” 
 
5.45  “In a moment I’m going to tell you to stop. When I do, just 
stop right where you are and I will come to you.” 
 
6th minute “Stop.” 
 
Walk over to the patient. Take a chair if needed. Mark the spot on the floor. 
 
Congratulate and offer a glass of water. 
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Raw data from Chapter five 
 
Effects of salbutamol on arterial blood gases in patients with stable 
hypercapnic Chronic Obstructive Pulmonary Disease 
 
 
 Time (minutes) 
 0 10 15 20 30 45 60 70 75 80 90 105 120 
1 5.31 5.29 5.32 5.32 6.02 5.91 5.95 5.46 5.84 5.7 5.87 6.05 6.11 
2 7.58 7.27 7.4 7.3 7.26 7.01 6.75 7.08 7 7.05 6.97 6.69 7.18 
3 7.93 8.7 8.04 7.88 8.11 8.21 8.08 8.34 8.08 7.99 7.86 8.19 8.02 
4 6.45 6.36 6.49 6.39 6.59 6.12 6.36 6.33 6.29 6.47 6.31 6.24 6.39 
5 8.57 8.59 8.12 8.12 7.4 7.4 7.24 7.63 7.61 7.23 7.04 8.11 7.54 
6 8.74 8.47 8.05 8.48 8.64 7.99 8.37 8.28 8.75 8.02 8.03 7.91 8.68 
7 9.04 8.4 8.13 8.3 7.91 8.1 8.01 8.08 7.95 7.92 8.02 8.13 7.92 
8 7.96 7.42 7.58 7.21 7.27 7.86 7.3 7.62 7.56 7.26 7.77 7.24 7.31 
9 10.05 9.74 10.52 9.32 9 9.01 9.34 9.25 9.72 9.8 9.34 9.07 9.42 
10 6.25 5.98 5.94 5.99 5.96 6.12 5.87 5.92 5.93 5.78 5.85 5.69 5.66 
11 6.03 7.26 6.26 6.41 6.11 6.39 6.35 6.51 6.39 6.51 6.22 5.81 5.75 
12 6.75 6.42 6.79 6.79 6.6 6.76 6.55 6.25 6.23 6.65 6.68 6.03 6.1 
13 8.07 7.29 7.14 6.94 6.88 6.99 6.6 6.9 7.18 7.24 7.08 7.18 7.18 
14 8.3 8.41 8.23 8.19 8.11 7.96 8.03 8.08 8.02 8.05 8.25 8.12 8.26 
 
 
Change in PaCO2 (kPa) from baseline to 120 minutes after 10 mg 
salbutamol. 
 
 Time (minutes) 
 0 10 15 20 30 45 60 70 75 80 90 105 120 
1 9.4 9.49 8.69 7.58 8.27 9.53 7.86 9.19 7.8 8.87 8.58 7.92 7.93 
2 8.17 8.42 7.97 7.95 7.69 7.83 7.89 7.9 7.67 7.53 7.31 7.62 7.46 
3 7.18 6.56 6.94 6.93 7.06 6.96 7.12 6.91 6.8 6.81 6.67 6.64 6.8 
4 7.76 7.85 7.77 7.76 7.59 7.86 7.9 7.89 7.81 7.74 7.56 7.85 7.82 
5 7.91 7.74 7.58 7.42 7.56 7.47 7.9 7.5 7.55 7.47 7.52 7.19 7.32 
6 5.59 5.72 5.46 5.42 5.52 5.63 5.48 5.29 5.31 5.2 5.33 5.15 5.68 
7 7.71 7.98 7.12 7.07 7.31 7.25 7.22 7.19 7.2 7.24 6.92 7.05 7.22 
8 7.97 7.82 7.84 7.83 7.92 7.75 7.72 7.53 7.4 7.6 7.31 7.37 7.15 
9 5.82 5.75 5.43 5.71 5.76 5.71 5.82 5.54 5.49 5.49 5.42 5.55 5.58 
10 8.1 8.7 8.55 8.57 7.87 7.68 7.83 7.49 7.63 7.56 7.29 7.55 7.3 
11 6.97 7.06 7.07 7.06 7.31 7.08 7.29 7.25 7.11 7.11 6.97 6.9 6.97 
12 8.3 8.36 8.24 8.17 8.19 8.07 8.02 8.1 8 7.83 7.61 8 7.7 
13 6.81 6.49 6.48 6.35 6.42 6.18 6.3 6.4 6.24 6.15 6.07 6.04 6.01 
14 6.69 6.66 6.52 6.53 6.74 6.63 6.79 6.5 6.62 6.46 6.74 6.54 6.55 
 
 
Change in PaO2 (kPa) from baseline to 120 minutes after 10 mg salbutamol 
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 Time (minutes) 
 0 10 15 20 30 45 60 70 75 80 90 105 120 
1 75 79 74 73 72 75 72 77 74 74 73 75 72 
2 106 106 103 105 108 106 110 105 108 110 110 110 110 
3 87.5 84 91 84 85 88 88 90 93 92 90 91 91 
4 76.5 79 77 79 78 84 78 79 80 81 81 82 85 
5 65.5 72 68 69 71 73 77 77 81 8 85 83 84 
6 74 76 78 78 78 76 75 80 78 76 81 83 78 
7 80.5 93 94 84 85 86 94 95 93 95 95 93 94 
8 65 66 63 64 64 70 64 74 67 70 68 70 73 
9 109 109 110 108 112 110 113 109 113 113 112 113 113 
10 87 90 89 89 88 90 90 92 90 90 91 93 82 
11 93 93 93 91 95 98 95 91 90 94 92 97 97 
12 80.5 80 81 78 78 79 77 78 77 78 81 85 81 
13 70 74 75 75 79 79 80 81 82 82 86 83 87 
14 91 91 91 89 90 92 90 90 90 91 93 93 96 
 
 
 
Change in heart rate (bpm) from baseline to 120 minutes after 10 mg 
salbutamol 
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Raw data from Chapter six 
 
Systemic and bronchodilator effects of formoterol in Chronic 
Obstructive Pulmonary Disease: a dose response study 
 
 Time (minutes) 
Dose 
(mcg) 0 30 60 120 180 240 
0 0.86 0.79 0.7 0.69 0.58 0.65 
0 1.2 1.18 1.15 1.3 1.22 1.17 
0 1.04 1.2 1.04 1.1 1.06 1.18 
0 1.2 1.27 1.36 1.1 1.21 1.03 
0 0.92 0.84 0.91 0.82 0.87 0.82 
0 0.64 0.52 0.5 0.44 0.5 0.52 
0 0.54 0.57 0.51 0.5 0.52 0.5 
0 0.98 0.96 0.89 0.86 0.84 0.75 
0 0.74 0.71 0.71 0.69 0.68 0.68 
0 0.75 0.79 0.76 0.75 0.83 0.9 
0 0.97 0.95 1.01 0.98 1.03 0.93 
0 1.76 1.49 1.6 1.3 1.39 1.15 
0 0.42 0.55 0.71 0.71 0.7 0.7 
0 2.52 2.63 2.6 2.7 2.67 2.58 
0 1.01 1.02 1.09 1.12 1.12 1.15 
0 0.6 0.54 0.48 0.42 0.39 0.35 
0 1.16 1.31 1.3 1.24 1.33 1.18 
0 0.7 0.82 0.74 0.8 0.78 0.72 
0 1.94 1.93 1.95 1.9 1.94 1.94 
0 1.9 1.7 1.84 1.66 1.6 1.62 
6 0.78 0.84 0.79 0.75 0.66 0.61 
6 1.21 1.05 1.2 1.33 1.25 1.25 
6 1.06 1.24 1.3 1.32 1.23 1.1 
6 0.98 1.31 1.3 1.31 1.25 1 
6 0.82 0.9 0.88 0.89 0.85 0.75 
6 0.72 0.68 0.7 0.65 0.65 0.61 
6 0.61 0.59 0.66 0.67 0.67 0.65 
6 0.87 0.9 0.93 0.95 0.99 0.85 
6 0.75 0.73 0.75 0.71 0.74 0.72 
6 0.82 0.77 0.87 1 0.77 1.01 
6 1.15 1.15 1.2 0.93 1.17 1.17 
6 1.35 1.75 2 1.78 2.02 1.98 
6 0.51 0.74 0.8 0.69 0.75 0.7 
6 2.51 2.72 2.7 2.77 2.7 2.74 
6 1.03 1.14 1.1 1.14 1.1 1.23 
6 0.73 0.64 0.7 0.66 0.6 0.55 
6 1.32 1.29 1.2 1.58 1.42 1.35 
6 0.77 0.86 0.8 0.83 0.84 0.83 
6 2.06 2.2 2.17 2.12 2.01 2.19 
6 1.62 1.69 1.66 1.78 1.65 1.72 
12 0.98 0.8 0.93 0.82 0.81 0.67 
12 1.03 1.15 1.21 1.15 1.23 1.27 
12 1.2 1.5 1.55 1.42 1.5 1.43 
12 1.65 1.69 1.48 1.65 1.35 1.01 
12 0.92 0.93 0.85 0.92 0.84 0.84 
12 0.62 0.61 0.61 0.6 0.61 0.62 
12 0.67 0.6 0.61 0.58 0.67 0.55 
12 1.07 1.05 1.1 1.13 1.2 1.01 
 191
12 0.74 0.75 0.74 0.76 0.8 0.75 
12 0.83 1 1.02 1.02 1.05 0.95 
12 1.17 1.34 1.36 1.33 1.29 1.21 
12 1.25 1.19 1.12 1.68 1.2 1.15 
12 0.52 0.93 1 0.95 0.81 1.02 
12 2.5 2.62 2.68 2.69 2.69 2.61 
12 1.04 1.2 1.26 1.25 1.29 1.29 
12 0.7 0.57 0.66 0.6 0.57 0.54 
12 1.2 1.44 1.3 1.43 1.42 1.49 
12 0.84 0.9 0.93 0.9 0.93 0.79 
12 2.04 2.09 2.12 2.14 2.09 2.09 
12 1.7 1.85 1.88 1.85 1.57 1.7 
24 0.97 0.95 0.96 0.88 0.78 0.71 
24 0.83 1 1.21 1.2 1.23 1.2 
24 1.29 1.56 1.53 1.4 1.26 1.42 
24 1.28 1.38 1.4 1.33 1.3 1.1 
24 0.87 0.95 0.8 0.85 0.76 0.65 
24 0.56 0.64 0.62 0.65 0.6 0.59 
24 0.62 0.6 0.65 0.67 0.57 0.64 
24 0.78 0.88 0.9 0.86 0.96 0.8 
24 0.76 0.85 0.87 0.8 0.89 0.83 
24 0.88 1.21 1.03 0.99 1.08 1.14 
24 1 1.18 1.11 1.2 1.18 1.05 
24 1.54 1.87 1.86 1.42 1.46 1.1 
24 0.58 1.1 1.09 1.23 0.93 1.01 
24 2.49 2.69 2.68 2.75 2.8 2.73 
24 1.1 1.15 1.2 1.19 1.32 1.21 
24 0.65 0.75 0.71 0.66 0.64 0.58 
24 1.21 1.53 1.64 1.68 1.64 1.53 
24 0.79 0.94 0.92 0.91 0.8 0.87 
24 2.01 2.15 2.15 2.14 2.15 2.11 
24 1.47 1.94 1.95 2.01 2.09 1.81 
48 0.8 0.95 1.05 1.05 0.92 0.73 
48 1.12 1.14 1.27 1.25 1.21 1.37 
48 1.11 1.42 1.42 1.43 1.33 1.21 
48 1.51 1.56 1.65 1.54 1.36 1.4 
48 0.77 0.91 0.9 0.92 0.93 0.82 
48 0.66 0.65 0.71 0.69 0.72 0.7 
48 0.72 0.81 0.8 0.65 0.76 0.71 
48 1 1.01 1.11 1.15 1.07 1.12 
48 0.93 0.89 0.93 0.93 0.91 0.93 
48 0.82 0.99 1.2 1.08 1.07 1.11 
48 1.11 1.23 1.45 1.53 1.42 1.48 
48 1.52 1.62 1.52 1.61 1.71 1.7 
48 0.46 0.95 1.12 1.14 0.94 1.15 
48 2.64 2.77 2.8 2.85 2.89 2.86 
48 0.98 1.14 1.26 1.27 1.3 1.25 
48 0.6 0.7 0.75 0.66 0.65 0.64 
48 1.04 1.02 1.45 1.24 1.38 1.35 
48 1.01 1.03 1.08 0.96 1 0.92 
48 2.12 2.17 2.25 2.25 2.12 2.12 
48 1.67 2.08 2.01 2.14 2.06 2.06 
 
Change in FEV1 (L) over 240 minutes after a range of doses of inhaled 
formoterol 
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 Time (minutes) 
Dose 
(mcg)       
0 77 75 80 79 80 88 
0 74 76 72 80 69 73 
0 80 74 76 76 86 80 
0 75 73 74 74 71 75 
0 65 61 64 65 68 70 
0 77 76 71 68 72 66 
0 82 76 75 77 76 76 
0 60 68 59 56 65 62 
0 75 75 73 72 80 77 
0 75 83 87 87 85 70 
0 70 75 70 61 70 76 
0 59 61 60 58 61 60 
0 75 69 68 69 64 66 
0 84 86 86 85 82 80 
0 65 67 60 58 61 58 
0 82 84 84 76 77 80 
0 63 58 56 54 55 53 
0 58 59 54 57 62 70 
0 93 87 82 82 78 82 
0 80 65 60 62 61 72 
6 74 72 72 71 72 74 
6 77 79 73 79 73 70 
6 72 76 78 90 82 82 
6 80 76 77 76 75 87 
6 62 64 64 66 67 71 
6 64 65 62 64 67 66 
6 80 73 72 72 72 76 
6 64 65 58 62 62 66 
6 72 70 72 80 83 81 
6 74 76 80 68 83 83 
6 70 71 76 69 76 73 
6 59 62 66 59 62 61 
6 72 65 66 67 61 63 
6 88 85 89 90 88 84 
6 73 65 66 73 61 63 
6 83 85 80 76 79 75 
6 62 55 58 53 53 55 
6 60 59 58 68 66 64 
6 91 91 104 84 74 85 
6 72 67 66 74 63 64 
12 73 70 72 76 72 75 
12 70 81 78 69 66 70 
12 79 79 79 85 78 94 
12 78 75 73 76 77 73 
12 61 62 67 66 72 76 
12 64 64 63 62 67 58 
12 86 78 77 79 84 85 
12 61 60 58 57 59 57 
12 65 71 76 72 75 75 
12 71 75 71 77 70 75 
12 70 72 70 77 67 75 
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12 60 60 62 59 64 60 
12 72 65 65 68 64 64 
12 87 84 80 76 81 76 
12 70 72 72 69 64 71 
12 84 82 82 84 82 77 
12 60 56 56 54 53 53 
12 57 57 56 56 58 64 
12 86 87 81 79 82 86 
12 68 61 64 64 66 63 
24 82 79 73 78 79 79 
24 79 80 77 68 70 67 
24 89 85 84 85 83 82 
24 73 71 76 71 74 79 
24 70 68 65 65 68 71 
24 64 71 63 89 63 70 
24 82 81 75 73 75 75 
24 58 63 64 60 64 55 
24 75 68 75 77 69 75 
24 74 77 72 70 79 75 
24 70 66 72 79 75 71 
24 62 62 64 62 60 64 
24 71 71 66 66 63 67 
24 85 76 81 77 78 84 
24 62 68 70 64 65 63 
24 78 81 77 79 78 76 
24 58 56 61 56 53 55 
24 62 56 56 60 60 56 
24 95 91 92 96 81 82 
24 66 66 63 60 62 65 
48 75 81 82 83 80 85 
48 75 79 76 72 72 65 
48 89 85 79 86 82 81 
48 76 78 74 75 75 78 
48 62 64 66 66 70 72 
48 64 63 70 81 81 84 
48 74 72 74 73 74 71 
48 59 61 61 63 59 59 
48 82 82 80 79 80 80 
48 64 79 85 82 85 84 
48 68 67 70 73 67 67 
48 60 59 64 66 66 62 
48 75 72 70 76 75 71 
48 85 93 89 93 92 87 
48 67 70 65 63 68 64 
48 82 82 83 75 75 71 
48 65 61 58 59 59 57 
48 71 60 63 66 60 60 
48 90 94 85 84 82 80 
48 78 66 64 62 64 67 
 
Change in heart rate (bpm) over 240 minutes after a range of doses of 
inhaled formoterol 
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 Time (minutes) 
Dose 
(mcg)       
0 92 94 92 92 94 92 
0 94 96 94 96 96 95 
0 93 96 96 92 95 93 
0 99 98 98 99 97 98 
0 94 92 95 94 93 92 
0 93 92 92 92 93 91 
0 94 93 93 95 94 94 
0 95 95 96 95 95 96 
0 96 96 96 97 97 96 
0 96 95 95 93 94 94 
0 96 96 95 95 95 95 
0 94 93 94 95 95 95 
0 95 95 95 95 96 96 
0 95 95 97 97 97 96 
0 97 96 97 97 98 98 
0 96 96 96 96 97 96 
0 95 94 94 95 94 95 
0 97 97 97 95 96 96 
0 95 94 94 96 97 94 
0 93 95 93 95 94 96 
6 93 93 94 93 94 94 
6 94 91 95 95 95 95 
6 93 94 96 99 91 94 
6 97 97 97 98 96 97 
6 94 94 95 95 94 91 
6 93 91 92 94 94 90 
6 95 95 94 95 94 95 
6 95 93 94 94 95 95 
6 96 97 95 96 95 95 
6 97 96 97 96 96 95 
6 94 96 95 94 95 95 
6 94 93 94 95 94 95 
6 95 95 96 97 96 96 
6 96 95 97 97 96 96 
6 95 97 97 97 97 98 
6 94 95 95 95 93 95 
6 95 94 95 95 94 95 
6 95 96 96 96 96 96 
6 96 95 95 95 95 95 
6 95 95 93 95 97 96 
12 93 93 93 93 93 93 
12 94 92 94 94 93 92 
12 93 96 92 95 92 92 
12 95 95 94 95 96 95 
12 89 92 94 94 93 91 
12 92 91 93 92 93 94 
12 94 94 92 93 94 94 
12 96 96 93 94 95 96 
12 97 96 95 96 96 97 
12 95 95 94 96 95 95 
12 96 95 96 95 96 96 
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12 95 94 95 96 95 94 
12 96 96 96 97 99 97 
12 96 97 96 97 97 96 
12 96 97 95 96 97 96 
12 95 92 94 94 94 93 
12 95 94 95 94 95 96 
12 97 96 96 96 96 97 
12 95 94 95 96 94 95 
12 95 96 95 97 96 96 
24 93 94 94 95 94 94 
24 93 94 93 92 92 93 
24 92 96 95 92 93 95 
24 98 98 97 98 98 97 
24 95 96 95 95 94 94 
24 93 90 90 92 91 94 
24 94 92 93 94 94 95 
24 96 93 94 95 95 95 
24 97 95 94 97 95 96 
24 96 96 94 95 94 95 
24 95 95 94 95 94 95 
24 95 93 94 95 94 94 
24 96 97 95 96 97 97 
24 94 95 96 98 97 97 
24 96 96 95 97 95 95 
24 96 95 93 94 93 93 
24 94 92 93 93 95 95 
24 97 96 96 97 96 97 
24 95 95 94 96 96 95 
24 96 97 95 96 95 96 
48 91 92 90 93 94 94 
48 93 91 93 94 93 94 
48 91 91 93 93 93 96 
48 97 95 94 96 96 97 
48 94 93 95 93 94 94 
48 94 92 90 93 94 94 
48 94 92 93 92 94 94 
48 95 92 94 94 95 95 
48 97 94 96 95 96 96 
48 96 94 95 96 96 94 
48 96 96 96 97 95 95 
48 92 93 94 95 94 95 
48 96 96 96 96 96 96 
48 94 93 95 95 96 97 
48 94 94 95 96 98 96 
48 93 97 97 96 96 95 
48 95 93 93 94 94 93 
48 96 96 95 97 96 95 
48 95 94 96 96 95 95 
48 94 93 93 95 97 95 
 
Change in SpO2 (%) over 240 minutes after a range of doses of inhaled 
formoterol 
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 Time (minutes) 
Dose 
(mcg)       
0 36 14 12 8 13 80 
0 13 13 7 10 12 6 
0 0 0 0 0 0 0 
0 2 1 2 2 2 4 
0 7 9 7 8 9 17 
0 7 7 7 10 9 7 
0 14 9 9 10 19 19 
0 1 2 29 38 36 49 
0 1 1 1 1 1 1 
0 0 0 0 0 0 0 
0 0 0 0 0 0 0 
0 17 17 8 10 10 9 
0 8 6 2 2 1 1 
0 4 6 4 3 2 3 
0 0 0 0 0 0 0 
0 30 34 43 37 10 14 
0 24 8 9 11 8 6 
0 4 3 7 0 0 0 
0 0 1 0 2 2 0 
0 3 2 2 2 3 3 
6 15 12 15 12 11 14 
6 15 14 11 12 16 16 
6 0 0 0 0 0 0 
6 5 5 4 3 3 4 
6 6 8 12 10 10 12 
6 11 12 8 10 8 8 
6 11 5 7 4 6 4 
6 17 28 7 8 4 11 
6 1 2 1 1 1 1 
6 0 0 0 0 0 0 
6 0 0 0 0 0 0 
6 2 3 2 2 2 3 
6 8 4 5 4 1 2 
6 3 4 2 2 2 3 
6 0 0 0 0 0 0 
6 33 36 23 38 28 29 
6 12 12 14 7 6 5 
6 0 15 0 0 1 0 
6 1 0 1 2 0 1 
6 2 2 2 2 1 2 
12 19 10 7 10 5 7 
12 67 15 14 15 12 16 
12 0 0 0 0 0 0 
12 2 3 3 3 4 2 
12 8 7 8 13 18 7 
12 18 10 9 11 11 13 
12 18 8 16 11 13 9 
12 22 5 12 9 15 8 
12 2 2 2 2 2 2 
12 0 0 0 0 0 0 
12 0 0 12 0 0 0 
12 4 4 4 5 3 0 
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12 1 2 2 1 1 0 
12 3 2 4 2 4 2 
12 0 0 0 1 0 0 
12 2 3 8 10 10 10 
12 19 9 8 6 6 4 
12 24 0 1 0 1 1 
12 0 1 0 1 1 0 
12 2 3 3 3 2 2 
24 11 12 11 13 10 8 
24 52 34 49 75 73 83 
24 0 0 0 0 12 0 
24 2 3 2 3 2 2 
24 9 4 8 4 1 4 
24 10 12 14 13 11 11 
24 5 5 6 7 5 7 
24 43 31 40 48 6 9 
24 1 1 1 2 2 1 
24 0 3 0 0 0 0 
24 0 0 0 0 0 0 
24 3 4 3 1 2 2 
24 2 8 7 4 2 1 
24 2 4 3 4 2 3 
24 0 1 0 0 0 0 
24 17 20 21 21 20 19 
24 5 5 6 7 6 5 
24 0 0 0 0 1 1 
24 0 1 0 2 1 0 
24 2 2 2 2 2 2 
48 46 41 62 48 48 42 
48 13 15 27 18 16 15 
48 0 0 0 0 0 0 
48 5 3 3 2 2 3 
48 4 6 7 9 5 6 
48 11 10 8 10 12 10 
48 4 6 3 3 7 8 
48 6 15 8 3 1 2 
48 1 1 1 2 2 11 
48 0 0 0 0 0 0 
48 0 0 0 0 0 0 
48 3 4 5 3 3 4 
48 2 3 14 9 3 25 
48 7 4 7 12 2 3 
48 0 0 0 0 0 0 
48 39 33 28 41 34 31 
48 0 6 8 4 4 4 
48 3 0 0 0 0 1 
48 2 1 0 2 0 1 
48 2 2 2 2 2 3 
 
Change in VAS (mm) over 240 minutes after a range of doses of inhaled 
formoterol 
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 Time (minutes) 
Dose 
(mcg)       
0 1.105 1.364 1.096 1.082 0.876 1.2 
0 0.259 0.274 0.169 0.35 0.33 0.203 
0 0.313 0.29 0.208 0.229 0.167 0.163 
0 1.233 0.753 1.128 0.604 0.892 1.295 
0 0.488 0.721 0.421 0.367 0.57 0.493 
0 1.125 0.712 0.9 0.563 0.446 0.399 
0 0.922 0.97 0.999 0.612 0.735 0.968 
0 1.324 1.362 1.787 1.489 1.303 1.311 
0 0.305 0.204 0.22 0.308 0.266 0.337 
0 1.408 1.34 1.588 1.454 1.418 1.276 
0 0.765 0.659 0.531 0.747 0.663 0.594 
0 1.889 1.363 1.148 1.06 1.548 1.395 
0 0.637 0.922 0.575 0.531 0.455 0.359 
0 0.327 0.275 0.278 0.23 0.247 0.317 
0 0.354 0.344 0.283 0.298 0.298 0.32 
0 0.755 0.693 0.893 0.851 0.914 0.797 
0 1.432 1.63 1.657 1.61 1.936 1.481 
0 1.204 0.987 0.931 0.84 0.846 0.983 
0 0.433 0.33 0.316 0.211 0.272 0.24 
0 0.476 0.417 0.426 0.444 0.399 0.461 
6 1.816 1.26 1.358 0.974 1.195 1.027 
6 0.236 0.218 0.207 0.426 0.399 0.236 
6 0.289 0.22 0.205 0.25 0.193 0.299 
6 0.891 0.607 0.614 0.535 0.722 1.017 
6 0.558 0.528 0.424 0.531 0.567 0.429 
6 1.224 1.27 0.746 0.842 1.45 1.308 
6 0.718 0.736 0.76 1.091 0.72 0.67 
6 0.971 1.329 1.213 1.148 1.395 1.306 
6 0.251 0.313 0.331 0.288 0.285 0.272 
6 1.377 1.267 1.274 1.056 1.476 1.277 
6 0.608 0.631 0.592 0.56 0.676 0.685 
6 1.516 1.681 1.29 1.381 1.451 1.146 
6 0.693 0.918 0.735 0.312 0.964 0.391 
6 0.276 0.269 0.268 0.276 0.248 0.33 
6 0.391 0.357 0.277 0.405 0.476 0.327 
6 0.72 0.566 0.648 0.629 0.794 0.965 
6 1.352 1.677 1.965 1.365 1.497 1.606 
6 1.582 0.924 1.142 1.201 1.135 1.327 
6 0.512 0.41 0.372 0.304 0.263 0.277 
6 0.773 0.565 0.586 0.575 0.62 0.634 
12 1.381 1.291 1.131 1.046 1.557 0.886 
12 0.415 0.401 0.298 0.463 0.518 0.303 
12 0.221 0.206 0.292 0.297 0.375 0.642 
12 2.2 1.921 1.469 1.419 1.382 1.833 
12 0.68 0.41 0.541 0.59 0.634 0.622 
12 0.807 0.822 0.904 0.777 0.565 0.982 
12 0.701 0.525 0.658 1.207 0.881 0.677 
12 1.535 1.385 1.581 1.954 1.441 2.062 
12 0.193 0.278 0.259 0.255 0.262 0.342 
12 1.125 2.032 1.535 1.282 1.107 1.223 
12 0.773 0.689 0.509 0.39 0.468 0.493 
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12 1.049 0.974 0.732 0.829 1.236 1.106 
12 0.793 0.699 0.818 1.493 0.654 0.44 
12 0.338 0.318 0.357 0.36 0.271 0.312 
12 0.396 0.443 0.42 0.494 0.5 0.396 
12 0.802 0.628 0.679 0.721 0.921 0.991 
12 1.873 1.445 1.49 1.655 1.801 2.034 
12 1.199 1.276 0.951 1.223 1.113 1.149 
12 0.324 0.274 0.482 0.51 0.279 0.384 
12 0.67 0.671 0.736 0.887 0.957 0.694 
24 1.04 1.503 1.351 1.137 1.423 2.11 
24 0.273 0.265 0.4 0.435 0.406 0.375 
24 0.321 0.639 0.449 0.289 0.443 0.309 
24 1.623 1.163 1.369 1.445 1.06 1.362 
24 0.587 0.523 0.569 0.675 0.915 0.537 
24 1.039 0.589 1.204 1.714 1.153 1.119 
24 0.694 0.819 1.095 1.081 1.167 1.535 
24 1.365 2.265 1.954 2.2 1.769 1.931 
24 0.293 0.26 0.28 0.267 0.232 0.348 
24 1.903 1.667 1.613 1.623 1.721 1.176 
24 0.749 0.581 0.684 0.703 0.71 0.775 
24 1.381 2.177 1.695 1.678 2.092 1.075 
24 0.56 0.689 0.908 0.468 1.288 0.486 
24 0.285 0.425 0.384 0.407 0.315 0.46 
24 0.293 0.44 0.503 0.481 1.047 0.918 
24 0.77 0.78 1.049 1.046 0.715 0.902 
24 1.915 2.241 2.335 2.274 2.249 2.073 
24 1.085 1.162 1.571 1.433 0.935 1.475 
24 0.368 0.475 0.346 0.343 0.377 0.369 
24 0.745 0.848 0.786 0.628 0.708 0.806 
48 1.694 1.733 1.424 1.757 2.154 1.92 
48 0.384 0.37 0.322 0.442 0.38 0.276 
48 0.239 0.245 0.325 0.268 0.262 0.257 
48 1.836 1.754 1.673 1.746 1.972 2.179 
48 0.238 0.647 1.086 0.779 0.94 0.529 
48 0.912 1.082 1.442 1.02 1.895 1.037 
48 0.794 1.601 1.593 1.354 1.18 1.144 
48 1.053 1.636 1.978 1.897 1.801 1.723 
48 0.247 0.397 0.371 0.507 0.546 0.493 
48 0.989 1.093 1.435 1.491 1.75 1.652 
48 0.841 0.928 0.778 0.97 1.008 1.048 
48 1.427 1.036 1.21 1.474 1.718 2.905 
48 1.138 1.358 2.286 1.382 0.588 0.918 
48 0.247 0.367 0.376 0.463 0.357 0.41 
48 0.349 0.523 0.353 0.368 0.466 0.316 
48 0.801 0.965 1.107 1.099 1.3 0.738 
48 1.81 2.01 1.881 1.48 2.33 2.4 
48 0.994 0.989 1.312 0.99 1.213 0.944 
48 0.626 0.53 0.574 0.609 0.457 0.676 
48 0.652 0.709 0.728 0.639 0.941 0.686 
 
Change in tremor (accelerometer, m/s/s.h) over 240 minutes after a range of 
doses of inhaled formoterol 
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 Time (minutes) 
Dose 
(mcg)       
0 63.5 76 31 41.5 50 73 
0 15 12 5.5 7 10 9.5 
0 6 0.5 3 3 23 18 
0 67 37 37 40 43 49 
0 6.5 8.5 6.5 8 9 10 
0 5.5 10.5 15 22 21.5 25 
0 24 5 7 13.5 22 20 
0 0 0 2.5 3 2.5 58 
0 1 1 1 1 1 2 
0 19 4 5 2 5 4 
0 60 41.5 0 46 45 41 
0 17 7.5 2 5 5 6 
0 25 9 2.5 2 2 1.5 
0 2.5 9.5 2 3 3 3.5 
0 4 2 1.5 0 0 0 
0 22.5 24 26 30 37 46.5 
0 24 20 26 24 21 12.5 
0 41 22.5 17.5 37 38 34 
0 7 1.5 1 2 1 1 
0 26 9.5 2.5 2.5 2 0.5 
6 42.5 32 46 42 50 56.5 
6 16 14.5 7.5 13 13 15.5 
6 38 4.5 1 0.5 2.5 0.5 
6 75 43 36 24.5 24 20 
6 6 11 9.5 10.5 9.5 12 
6 22 6.5 6.5 7 6 6.5 
6 3 4 2.5 2.5 7 2 
6 15.5 10 1.5 3 1.5 2 
6 13 1 1 1 0.5 1 
6 39.5 29 14.5 4 8 3 
6 42 13 14 30 39 35 
6 1.5 1 2 1 1 1 
6 35.5 7 5 3 1.5 0.5 
6 2.5 1.5 2.5 1.5 1.5 3 
6 2 1 0 0 0 0 
6 30 36 21 30 27 28.5 
6 28 25 28 10 13 6.5 
6 61 64 23 41 19 32 
6 11.5 4 4 3 6 4.5 
6 1.5 1.5 1 1.5 2 2 
12 50 54 49 40.5 51 74.5 
12 12 22 17.5 15.5 10.5 19 
12 65.5 39 23.5 6 0.5 15 
12 61 53 51.5 40 48 46.5 
12 7.5 14 8 16.5 19 5.5 
12 32.5 10.5 9.5 11.5 11 11.5 
12 36 2.5 8 6 5.5 7 
12 2 1 5 0 0 0 
12 3 1 2 1 1 1 
12 4.5 3 2.5 1 1 5 
12 0 12.5 18 21 33 20 
12 4.5 1.5 1.5 4.5 1.5 1.5 
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12 12.5 0.5 1 1 1 0 
12 5.5 2 2 2 2.5 2 
12 4 1 0 0 1.5 0 
12 48 13 23.5 15 16.5 16 
12 29 19 10 13 8.5 8.5 
12 59 18 22 32 21 29.5 
12 1 0.5 1 0 2 2 
12 13 2 2 1 2 2 
24 49.5 43 38 48.5 41 63 
24 66.5 40 58.5 74 80 80 
24 23 1 3 4 11 0.5 
24 56 54 45 43.5 41 29 
24 13.5 6.5 31 6 3.5 3.5 
24 26.5 12 11 11.5 9.5 11.5 
24 3.5 7 3 4 3 3 
24 48 20 10 14 4.5 3.5 
24 1.5 2 1.5 1.5 1.5 1 
24 39.5 6 1.5 0 1 1 
24 66 0 0 33 26.5 31.5 
24 2 2 2 1.5 1.5 1.5 
24 21 8.5 15 5 3 2.5 
24 2 3 2.5 2 2 3 
24 1.5 1.15 0.5 1.5 1.5 0 
24 26 22.5 30 26 24 21.5 
24 17.5 20.5 16 13 14 14.5 
24 65.5 17 24.5 13 21.5 33 
24 13 3 2 4.5 1.5 0.5 
24 1.5 2.5 2.5 2 2 2 
48 83 56.5 57 52.5 52 34 
48 15.5 15 15 16.5 18.5 16.5 
48 48 23.5 6.5 8 8 7.5 
48 77.5 45 55 53 46 48 
48 4 7 7 7.5 8 6 
48 11.5 11 8.5 10 11.5 7.5 
48 7 4 3 3 3 4 
48 10 4.5 2 1 0 0 
48 1.5 1 1.5 1.5 1.5 1.5 
48 13 7 2 1 1.5 2 
48 32 25 20 9 20 17.5 
48 1 4.5 3 3 2 2 
48 46.5 27 10 13.5 2 8 
48 23 4.5 6 5 4.5 2.5 
48 0 0 0 0 0 0 
48 33.5 35.5 29 36 32 28 
48 39.5 49 31.5 24 18 17 
48 38.5 22 25 34 35 27 
48 17.5 2 1.5 2.5 0 7 
48 16 3 2.5 2.5 3 3.5 
 
Change in VAS dyspnoea (mm) over 240 minutes after a range of doses of 
inhaled formoterol 
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Placebo 
Baseline 30 mins 60 mins 120 mins 180 mins 240 mins 
202/111 152/91 158/82 153/82 158/93 162/99 
151/85 151/90 126/84 128/80 130/80 126/82 
98/77 96/77 103/75 99/82 107/76 105/89 
122/103 133/77 132/84 134/82 128/99 141/94 
158/73 150/81 149/78 159/78 155/83 153/80 
158/82 120/60 111/65 118/65 117/68 141/84 
145/61 140/66 127/60 138/63 138/63 147/67 
145/82 135/71 134/85 127/64 142/79 133/77 
129/60 129/71 128/72 143/78 152/75 152/78 
164/96 147/94 138/86 139/82 154/92 141/91 
125/81 123/80 128/95 133/86 136/84 129/78 
189/106 190/105 182/101 199/111 174/120 192/106 
108/86 106/59 106/63 111/67 99/73 101/61 
135/82 130/88 131/86 124/80 122/82 142/86 
142/75 145/78 150/85 157/73 154/72 147/77 
134/87 110/81 112/77 124/82 126/81 106/74 
122/69 130/71 136/76 136/79 149/79 132/82 
176/94 166/99 163/99 178/97 171/102 182/107 
113/76 116/74 112/73 110/76 117/75 120/78 
135/86 130/91 132/89 149/92 143/93 143/95 
 
 
 
6 mcg 
Baseline 30 mins 60 mins 120 mins 180 mins 240 mins 
157/83 152/86 154/82 164/77 148/100 153/96 
154/93 136/84 119/80 137/90 131/85 134/88 
116/79 92/73 97/77 98/76 106/78 112/75 
118/80 134/101 133/90 149/106 124/73 136/117 
148/77 153/83 151/82 160/86 164/95 156/83 
118/60 104/63 128/62 129/66 148/85 153/86 
157/89 133/62 132/59 137/66 131/67 139/68 
145/81 134/81 123/76 142/72 152/76 134/75 
152/77 145/66 136/77 152/77 143/76 138/77 
122/76 126/89 129/89 131/80 141/88 131/86 
124/97 149/101 136/89 150/97 140/87 139/91 
154/108 153/107 152/97 166/108 161/107 156/102 
99/62 102/61 106/63 107/60 113/64 112/67 
116/77 122/93 119/88 132/86 144/89 121/83 
131/78 134/75 130/70 142/75 147/74 144/78 
110/71 109/76 126/73 106/76 110/81 122/86 
150/76 132/83 142/79 154/82 141/88 154/84 
161/98 158/96 187/99 181/99 167/95 167/100 
182/101 106/90 105/73 122/72 119/74 119/80 
143/87 136/88 147/96 152/94 151/97 156/98 
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12 mcg 
Baseline 30 mins 60 mins 120 mins 180 mins 240 mins 
152/91 167/77 158/92 157/108 150/100 152/94 
133/99 137/91 136/80 134/82 147/88 138/87 
158/80 128/76 137/79 101/79 108/75 122/80 
135/80 128/86 132/81 141/81 142/82 129/92 
154/77 152/76 150/78 159/84 162/88 160/86 
138/76 123/69 130/78 144/73 132/70 150/74 
153/61 152/64 141/63 142/63 144/65 159/63 
123/68 110/72 131/71 134/76 119/73 133/75 
129/67 152/69 130/81 149/85 146/77 155/74 
145/91 131/94 133/97 155/92 150/89 140/94 
141/98 128/89 137/82 149/83 145/88 135/77 
161/108 159/102 170/108 154/113 165/110 174/114 
111/65 116/75 131/68 117/71 111/80 116/83 
141/85 114/77 131/79 130/87 143/90 138/82 
132/77 137/79 140/73 151/85 146/79 132/76 
112/76 108/84 119/87 107/80 112/77 113/81 
150/84 139/83 158/79 158/88 174/101 171/85 
208/106 183/95 187/99 181/96 193/104 174/102 
133/91 120/84 123/82 130/81 113/82 123/86 
142/89 136/87 150/91 145/98 157/96 162/99 
 
 
 
 
24 mcg 
Baseline 30 mins 60 mins 120 mins 180 mins 240 mins 
153/92 149/93 161/93 153/90 146/89 142/91 
159/95 139/87 124/77 140/90 143/90 141/94 
99/80 98/82 102/73 99/80 113/86 104/83 
132/82 136/77 135/80 147/87 131/83 131/101 
136/92 149/87 143/84 141/83 138/81 141/81 
138/76 143/81 125/72 152/76 120/70 137/92 
148/52 150/68 165/57 153/74 153/69 153/74 
189/91 150/80 162/80 163/81 161/83 165/86 
119/767 106/62 129/77 132/74 130/64 139/68 
130/81 133/89 126/81 128/83 124/83 152/89 
121/86 133/85 118/99 129/80 142/88 139/87 
192/104 157/91 153/103 156/102 161/92 159/107 
137/78 99/57 99/58 108/62 108/66 106/63 
120/86 131/82 135/83 141/85 136/87 160/98 
136/79 138/78 143/73 152/75 144/79 142/76 
98/66 114/77 117/79 125/78 122/80 13181 
128/73 142/72 141/74 144/81 144/75 161/80 
156/86 171/97 162/88 187/103 192/100 192/106 
115/70 142/82 151/85 115/74 121/77 121/75 
133/88 137/90 142/87 139/89 159/94 159/102 
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48 mcg 
Baseline 30 mins 60 mins 120 mins 180 mins 240 mins 
152/76 147/95 145/92 157/98 154/80 153/71 
139/87 140/120 120/68 103/71 130/82 121/81 
111/72 103/76 105/78 105/83 104/75 104/79 
136/81 130/70 131/80 122/79 133/78 152/85 
158/78 156/79 153/79 163/85 158/82 153/83 
165/83 141/81 129/79 135/66 145/82 145/89 
138/64 134/64 148/64 129/67 132/65 149/71 
136/81 136/73 139/77 130/76 122/75 164/95 
118/66 119/67 125/70 133/75 122/74 160/85 
139/86 139/86 129/89 131/81 134/85 140/91 
126/78 127/76 141/78 135/85 131/84 135/75 
192/103 193/104 199/101 184/107 183/103 192/98 
103/81 105/55 114/67 109/65 103/79 106/79 
121/80 140/88 131/76 140/81 133/79 152/91 
130/67 120/71 130/72 136/76 138/73 120/72 
114/76 111/72 123/79 128/76 131/83 116/81 
147/81 137/71 122/69 148/73 147/82 142/105 
127/77 135/86 154/87 169/90 176/95 179/97 
138/79 117/83 137/100 137/100 139/102 123/80 
144/93 127/87 153/92 153/91 156/91 163/96 
 
 
Change in Blood Pressure (mmHg) over 240 minutes after a range of doses 
of inhaled formoterol 
 
 
 
Placebo 6mcg 12mcg 24mcg 48mcg 
Pre Post Pre Post Pre Post Pre Post Pre Post 
3.8 3.8 3.9 4.3 4 4 3.8 4 3.9 4.2 
4.6 4.5 4.1 4.5 4.4 4.4 4.1 4.5 4.5 4.5 
4.3 4.4 4.5 4.5 4.2 4.1 4.3 3.7 4.7 4.2 
4.2 4.2 4.1 4.2 4.3 4.1 4.3 4 4.1 4.1 
4.3 3.9 4.1 4.4 4.1 4.1 4.2 3.9 4.3 4.2 
4.2 4 4.1 4.2 4.1 4.3 4.3 4 4.3 4.3 
4.4 4.6 4.1 4.6 4.6 3.9 4.1 4.7 4.4 4.6 
4 4.4 4.3 4.4 3.9 4 4.5 4.1 4.4 4.1 
3.6 3.9 4.1 4.3 4 4.2 4 4.3 4 4.2 
4.3 4.2 3.5 3.9 4.6 4.1 3.5 3.9 3.6 3.5 
4.4 4.4 4.3 3.8 4.5 4.1 4.7 4 4.1 3.9 
4.4 4.4 4.2 4.1 4.5 4.5 4.5 4.1 4.2 4.2 
4.1 4.1 4.4 4.2 4.1 4.3 4.4 4.2 4.4 4.2 
4.3 4.1 4.1 4.1 3.9 4 4 4.5 3.8 4.1 
4.5 4.5 4.1 4.1 4.3 4.1 4.1 4.1 4 4.1 
4.1 4 4.2 4.1 3.9 4.1 3.9 4.3 4.1 4.3 
4.3 4.5 4.1 4.1 4.5 4.1 4.5 4.1 4.1 4.4 
4 4.1 4.1 4.2 4.1 4.3 4.2 4.1 4.6 4.6 
4 4.1 4.2 4.5 4.2 4.1 4.1 3.9 4.1 4.1 
 
Change in plasma potassium (mmol/l) over 240 minutes after a range of 
doses of inhaled formoterol 
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Placebo 6mcg 12mcg 24mcg 48mcg 
Pre Pre Pre Post Pre Post Pre Post Pre Post 
122 75 123 65 120 101 120 119 150 128 
421 427 417 399 417 408.75 406 401.6 418 418 
334 316 333 329 300 321 321 331 317 327 
375 390 378 405 390 405 388 405 387 383 
291 303 281 285 277 286 291 292 285 281 
293 233 298 314 284 307 316 324 300 322 
303 273 302 305 313 288 309 307 311 307 
397 340 370 372 399 402 354 360 373 380 
336 345 327 333 358 360 367 360 367 381 
323 331 299 315 308 316 308 312 292.5 302 
362 360 355 359 363 363 357 360 368 375 
430 426 455 441 440 443 447 451 439 448 
411 420 390 423 420 453 435 450 450 462 
396 395 410 396 437 445 444 440 425 400 
378 368 388 395 391 390 375 378 404 405 
387 365 402 375 396 387 386 399 375 383 
344 351 333 330 337 351 343 351.5 283 313 
344 355 322.5 351 354 354 349 361 360 363 
444 450 469 478 405 427 429 449 410 436 
466 469 485 472 486 488 480.5 475 482 478 
 
 
Change in walk distance (m) over 240 minutes after a range of doses of 
inhaled formoterol 
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Publications arising from this thesis 
 
 
A benefit-risk assessment of inhaled long-acting ȕ2-agonists in the 
management of obstructive pulmonary disease. Sovani MP, Whale CI, 
Tattersfield AE. Drug Safety 2004;27(10):689-715. 
 
Effects of rac-albuterol on arterial blood gases in patients with stable 
hypercapnic chronic obstructive pulmonary disease. Whale CI, Sovani MP, 
Mortimer KJ, Oborne J, Cooper S, Harrison TW, Tattersfield AE. Br J Clin 
Pharmacol 2006;62(2):153-157. 
 
Systemic and bronchodilator effects of inhaled rac-formoterol in subjects 
with chronic obstructive pulmonary disease: a dose response study. Whale 
CI, Sovani MP, Mortimer KJ, Harrison TW, Tattersfield AE. Br J Clin 
Pharmacol 2008;65(6):841-847. 
 
Related publications 
 
Poor adherence with inhaled corticosteroids in asthma: can a single inhaler 
containing budesonide and formoterol help? Sovani MP, Whale CI, Oborne 
J, Cooper S, Mortimer KJ, Ekstrom T, Tattersfield AE, Harrison TW. Br J 
Gen Pract 2008;58(546):37-43. 
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